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Abstract 
 
The work presented in this thesis investigates the use of new luminescent lanthanide 
complexes, both free and bound to the surface of gold nanoparticles, for protein labelling. 
Lanthanide complexes were shown to maintain their luminescence properties when 
conjugated to proteins and one complex also demonstrated participation in Förster resonance 
energy transfer when conjugated to a protein in an appropriate system. Furthermore, it was 
found that bovine serum albumin can act as a vehicle to transport luminescent lanthanide 
complexes into two human cell lines. 
 
Lanthanide complexes were then used to coat 13 nm gold nanoparticles for protein labelling 
within cells. The aim was to find a peptide sequence to preferentially bind to gold 
nanoparticles which could be expressed as part of a protein of interest, acting as a binding site 
within the cell. The interaction of peptides with gold nanoparticles was examined using 
several methods and, of the sequences tested, CCPGCC was found to have the highest affinity 
for the nanoparticles. This peptide was expressed in HeLa cells as part of green fluorescent 
protein. Co-localisation of the nanoparticles with the protein in cells could not be established 
through fluorescence microscopy, however, cell lysis revealed green fluorescence protein 
associated with nanoparticle aggregates. 
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1. Introduction 
 
1.1 Background 
The focus of this thesis is the exploration of protein labelling strategies in vitro and in cells 
using luminescent probes. Lanthanide complexes offer advantages over many commonly used 
optical probes, as discussed within this chapter, and as such are employed throughout this 
research. In addition to the use of lanthanide complexes as individual probes, coating of 
AuNPs with these complexes allows the delivery of a large number of probes to a protein of 
interest; the interactions of proteins and peptides with AuNPs was, therefore, also of great 
interest. Furthermore, the techniques routinely utilised for protein labelling in cells have their 
drawbacks and may not be applicable for the use of luminescent AuNPs as protein labels in 
cells, thus adaptation of these techniques was relevant.  
 
1.2 Protein Labelling In Vitro and in Cells 
Protein labelling has been carried out for many years in vitro and in cells with the aim of 
better understanding phenomena such as protein production, protein folding and protein-
protein interactions, which are all of significance when studying overall cell behaviour. More 
recently, in the field of protein labelling within cells, efforts have been aimed at overcoming 
the necessity of isolating proteins before labelling and reintroducing them, Scheme 1.1. Up to 
now, however, the choice of label for protein tagging in cells has been limited with each 
having disadvantages to overcome.
1
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Scheme 1.1 Left: Labelling of isolated protein in vitro. 
Right: Labelling protein inside the cell.
2
 
 
Protein labelling in vitro can provide information about the conformation of a protein and its 
interaction with other proteins or molecules. One of the key considerations when labelling 
proteins is that the label, or labelling process, should not affect the structure or function of the 
protein of interest; in order to achieve this, labelling reactions should take place under mild 
conditions in aqueous solvent and using reactants that are inert to biological media and are not 
endogenous to biomolecules in order to prevent unwanted reactions. The advent of 
bioorthogonal reactions has facilitated the labelling of biomolecules such as proteins within 
their natural environments and without perturbing their intrinsic nature, Scheme 1.2.
3, 4
 
Popular chemistries used for bioorthogonal labelling include cycloaddition reactions or polar 
reactions such as condensation of ketones or aldehydes. Ketones and aldehydes are examples 
of electrophiles which are not commonly present in biomolecules which means that they can 
be easily targeted with an appropriate nucleophile such as an aminoxy compound or a 
hydrazide.
4
 Many cycloaddition reactions are employed for bioorthogonal labelling purposes 
and include variations of Diels-Alder reactions, such as inverse electron-demand Diels-Alder 
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which can proceed at exceptionally fast rates under biological conditions, and copper-
catalyzed azide-alkyne reactions which, unlike the uncatalysed reaction, can proceed in 
aqueous conditions at room temperature and provide control over the regioisomer produced. 
 
 
Scheme 1.2 a) Covalent labelling of a biomolecule containing a unique functional group using 
a complementary probe. Examples of bioorthogonal chemistries b) polar reaction between an 
electrophile and a nucleophile and c) a cycloaddition represented by a copper-catalyzed azide-
alkyne cycloaddition.
4
 
 
1.2.1 Genetic Modification of Proteins for Labelling In Vitro and at Cell Surfaces 
Copper-catalyzed azide-alkyne cycloadditions, an example of so-called click chemistry, have 
been widely used in labelling of proteins. The modification of the amino acid pyrrolysine has 
allowed the utilisation of this reaction to label recombinant proteins in vitro. Pyrrolysine is a 
naturally occurring amino acid and is coded for in some archaea species, but its expression in 
bacteria, yeast and mammalian cells has now been established. A pyrrolysine variant with an 
alkyne modification was expressed as part of calmodulin. The alkyne underwent reaction with 
biomolecule
bioorthogonal
reaction
E
Nu
  
E Nu
a
b
c
Cu(I) (cat.)
H2O
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azidocoumarin using a copper catalyst in vitro.
5
 The coumarin dye demonstrated a vast 
increase in fluorescence after the cycloaddition reaction, and did not show any non-specific 
interactions with native calmodulin. Additionally, a cysteine residue on the recombinant 
calmodulin protein was labelled with Alexa Fluor 488 C5-maleimide, a potential FRET 
partner for the coumarin dye. The FRET efficiency of the pair increased when Ca
2+
 was 
introduced because the binding of the ion by calmodulin changed the conformation of the 
protein and reduced the distance between the two dyes, Scheme 1.3.
5
 
 
 
Scheme 1.3 The use of FRET to indicate the binding of Ca
2+
 by calmodulin. 
 
A study using similar chemistry introduced a pyrrolysine residue functionalised with an azide 
into a protein.
6
 The functionalised protein was then labelled with a rhodamine derivative 
bearing an alkyne group in vitro using a copper catalyst. The recombinant protein was also 
expressed in Escherichia coli and labelled with alkyne-coumarin, demonstrating the 
possibility of using the reaction for labelling proteins inside bacterial cells. Furthermore, the 
click reaction was used to label a recombinant protein on the surface of embryonic human 
kidney cells in culture. Whilst the latter study demonstrates the possibility of translating in 
vitro protein labelling techniques to studies within cells, it also highlights an obstacle to 
achieving this; many protein labels that have been effectively used in vitro are not able to 
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permeate the cell membrane of mammalian cells and as such can only be of use in labelling 
cell surface proteins unless other methods of introduction are used which may perturb the 
cells in question.
7
 
 
There have been many examples of labelling cell surface proteins, with a common approach 
exploiting the expression of a recombinant version of the protein of interest, as used in the 
two in vitro studies described earlier. Another example of this uses peptide sequences 
containing heptad repeats known to form coiled-coil structures when the appropriate amino 
acids are present. The peptides used were expected to be unable to permeate the cell 
membrane due to their net charges and as such were used to label a cell surface receptor.
8
 
Genetic modification of Chinese hamster ovary cells allowed the expression of one peptide 
sequence fused to the cell receptor proteins. The complimentary peptide labelled with a 
fluorophore was then introduced and found to bind selectively to the peptide expressed as part 
of the receptor, Scheme 1.4. The function of the receptor was not affected by the labelling 
process and the process was shown to be fully reversible.
8
 
 
 
Scheme 1.4 Labelling of a cell surface receptor using coiled-coil peptide interactions. 
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1.2.2 Genetic Modification of Proteins for Labelling Inside Cells 
There have been examples of the genetic modification of endogenous proteins in order to bind 
a specifically engineered probe that is membrane permeable. However, arguably the most 
widely used example of genetic modification for protein imaging within cells is the 
expression of GFP, which requires no probe interaction to generate a response because GFP is 
itself fluorescent when excited with the appropriate wavelength of light.
9
 Furthermore, 
because the incorporation of GFP into a particular protein is genetically controlled it is 
specific to the target protein alone. The barrel structure of GFP allows its chromophore some 
protection from the cellular environment, however, this also prevents GFP from responding 
effectively to any environmental changes which may be of interest.
10, 11
 The large size of 
GFP, around 235 amino acids, means that it may affect the protein it is incorporated into by 
altering its function, localisation and overall structure.
10, 12, 13
 Another drawback of fluorescent 
proteins is that they are often spectrally limited and if they are modified in an attempt to alter 
their spectral properties, their fluorescence is often reduced as a result.
10
 Furthermore, GFP 
has been shown to lose fluorescence as a function of pH, with no fluorescence observed at pH 
6.5, and upon exposure to oxyradicals which can be present in large amounts in disease states 
that may be the focus of an investigation such as diabetes, Alzheimer’s disease, cancer, heart 
disease and Parkinson’s disease.14, 15 
 
A pioneering technique for fluorescent labelling of recombinant proteins, developed by Roger 
Tsien’s group, is the introduction of tetracysteine motifs into proteins that can bind to 
membrane-permeable biarsenical probes.
16-18
 In addition to the design of an appropriate 
peptide binding motif it was also necessary to develop an appropriate biarsenical probe that 
holds the arsenics in the right position for interaction with the cysteine residues, becomes 
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fluorescent only upon interaction with the peptide, and is able to penetrate the cell membrane. 
The biarsenical probe first adopted by the group was FlAsH-EDT2.
17, 18
 Analogues of the 
green emitting FlAsH-EDT2 (λex = 508 nm, λem = 528 nm), CHOxAsH and ReAsH were later 
developed to emit in the blue (λex = 380 nm, λem = 430 nm) and red (λex = 593 nm, λem = 608 
nm) areas of the spectrum respectively.
16
 This approach has been successfully applied to the 
investigation of many biological phenomena such as connexin trafficking and inhibition of 
NF-κB activation.19-21 The former study expressed the tertacysteine motif within the connexin 
protein, which forms part of the gap junction channels between cells, and labelled the cells 
first with FlAsH-EDT2 and later with ReAsH, which was only able interact with the 
tetracysteine domains not already occupied by FlAsH-EDT2, in order to see a comparison of 
the location of older and newer connexin based on their different fluorescent colours. It was 
found that newer connexin surrounded the older connexin which was in the middle of the gap 
junction. The study also concluded that the tetracysteine motif did not affect the function of 
the connexin.
19, 21
 The latter study used FlAsH-EDT2 to fluorescently label the naturally 
occurring cysteine containing activation loop of IκB catalytic subunits. The purpose of this 
was to show that the route of toxicity of arsenites is attachment to this particular protein, 
resulting in its inhibition and subsequently the inhibition of Nf-κB activation, which is a 
transcription factor. The fluorescence of the biarsenical compound FlAsH-EDT2 when 
incubated with the domain of interest in vitro showed that arsentites are able to bind to this 
particular activation loop.
20
 
 
The tetracysteine motif is much smaller than GFP and as such affects the target protein to a 
lesser extent when fused with it. In addition, the membrane permeable biarsenical compound 
can be modified to alter its spectral properties allowing it to be compatible with a range of 
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other cellular stains which may be useful in the case of co-localisation studies, for example, 
which perhaps presents it as a more flexible fluorescent probe than GFP. Drawbacks of using 
the tetracysteine motif, however, include the high detection of background, limited use in 
oxidative environments and the potential toxicity of the biarsenical probes.
7
 Furthermore, the 
biarsenical probes have small Stokes shifts; indeed the emission and excitation spectra of each 
of the biarsenical derivatives when bound to the peptide overlap, Scheme 1.5, making their 
use in practice quite difficult due to exclusion of excitation light from detection and self-
quenching effects. 
 
 
Scheme 1.5 Structure (top) and excitation (---) and emission (―) spectra (bottom) of a) 
FlAsH and b) ReAsH. 
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Further research in this field has seen the adaption of a rhodamine-derived bisboronic acid, 
originally designed as a monosaccharide sensor, to the labelling of recombinant proteins 
containing a tetraserine motif within cells.
22
 Although this probe offers an alternative to 
biarsenical probes with reduced toxicity, its photophysical properties do not offer much over 
the biarsenical probes because it also exhibits a small Stokes shift. Alternative genetic 
modifications have also been developed and used to great effect by the expression of so-called 
SNAP-tag® or Halo Tag® fusion proteins and subsequent labelling with organic 
fluorophores.
23, 24
 
 
Another approach that has been explored for protein labelling in cells is devising chemical 
reactions that will occur at the site of the protein of interest resulting in a detectable signal. 
This method has been successfully applied to the labelling of carbonic anhydrase enzymes 
with a ligand complex;
25
 the ligand portion of the complex binds to the protein surface, 
however, the ligand, which is bound to the probe via a phenylsulfonate linkage, is released 
when tosyl chemistry occurs at the protein surface, leaving only the probe non-covalently 
linked to the protein surface and is activated upon binding of a particular analyte to the 
protein, Scheme 1.6. Whilst this technique can boast the advantage of eliminating the need for 
genetic modification of endogenous proteins, which may be difficult in some cell types, or 
indeed in whole organisms, it does require that the ligand is specific for a particular protein, 
and thus must be designed and synthesised for each labelling scenario. 
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Scheme 1.6 Protein labelling using chemical reactions at the protein surface. 
 
Examples of alternative protein labelling techniques are available in review articles, but it is 
clear that expression of recombinant proteins is widely used.
1, 2, 7
 The extensive adoption in 
research of genetic modification of the protein of interest and subsequent labelling with a 
fluorescent probe confirms the suitability of the method to scientific investigations. Having 
said this, the current use of fluorescent probes within this method could be improved by using 
lanthanide complexes that offer superior photophysical properties.
26
 
 
1.3 Lanthanide Complexes in Biological Imaging 
The paramagnetic properties of gadolinium(III) have seen it become widely used in MRI and 
research is still continuing to improve the properties of gadolinium complexes for this 
purpose.
27-35
 Aside from this, however, the photophysical differences between lanthanide 
luminescence and organic fluorescence give lanthanide complexes many advantages when 
applied to biological imaging techniques such as microscopy. Autofluorescence from 
biological samples is caused by endogenous organic fluorophores, which, by the nature of 
organic fluorescence, have small Stokes shifts and short fluorescence lifetimes on the order of 
nanoseconds. Any applied organic fluorescent labels will, therefore, have similar properties 
themselves and as such may be masked greatly by background autofluorescence. Lanthanide 
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complexes, however, are able to overcome this in several ways. Firstly, their effective Stokes 
shift is so large that it is unlikely that any endogenous species will emit in the same 
wavelength range as the lanthanide given the far removed excitation used. Secondly, the 
detection of the lanthanide emission can be time-gated to begin after the decay in fluorescence 
from organic fluorophores since lanthanide lifetimes are so much longer. Finally, the emission 
spectrum of the lanthanide can be used to confirm that the lanthanide is the species being 
detected since its line-like bands of emission are characteristic and unlike the broad emission 
bands of organic fluorophores, Scheme 1.7. 
 
                      
Scheme 1.7 Left: Emission spectra of a Tb
3+
 complex (―) and fluorescein isothiocyanate(---). 
Right: Principle of time-gated fluorescence demonstrated by the difference in luminescence 
decay of a lanthanide complex (―) and an organic fluorophore (---). 
 
1.3.1 Luminescence Properties of Lanthanides 
Compounds that emit light are usually referred to as fluorescent if the emission is due to a 
singlet-singlet transition, or phosphorescent if a triplet-singlet transition, requiring a change in 
spin, results in photon emission. Luminescence, is generally an umbrella term for 
fluorescence and phosphorescence, but is used in relation to lanthanide emission because their 
transitions are between states with spin multiplicity and do not involve singlet-singlet or 
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triplet-singlet transitions. Lanthanide luminescence is a result of the excitation and subsequent 
relaxation of an f-electron which results in the emission of a photon. The redistribution of 
electrons within the 4f sub-shell is not allowed according to the Laporté selection rule and as 
such f-f transitions are parity forbidden. The prohibited nature of these transitions means that 
the direct excitation of lanthanide ions is very inefficient with molar absorption coefficients 
typically less than 3 M
-1
 cm
-1
, however, it also means that once an f-electron has been excited, 
the relaxation of the electron is equally inefficient resulting in long luminescence lifetimes in 
the order of milliseconds.
36-38
 The luminescence spectra of lanthanides are characterised by 
narrow, line-like, emission bands resulting from the lack of interaction between the 4f 
electrons and the external environment. However, interaction with solvent molecules, water in 
particular, can quench the luminescence by vibrational coupling causing an excited electron to 
relax via a non-radiative deactivation pathway. The lanthanides display emission across the 
visible, from thulium, terbium, europium, dysprosium and samarium, and NIR from erbium, 
neodymium and ytterbium.
26
 
 
1.3.1.1 Lanthanide Sensitisation 
Organic chromophores are often included in the structure of lanthanide binding ligands in 
order to facilitate the luminescence of the lanthanide ion. As previously discussed, the 
advantageous luminescence properties of the lanthanides, such as their long luminescence 
lifetimes and characteristic bands of emission, cannot readily be accessed by direct lanthanide 
excitation, however, an organic chromophore with a high molar absorption coefficient can 
absorb light easily and can then transfer this energy to the excited state of the lanthanide ion 
allowing the relaxation to take place through the energy levels of the lanthanide and 
producing lanthanide luminescence.
26, 36, 37, 39
 This is known as the antenna effect and its 
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principle is demonstrated in Scheme 1.8. Antenna groups usually absorb light in the UV range 
so when used to sensitise lanthanide emission there is a large effective Stokes shift of up to 
hundreds of nanometres. 
 
 
Scheme 1.8 Sensitisation of luminescence from Eu
3+
 by excitation of a ligand bearing an 
antenna group. 
 
The sensitiser used must be chosen with care with some being more applicable to use with 
certain lanthanides over others; the antenna must have efficient intersystem crossing capacity 
and its triplet state should be at least 1850 cm
-1
 higher in energy than the emitting state of the 
lanthanide in order to prevent repopulation of the triplet state which would not result in 
lanthanide emission.
39
 In some cases the sensitiser group is directly involved in chelating the 
lanthanide ion, as demonstrated by the cryptand in Figure 1.1, or it may be appended onto the 
chelating molecule in order to be held in close proximity to the lanthanide centre; DTPA and 
DOTA are commonly modified to include antenna molecules such as quinoline or 
azaxanthone.
40, 41
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1.3.2 Lanthanide Coordination 
Chelation of lanthanide ions is extremely important if they are to be used in biological 
systems because lanthanide ions are toxic when free in vivo and as such must be incorporated 
into a complex for in vivo or cell based studies. Indeed, the popular use of gadolinium 
complexes for MRI applications has lead to investigations into the stability of such species 
due to the fact that free Gd
3+
 forms aggregates in the spleen, bone marrow and liver which can 
lead to hepatic necrosis.
27, 42
 Furthermore, a chelating ligand is able to compete with 
coordinating solvent reducing the luminescence quenching caused by solvent molecules, and, 
as discussed previously, a chelating ligand may be comprised of, or introduce, a sensitiser 
moiety. 
 
Lanthanides are hard Lewis acids and as such demonstrate a preference for coordination with 
hard donor atoms such as oxygen and nitrogen.
43, 44
 Lanthanide ions are most commonly 
chelated by cryptands, macrocycles and polydentate ligands, containing oxygen and nitrogen 
donor atoms. 
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Figure 1.1 Common ligands used to chelate Ln
3+
. DOTA is an example of a macrocycle, 
DTPA of a polydentate ligand and the cryptand is taken from work by the Lehn group.
45
 
 
The research of Raymond and Lehn utilises cryptands,
45, 46
 Parker and Gunnlaugson employ 
macrocycles
41, 47
 and Pikramenou and Parac-Vogt exploit polydentate ligands for Ln
3+
 
chelation.
40, 48
 Of course, there is a great interest in the complexation of lanthanide ions and as 
such these examples are just a few of many as described in review articles.
49-52
 
 
In addition to negating the toxic effects of free lanthanide ions and enhancing the luminescent 
properties of the lanthanide, chelating ligands can also be functionalised in order to allow the 
covalent attachment of lanthanide complexes to biomolecules, surfaces or nanoparticles. The 
use of lanthanide chelating ligands modified with functional groups for attachment to AuNPs 
and their use in biological assays and cellular studies will be discussed later in this chapter, 
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whereas the covalent attachment of lanthanide complexes to proteins will be reported in 
Chapter 2. 
 
1.3.3 Examples of Luminescent Lanthanide Complexes in Cellular Studies 
Owing to the advantageous photophysical properties of lanthanide complexes, they have been 
used in many biological studies, including protein labelling. The development of cell 
permeable complexes has allowed lanthanides to be utilised as cellular probes, with research 
aimed at studying and directing cellular localisation of lanthanide complexes.
53
 For those 
complexes requiring some assistance in crossing the cell membrane, peptide sequences known 
to facilitate cellular uptake, so-called cell penetrating peptides, have been grafted onto the 
ligands chelating the lanthanide.
54-57
 
 
One of the many reported uses of lanthanide complexes in cells is to act as cellular stains. A 
range of luminescent lanthanide complexes have been used as general luminescent stains for 
living cells and fixed tissue samples.
58-61
 Specific targeting of cellular receptors have also 
been reported.
62
 Parker and co-workers have demonstrated the use of luminescent lanthanide 
complexes for cellular staining, previously reporting a terbium complex capable of selectively 
staining the cell nucleus of dividing HeLa cells, allowing the visualisation of mitotic 
chromosomes.
63
 In this case the lanthanide was chelated by a DOTA based ligand modified 
with azaxanthone antennas, Figure 1.2a. More recently, however, a series of europium 
complexes were designed based on a triazacyclononane chelating moiety appended with aryl–
alkynyl antennas bearing phosphinate or carboxylate substituents, Figure 1.2b.
64
 These 
complexes were noted for their superior brightness and luminescence quantum yields, 
  Chapter 1
   
17 
however, not all of the complexes synthesised were soluble in aqueous solution, precluding 
their use in biological systems. 
 
 
Figure 1.2 Examples of luminescent lanthanide complexes consisting of a) DOTA based 
ligand modified with azaxanthone antennas and b) triazacyclononane ligand appended with 
aryl–alkynyl antennas. 
 
a
b
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The europium complex taken forward for cellular studies was successfully imaged within 
Chinese hamster ovary cells, human prostate cancer cells and embryonic mouse fibroblast 
cells and was found to be taken up into cells by macropinocytosis after which selective 
staining of the mitochondria was observed.
64
 In addition to using lanthanide complexes as 
luminescent stains for mammalian cells, europium analogues of the complexes described 
above were used to label plant cells and tissues.
65
 In all cases the complexes were unable to 
penetrate the cell walls of healthy cells, with the exception of one complex shown to label the 
mitochondria of root hairs.
65
 It is suggested that the luminescent complexes could be used to 
study the viability of plant cells because in order for the complexes to penetrate further than 
the cell wall the cell must either be dying or its cell wall must be compromised. 
 
An alternative approach utilised recently by Yuan and colleagues exploits the encapsulation 
of a luminescent lanthanide complex by apoferritin for cellular delivery into HeLa cells via 
endocytosis.
66
 Modification of the protein allows the attachment of targeting moieties 
demonstrated by the attachment of a mitochondrial targeting molecule and subsequent 
observation of the europium luminescence localised within the mitochondria of HeLa cells.
66
  
 
Another widely exploited use of lanthanide complexes in cells is to act as reporter molecules 
for species present.
67
 The work of Parker and colleagues has explored the use of luminescent 
lanthanide complexes as cellular reporter molecules.
68
 Analytes may alter the coordination 
environment, allowing reports to be gained by changes in circular polarised luminescence 
signals or by a change in ratio of two emission bands of the lanthanide centre. DOTA based 
chelating ligands appended with various sensitiser molecules have been used as cellular 
sensors for pH and anion concentrations such as carbonate and citrate.
41, 69-72
 For example, a 
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series of complexes of europium and terbium, similar to those used for general cell staining, 
Figure 1.2a, consisting of a DOTA ligand appended with an azaxanthone antenna were used 
in a ratiometric manner to determine bicarbonate concentration.
73
 It was found that anions are 
able to displace the coordinated water molecules, thus affecting the circularly polarised 
luminescence and luminescence intensity of the lanthanide complexes. The emission response 
of the europium analogue was greater than that of terbium and as such the two signals could 
be compared in a ratiometric manner to find the concentration of bicarbonate present. The 
presence of a variety of biologically relevant anions and protein was assessed, however, the 
ability to sense for bicarbonate remained. The complexes were also incubated with various 
mammalian cell lines and were subsequently taken up by the cells. Imaging of the cells whilst 
varying the atmospheric CO2 caused a response in the signals from the probes as the 
bicarbonate concentration altered.
73
 A similar approach was used to sense for pH changes by 
conjugating a substituted sulphonamide group onto the ligand able to coordinate the 
lanthanide centre at certain pH values.
74
 Again, the response of europium and terbium 
analogues differed allowing their emission intensities to be compared in order to measure pH. 
This was demonstrated by treating various mammalian cell lines with the complexes and 
monitoring the change in emission intensities of the probes, which were localised within 
lysosomes, as the pH of the medium was varied.
74
 More recently the use of modified versions 
of the brighter luminescent europium complexes, Figure 1.2b, was reported for bicarbonate 
quantification in solution.
75
 The modified complex has only two appended aryl–alkynyl 
moieties allowing coordination of water. As before, anions were shown to displace 
coordinated water from the europium centre affecting the emission profile of the complex. 
The ratio of the emission bands within the europium spectrum altered with anion 
concentration and could therefore be used for quantification of the analyte. In this case 
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alternative anions and HSA were also shown to cause a change in the luminescence measured, 
however, above a concentration threshold of 10 mM bicarbonate was found to bind 
selectively to the lanthanide. The luminescent complexes were also found to be taken up in a 
variety of mammalian cell lines and localised initially in the mitochondria before transport 
into lysosomes demonstrating the potential use of these complexes for bicarbonate sensing in 
cells.
75
 
 
Yuan and colleagues have also explored the use luminescent lanthanide species as reporter 
molecules within cells. A europium complex was developed that was only weakly 
luminescent until it reacted with nitric oxide under aerobic conditions, upon which a triazole 
was formed and the luminescence of the europium was effectively “switched on” allowing it 
to act as a sensor for NO.
76
 The initial complex was, however, sensitive to pH changes which 
affected its ability to act as a sensor, therefore the structure of the complex was modified to 
allow it to act independently of pH as a selective and rapid NO sensor.
77
 The acetoxymethyl 
ester of the complex was found to be taken up by cells and demonstrated its use as a NO 
sensor within rat neuronal cells, its luminescence intensity changing as a function of NO 
concentration.
77
 More recently the group have developed a lanthanide complex bearing a 4-
hydroxypyridine group which is deprotonated at certain pH values.
78
 When deprotonation 
occurs intramolecular charge transfer arises in the europium analogue, quenching its 
luminescence, but not in the terbium complex. The two species were, therefore, used to 
measure pH changes in solution in a ratiometric manner. The probes were also imaged within 
HeLa cells, however, the measurements taken from cell studies were not ratiometric, but 
individual species in isolation.
78
 Terbium and europium complexes have also been developed 
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for sensing of thiols in cells, however, the work has only been conducted in extract from cells 
to date and as such the system must be developed further for use inside living cells.
79
 
 
Alternatively, Nagano and co-workers have used europium complexes with a DTPA based 
chelating ligand to sense for Zn
2+
 in cells.
80, 81
 In this instance the antenna group was based 
around a quinoline motif with the ability to chelate Zn
2+
. The binding of the zinc cation 
induces a change in the photophysical properties of the antenna and the luminescence 
exhibited by the europium centre is increased, Scheme 1.9. This was successfully used to 
detect zinc within living cells, however, the probe had to be injected into the cells which is not 
ideal. 
 
 
Scheme 1.9 The conformational and photophysical change of a europium complex in the 
absence and presence of Zn
2+
. 
 
Luminescent lanthanide complexes have also found use as specific protein labels in cells. One 
of the many protein labelling techniques explored by Kikuchi includes the labelling of 
  Chapter 1
   
22 
epidermal growth factor receptor with a luminescent lanthanide complex.
82
 In this case a 
mutant of the β–lactamase enzyme was expressed as part of a recombinant epidermal growth 
factor receptor protein in embryonic human kidney cells. A europium complex covalently 
attached to the β-lactam ampicillin was then introduced and was able to label the protein by 
being held in the enzyme for a prolonged period of time because the mutant enzyme is very 
slow in releasing the modified substrate, Scheme 1.10. 
 
 
Scheme 1.10 a) Structure of the europium label incorporating ampicillin, b) representation of 
the retention of the label by β-lactamase and a mutant variant of β-lactamase and c) the 
expression of the mutant variant of β-lactamase on the cell surface to allow labelling with the 
europium label. 
 
The long luminescence lifetime of the europium complex was exploited by the use of time 
resolved microscopy of the labelled cells to reduce background signal. The lanthanide probe 
=
time
β-lactamase
mutant
β-lactamase
a
c
b
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used was limited to labelling proteins on the cell surface because its anionic nature prevented 
membrane permeation. A similar approach was taken by the Miller group where recombinant 
cell membrane proteins containing Escherichia coli dihydrofolate reductase, which is known 
to have a high affinity for trimethoprim, were labelled with a commercially available terbium 
complex grafted to a trimethoprim moiety.
83
 The proteins were expressed in embryonic mouse 
fibroblast cells and were labelled with the terbium complex, however, the membrane 
permeability of the probe allowed non-specific labelling of other areas of the cell. 
 
1.4. Gold Nanoparticles in Cells 
AuNPs have received a great deal of interest in terms of their applications in biology and 
medicine.
84-94
 AuNPs have the potential to deliver drugs, gene regulation agents and imaging 
agents to cells because of their surface properties that allow for the addition of a range of 
complexes to their exterior.
84, 86, 95
 Furthermore, AuNPs can be used for photothermal therapy 
due to their rapid conversion of light energy into heat, therefore, if they are modified with 
antibodies to target cancer cells can facilitate cell death of the cancer by overheating.
84, 96
 
 
The use of AuNPs for biological applications depends on their surface modifications. For 
instance, the ability of AuNPs to act as gene delivery agents is improved when their surface is 
functionalised with amines because these groups are positively charged at physiological pH 
allowing for interaction with negatively charged nucleic acids through electrostatic means. It 
has been found that using lysine residues, whose side chain terminates in an amine, to modify 
the AuNP surface results in a more efficient delivery of DNA plasmids than a commercial 
vector.
86
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Fluorescent AuNPs have been used for a variety of applications. One example reported 
recently uses 2 nm AuNPs modified with either fluorescein or doxorubicin dyes to examine 
AuNP uptake and distribution within a tumour model.
97
 Both fluorescent molecules were 
grafted onto the surface of AuNPs using alkane ethers terminated with thiol groups which 
were able to bind to the gold. The alkane ethers not attached to a dye molecule either all 
presented an amine or carboxylate group to solution creating AuNPs that were either 
positively or negatively charged. Fluorescence microscopy and mathematical modelling 
revealed that the positively charged AuNPs were more effectively taken up by proliferating 
cells when either fluorescent dye molecule was present, however, negatively charged AuNPs 
were able to penetrate deeper into the tumour tissue. Research such as this provides insight 
into the uses of AuNPs as anti-cancer agents. 
 
1.4.1 Gold Nanoparticles - Background 
AuNPs are aggregates of Au(0) with dimensions under 100 nm and stabilised by capping 
ligands on their surface. For example, citrate-stabilised AuNPs can be readily synthesised by 
the reduction of a gold salt by sodium citrate.
98, 99
 This leads to AuNPs with an associated 
layer of citrate ions on their surface. The size of the nanoparticles can be easily tuned by 
varying the ratio of gold salt to reducing agent.
100, 101
 The citrate capping layer 
electrostatically stabilises the AuNPs due to the repulsion of the anionic charges, resulting in 
monodisperse AuNPs in solution. Citrate capping ligands can be easily displaced by other 
desired species, providing steric stabilisation of the AuNPs, and as such AuNPs can act as 
carriers to deliver a large payload of cargo to a target destination. Furthermore, because of the 
large surface area of AuNPs they can be used to carry a variety of ligands allowing them to 
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act as multi-modal probes, delivering and fluorescently reporting on the location of 
therapeutics, for example. 
 
AuNPs have interesting optical properties because they are so much smaller than wavelengths 
of visible light. Valence electrons on the surface of AuNPs will oscillate coherently when a 
certain wavelength of light is applied, giving rise to a surface plasmon resonance band which 
is in the visible range for AuNPs; this means that AuNPs have a distinct colour and can be 
analysed by the measurement of their surface plasmon resonance band in absorption 
spectroscopy. Furthermore, the density of gold allows AuNPs to be easily imaged through 
TEM, which they most commonly are. The high scattering properties of AuNPs also allow 
their detection by dark-field and fluorescence microscopy. In addition to this, when using 
surface-enhanced Raman scattering to investigate cell samples AuNPs have been used for 
signal enhancement.
84
 
 
1.4.2 Lanthanide Functionalised Gold Nanoparticles 
A large proportion of lanthanide containing nanomaterials consists of quantum dots, polymer 
based nanoparticles and silica nanoparticles, however, as previously stated, the ligand 
responsible for chelating a lanthanide ion can also contain functional groups for attachment to 
AuNPs.
102
 Work by the Pikramenou group has described the coordination of Eu
3+
 by a DTPA 
based ligand containing thiophenol groups for lanthanide sensitisation and attachment of the 
complex to the surface of AuNPs through creation of a S-Au bond, Scheme 1.11.
103
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Scheme 1.11 The use of a ligand to coordinate Eu
3+
 and attach the complex to the surface of a 
gold nanoparticle. 
 
1.4.2.1 Lanthanide Functionalised Gold Nanoparticles in Biological Sensing 
The use of AuNPs functionalised with luminescent lanthanide complexes for various sensing 
applications has been reported by Gunnlaugsson and co-workers. Initially, a europium 
complex was developed that allowed attachment to the surface of AuNPs using an alkyl thiol 
group and did not contain an antenna group for the sensitisation of the lanthanide emission.
104
 
Attachment of the complex to AuNPs resulted in a non-luminescent species, however, when a 
naphthalene β-diketone antenna was added it was found to coordinate to the lanthanide centre 
and sensitise its emission, Scheme 1.12. 
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Scheme 1.12 a) Structure of lanthanide complex and β-diketone antenna and b) non-
luminescent AuNP capped with lanthanide complex and sensitisation when antenna present. 
 
The displacement of the antenna was then investigated using various biologically relevant 
anions and was achieved by flavin monophosphate which resulted in complete quenching of 
the europium luminescence. Alternative anions were found to quench the lanthanide emission 
to a degree, but no other species offered complete quenching.
104
 This displacement assay was 
the first example of the use of such a system for sensing of biologically relevant species and 
was further developed by the group. The interaction of the system with BSA was next 
a
b
  Chapter 1
   
28 
explored and it was found that although BSA did not displace the antenna it was able to 
interact with it in such a way as to quench the europium luminescence.
105
 Furthermore, the 
introduction of ibuprofen, known to bind to site II of BSA, resulted in a recovery of the 
europium emission leading to the conclusion that BSA interacts with the antenna molecule 
through its site II region and demonstrating the possibility of sensing for species that bind to 
BSA. Introduction of warfarin, a site I marker, resulted in a further reduction of the europium 
emission, but the presence of warfarin did not affect the sensing of ibuprofen.
105
 Most 
recently, a NIR emitting lanthanide, ytterbium, has been attached to the surface of AuNPs and 
has been used as a pH sensor.
106
 In this case the same chelating ligand was used as before 
with an alkyl thiol group for attachment of the complex to AuNPs, however, xylenol orange 
was used as the antenna. Xylenol orange is pH sensitive and as such its sensitisation of 
ytterbium emission is also dependent upon pH. In this case it was found that the luminescence 
of ytterbium was “switched on” above pH 4, but “switched off” in the range pH 2-4.106 
Although this represents the possibility of using a lanthanide modified AuNP system for pH 
sensing with NIR emission, modification of the system may be required for use in practice 
because of the low luminescence quantum yield of the ytterbium centre when attached to 
AuNPs and sensitised by xylenol orange which was measured to be 0.036%.
106
 Currently, 
however, development of ratiometric sensing using AuNPs co-coated with europium and 
terbium complexes each with different external antennas and sensing of chiral species, such as 
amino acids, using AuNPs coated with chiral lanthanide complexes is being pursued.
102
 In all 
cases the assays were carried out in aqueous buffer and as such are relevant for biological 
systems although the progression from in vitro to cellular studies has not been reported to 
date. 
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Previous work by Thomas and co-workers demonstrated that AuNPs coated with a derivative 
of 2,2’-dipyridyl containing a thiol group were able to chelate and sensitise the emission of 
lanthanide ions.
107
 It was found that the ligands chelated the lanthanide ions in a 3:1 
stoichiometry which most likely consisted of ligands from more than one AuNP rather than 
cooperation between the ligands on the surface of a single AuNP. Certainly, the introduction 
of Cu
2+
 in place of lanthanide ions caused superstructures to be formed by the cooperation of 
the AuNPs to chelate the metal ions. Both Eu
3+
 and Tb
3+
 were used in the study and it was 
found that the sensitised luminescence of both species was reduced as other metal cations, 
such as Ca
2+
 and Zn
2+
, were introduced due to displacement of the lanthanide ions from the 
ligands.
107
 Although this may be of some use in detecting specific cations, the scope for 
lanthanide displacement may not extend to molecular ions and certainly the fact that the 
experiments are carried out in acetonitrile and release free lanthanide ions prevents its use in 
biological systems. 
 
1.4.2.2 Lanthanide Functionalised Gold Nanoparticles in Cellular Imaging 
As previously discussed, complexes of gadolinium are currently used as contrast agents in 
MRI. However, such contrast agents could be improved by inclusion on nanoparticles. The 
main advantages of using nanoparticles in MRI is that more gadolinium can be trapped on the 
nanoparticle surface than a single gadolinium complex and nanoparticles show a longer half-
life in the blood stream which means that nanoparticles coated with gadolinium complexes 
can ultimately deliver more contrast agent to the desired site than traditional compounds. 
Furthermore, the addition of the gadolinium complex to a larger species will slow its tumbling 
rate and further improve its contrast properties.
108-111
 Moreover, the ability to create 
multifunctionalised nanoparticles allows for the addition of a targeting moiety which will 
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allow the nanoparticle to be delivered to the site of interest more effectively. It has also been 
shown that the AuNP itself can be of use, not in MRI, but as a contrast agent in X-ray 
computed tomography, with the gold showing a strong X-ray absorption, allowing any 
gadolinium functionalised AuNPs to be useful contrast agents in two widely used medical 
imaging techniques.
112
 
 
The modification of AuNPs with luminescent lanthanide complexes and subsequent cellular 
delivery has also been reported in the literature. Pikramenou and colleagues have described 
the delivery of AuNPs decorated with luminescent europium complexes into platelet cells.
113
 
In this instance the AuNPs were also functionalised with a pH responsive peptide capable of 
inserting itself across a cell membrane at a certain pH, therefore delivering its cargo of 
nanoparticles inside the platelet cells. The europium luminescence was detected and imaged 
within the cells demonstrating its use as a biological probe in combination with AuNPs. In an 
earlier study the location of europium coated AuNPs in human epithelial lung fibroblasts was 
established through the use of high-resolution synchrotron X-ray fluorescence and they were 
found able to penetrate the nuclei of the cells.
114
 
 
1.5 Project Overview 
The aim of the work in this thesis is to explore methods for protein labelling using 
luminescent lanthanide complexes and AuNPs modified with these complexes, examining the 
interaction of these complexes and AuNPs with proteins and peptides in the process. This 
presents the opportunity to build upon protein labelling techniques that have been developed 
previously for use in vitro and inside live cells, such as the tetracysteine motifs, which could 
also be used to bind AuNPs in vivo, and attempt to address some problems associated with 
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this approach, as well as offering an alternative to the use of GFP which has been shown to be 
unstable under certain conditions. Furthermore, although the use of the biarsenical compounds 
allows for the modification of fluorescence as required, the use of functionalised AuNPs 
instead allows a truly dual-modal approach to be adopted with the potential to deliver not only 
luminescent probes to the protein of interest in the first instance, but the possibility of further 
probe or therapeutic attachment in the future. The use of luminescent lanthanide complexes, 
both free and attached to AuNPs, have been shown to be of value in biological imaging 
applications and as such both species will be utilised herein. 
 
The direct labelling of serum albumin with luminescent lanthanide complexes will be 
described and evaluated in Chapter 2, with an investigation into the possible cellular uptake of 
fluorescently labelled proteins. Chapter 3 focuses on the binding of several peptide species to 
AuNPs and their relative binding affinities. The interactions of each peptide with the AuNPs 
will enable the selection of a binding motif with the potential to bind AuNPs selectively in 
cells if expressed as part of a protein of interest. Chapter 4 begins by investigating the 
interaction of AuNPs and lanthanide modified AuNPs with protein in vitro before using the 
expression of fusion protein with the previously identified AuNP binding motif to evaluate 
the ability of luminescent AuNPs to label a protein of interest within cells.  
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2. Luminescent Lanthanide Complexes as Covalent Protein Labels 
 
2.1 Introduction 
2.1.1 Lanthanide Complexes and Protein Labelling 
It is extremely useful to be able to label proteins in order to monitor their behaviour and 
lanthanide complexes are ideal candidates for such labelling due to their luminescence 
properties which lend themselves to biological studies, as discussed in Chapter 1. Serum 
proteins such as BSA and HSA are of interest due to their abundance in the circulatory system 
of mammals, representing the bulk of protein in the blood plasma, and because of their many 
important physiological roles such as maintaining the pH of the blood and oncotic pressure 
and binding molecules such as vitamins, hormones and drugs for transport around the body.
1
 
 
2.1.2 Non-Covalent Protein Labelling 
Metal complexes can label proteins through covalent or non-covalent interactions. In the latter 
case, metal complexes can bind either specifically or non-specifically to proteins and can be 
engineered in order to exploit these two processes. For example, metal complexes can be 
synthesised to include molecules such as biotin, known to have high affinity for certain 
binding sites or receptors such as avidin, thus allowing them to target these receptor sites 
specifically.
2, 3
 Alternatively, there have been many examples of metal complexes interacting 
with proteins non-specifically, and in many cases the proteins in question have been serum 
proteins such as HSA and BSA which both present a multitude of binding opportunities. For 
example, a series of luminescent cyclometalated iridium complexes attached through a spacer 
to an indole group, Figure 2.1, was bound non-covalently to BSA. 
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Figure 2.1 Structures of luminescent cyclometalated iridium(III) indole complexes used as 
non-covalent labels for BSA. The ligands consist of either two phenylpyridine groups (1), two 
benzoquinoline groups (2), or two phenylquinoline groups (3) in combination with a 
bipyridine group connected to an indole via a short (a) or long (b) alkane chain.
4
 
 
BSA is a known indole binding protein, and as a result of binding to the protein an increase in 
the emission and lengthening of the luminescence lifetime of each complex was observed. 
This was attributed to the protein creating a hydrophobic environment around the complexes 
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and increased rigidity in the structure of the complexes upon binding.
4
 Similarly, a series of 
luminescent lanthanide complexes utilising the DOTA motif for lanthanide chelation, Figure 
2.2, were bound to HSA through non-specific interactions. 
 
 
Figure 2.2 Structures of lanthanide complexes used for non-covalent HSA binding. The 
complexes employ DOTA based chelating ligands and either biphenyl (LnL1), 
diphenylmethane (LnL2), azathiaxanthone (LnL3 and LnL4a) or azaxanthone (LnL4b) based 
antennas. In the case of LnL1 and LnL2 the antennas are also used to bridge two DOTA 
chelated lanthanide centres.
5, 6
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Unlike the cyclometalated iridium(III) complexes, the lanthanide complexes did not all show 
the same change in photophysical behaviour in the presence of a serum protein. LnL1 showed 
no change in the emission intensity of either a europium or terbium centre when interacting 
with HSA, whereas TbL2 showed a small increase in emission intensity after addition of 
HSA, but greater still was the enhancement of EuL2 emission intensity after addition of 
HSA.
5
 In all cases, for EuL3, EuL4a, EuL4b and TbL4b, the emission intensity of the 
complexes was reduced upon interaction with HSA, however, the luminescence lifetime of 
EuL2 showed a decrease where an increase was observed for EuL4a and EuL4b.
6
  
Additionally, GdL3 demonstrated increased relaxivity when bound to HSA.
6
 Indeed, it would 
be expected that the relaxivity of an MRI contrast agent would be increased through binding 
to a macromolecule such as HSA because this would slow its tumbling rate and as such non-
covalent interactions between gadolinium based MRI contrast agents and serum albumins 
have been widely studied.
7-18
 A caveat of this, however, is that a complex may bind to a 
hydrophobic pocket of a protein which will exclude solvent molecules thus reducing water 
exchange at the paramagnetic centre. Non-covalent interactions between lanthanide 
complexes and proteins can, therefore, offer insight into the potential of a complex to act as a 
protein label based on its luminescent properties or relaxivity when in the presence of the 
protein, however, they may also allow dissociation of the lanthanide complex from the protein 
when other factors are involved such as the presence of alternative proteins or binding site 
competitors and as such covalent attachment of lanthanide complexes to proteins is the focus 
of this chapter. 
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2.1.3 Covalent Protein Labelling 
Covalent labelling of proteins can occur through the selective targeting of amino acid side 
groups such as the primary amine of lysine, which is one of the most commonly targeted 
groups, the thiol of cysteine, which is one of the most reactive functional groups found within 
proteins, or the imidazole of histidine. Aldehyde groups, NHS esters and isothiocyanates are 
often used to form covalent bonds with primary amines, whereas iodoacetamide and 
maleimide groups are used for targeting thiol groups.
19
 Metal complexes coordinated with 
solvent or Cl
-
 are able to form bonds with histidine through the replacement of these ligands 
with the imidazole moiety.
20
 
 
There have been many examples of covalent conjugation of transition metal complexes to 
serum proteins through specific targeting of the thiol groups,
21-23
 or more commonly, the 
primary amine groups of the proteins.
23-27
 In addition to the work with transition metals there 
is currently much research being carried out into the development of lanthanide complexes to 
act as biological probes through covalent attachment to proteins. Again, labels are 
predominately attached through the amine groups of the protein
28-32
 most routinely using a 
complex functionalised with an NHS ester, although maleimide thiol chemistry is also used.
33, 
34
 As with the study of non-covalent interactions, some of these conjugates were studied for 
their MRI properties,
29, 30, 33, 34
 and others for their photophysical properties.
28, 31, 32
 It is 
interesting to compare two luminescent lanthanide complex designs attached to BSA via an 
NHS ester reaction, Figure 2.3. 
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Figure 2.3 Structures of lanthanide chelates used for covalent BSA binding. The ligands 
consist of either a glutamic acid structure bis-functionalised at its nitrogen atom with 
bipyridine derivatives (LnL5) or an octadentate macrotricycle bearing phthalamide groups 
(L6). In both cases the ligands were modified with an NHS ester for covalent attachment to 
BSA through its primary amine groups (LnL5b and L6b). LnL5 shows the chelation of a 
lanthanide ion by the ligand whereas L6 shows the ligand only. 
28, 31
 
 
It was found that in the case of TbL5b a shortening of the luminescence lifetime of the 
lanthanide complex was observed after conjugation to BSA in comparison to unbound TbL5a 
in solution.
31
 Similarly, a BSA conjugate of TbL6b demonstrated a shortening of 
luminescence lifetime and a decrease in luminescence quantum yield when compared with 
free TbL6a, whereas the europium complex showed the reverse in that the BSA conjugate of 
EuL6b had a higher luminescence quantum yield and longer luminescence lifetime than free 
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EuL6a.
28
 When comparing the two studies it is interesting to note that where there was an 
observed increase in luminescence lifetime and quantum yield the lanthanide centre in 
question was europium, whereas the decreases seen were for terbium complexes. One 
explanation for this may be that interaction with a serum protein excludes a coordinated water 
molecule and this would reduce any luminescence quenching caused by the water upon the 
europium centre which is known to be sensitive to this non-radiative deactivation process, 
whereas the photophysics of terbium are much more complex and as such the exclusion of 
coordinating water may not have the same impact as with europium. 
 
2.1.4 Luminescent Protein Conjugates and FRET 
In addition to the use of lanthanide complexes simply as protein labels, their luminescence 
properties and the interaction of proteins with other biomolecules can be utilised to detect 
such biomolecules via FRET. This has been demonstrated using a terbium complex attached 
to Escherichia coli dihydrofolate reductase as a donor and GFP attached to claudin-1 as an 
acceptor. In this case the interaction of the two proteins within cells was detected by the 
FRET interaction of their labels, Scheme 2.1a.
35
 More recently a similar approach has been 
used by the covalent attachment of a terbium complex donor to a specific antibody and a dye 
acceptor to another antibody both against total prostate specific antigen, Scheme 2.1b. In this 
case when the two antibodies form an immunocomplex with total prostate specific antigen 
FRET occurs between terbium and the dye which allows for the detection of total prostate 
specific antigen, a known marker for prostate cancer.
36
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Scheme 2.1 Schematic representation of FRET between a) a terbium complex and GFP when 
attached to biomolecules where eDHFR = Escherichia coli dihydrofolate reductase and b) a 
terbium complex and a dye attached to antibodies where TPSA = total prostate specific 
antigen. 
 
2.1.5 Research Aims 
The main objective of the work detailed in this chapter is the synthesis of luminescent 
lanthanide complexes and the investigation into their potential as protein labels. The 
photophysical properties of these complexes will be compared when free in solution with after 
protein conjugation in order to assess their suitability for the desired application. The 
complexes in question, Figure 2.4, employ a ligand that fulfils the criteria of lanthanide 
chelation and sensitisation as discussed in Chapter 1. Additionally the complexes possess a 
thiol group which will later be used to anchor the complexes to AuNPs; these functionalised 
AuNPs will also be used as protein labels and as such the interaction of these complexes 
directly with proteins observed here will inform further work described in Chapter 4. The 
proteins selected for conjugation are BSA because of its biological importance and κ FLC 
which will interact with a labelled anti-κ FLC mAb for FRET applications. All of the 
complexes synthesised and used in this chapter are shown in Figure 2.4. 
FRET
FRET
FRET
FRET
a) b)
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Figure 2.4 Compounds used in this chapter. 
Ln = Eu, Tb or Nd. 
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2.2 Results and Discussion 
2.2.1 Syntheses of Compounds Used 
2.2.1.1 Synthesis of H3L
a
 
Synthesis of H3L
a
 followed that previously reported by the Pikramenou group.
37
 
 
 
Scheme 2.2 Synthetic route to ligand H3L
a
. 
 
DTPA-bis(anhydride) was subjected to nucleophilic attack by 4-aminothiophenol to give 
H3L
a
 in 23% yield. Full characterisation of the ligand concurs with that published previously 
and can be found in the experimental section of this chapter.
37
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2.2.1.2 Synthesis of LnL
a
 (where Ln = Eu, Tb or Nd) 
As for the H3L
a
 ligand, the synthesis followed was as previously described by the 
Pikramenou group.
37
 
 
 
Scheme 2.3 Synthetic route to complexes LnL
a
 
Ln = Eu, Tb or Nd. 
 
The appropriate lanthanide chloride hexahydrate was stirred together with H3L
a
 resulting in 
the chelation of the lanthanide ion to give LnL
a
. The yield of each complex was as follows: 
EuL
a
 94%, TbL
a
 89% and NdL
a
 97%. Electrospray mass spectrometry of all three lanthanide 
products confirmed the formation of the complexes. 
 
2.2.1.3 Synthesis of H3L
b
 
This ligand is a modification of the previous H3L
a
 ligand where one of the thiophenol 
sensitisers is replaced by a quinoline substituent. In this case the remaining thiophenol group 
possesses a thiol which provides a reactive group for protein conjugation, whereas the 
quinoline group allows the sensitisation of the lanthanide centre at a longer wavelength than 
the thiophenol which is more appropriate for studies involving biological materials. The 
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synthesis carried out here is an adapted version of that established previously by the 
Pikramenou group.
38
 
 
 
Scheme 2.4 Synthetic route to ligand H3L
b
. 
 
The ligand was formed by nucleophilic attack of DTPA-bis(anhydride), first by 6-
aminoquinoline and then 4-aminothiophenol. It was desired that each nucleophile would 
attack one of the anhydride rings of DTPA-bis(anhydride) to give an asymmetric product, 
however, it is clearly possible that in some cases the same nucleophile may attack both 
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anhydride rings leading to the possibility of two unwanted symmetrical products being 
formed, Scheme 2.4. Indeed, the reaction did yield a mixture of H3L
a
, H3L
c
 and the desired 
species H3L
b
 which were separated by HPLC. The desired asymmetric species, H3L
b
, was 
isolated in 3% yield. The formation and isolation of H3L
b
 was confirmed by mass 
spectrometry and the aromatic region of the 
1
H-NMR spectrum revealed the asymmetric 
nature of the ligand. 
 
 
Figure 2.5 Aromatic region of the 
1
H NMR spectrum of H3L
b
. 
 
The integration of the peaks shown in Figure 2.5 indicate that there are two protons in each of 
environments a and b to every proton in environments c-h which concurs with the intended 
structure of the ligand. The NMR spectra and other analyses also agree with that observed by 
David Lewis a previous researcher in the Pikramenou group.
38
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2.2.1.4 Synthesis of EuL
b
 
As for the H3L
b
 ligand, the synthesis followed was as previously described by a member of 
the Pikramenou group.
38
 
 
 
Scheme 2.5 Synthetic route to complex EuL
b
. 
 
Europium chloride hexahydrate was stirred in solution with H3L
b
 and the pH of the solution 
raised by drop-wise addition of aqueous tetrabutylammonium hydroxide. EuL
b
 was formed 
and recovered in 59% yield. The identity of the europium complex was confirmed by mass 
spectrometry and high resolution mass spectrometry was consistent with the calculated 
composition of C29H31EuN6O8S. 
 
2.2.1.5 Synthesis of H3L
x
 
The ligand H3L
x
 was designed to chelate Eu
3+
 and sensitise its emission. Its resulting 
lanthanide complex was also indented as a control compound where EuL
b
 was used for 
protein conjugation. The single difference between the two complexes is the absence of the 
thiol group in H3L
x
 which is the group used to attach the complex EuL
b
 to proteins. 
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Scheme 2.6 Synthetic route to ligand H3L
x
. 
 
As is evident from Scheme 2.6, the synthesis of H3L
x
 was the same as that for H3L
b
 with the 
only difference being the replacement of 4-aminothiophenol with aniline in the reaction. 
HPLC was again used to isolate the asymmetric species to yield H3L
x
 in 6% yield. 
 
2.2.1.6 Synthesis of EuL
x
 
Due to the similarity of the two ligands, it was possible to chelate europium using H3L
x
 
following the same method as that described for the synthesis of EuL
b
 in section 2.2.1.4. 
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Scheme 2.7 Synthetic route to complex EuL
x
. 
 
EuL
x
 was prepared in 64% yield and its identity confirmed by electrospray mass 
spectrometry. 
 
2.2.1.7 Synthesis of NHS-MAL 
The NHS-MAL linker is used here to create a covalent link between a luminescent lanthanide 
complex and a protein molecule. It comprises of an ester of NHS which is a good leaving 
group thus allowing the formation of a peptide bond between the linker and amines in a 
protein, such as those found on lysine residues, and maleic anhydride which forms a covalent 
bond with the sulphur of the lanthanide complex used as the desired protein label. The 
synthesis followed is that previously described by Buchardt.
39
 
 
Scheme 2.8 Synthetic route to linker NHS-MAL. 
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Firstly, β-alanine underwent a condensation reaction with maleic anhydride at its N-terminal 
end before esterification at its C-terminal end with NHS to give NHS-MAL in 29% yield. 
Mass spectrometry confirmed the synthesis and isolation of the desired product and the NMR 
spectra concurred with that previously published.
39
 
 
2.2.2 Examining the Conjugation of LnL
a
 to BSA (where Ln = Eu, Tb or Nd) 
2.2.2.1 Preparation of LnL
a
-BSA 
The linker NHS-MAL was used to covalently attach LnL
a
 complexes to BSA in a two stage 
approach where first the linker was attached to BSA and then lanthanide complex was added 
subsequently. 
 
Scheme 2.9 Conjugation of LnL
a
 to the primary amine of a protein. 
Ln = Eu, Tb or Nd. 
 
BSA was dissolved in phosphate buffer at pH 7.4 and to this a concentrated solution of NHS-
MAL was added in thirty times excess. The solution was stirred gently for 1 hour at 37 ºC 
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before being passed through a Sephadex G-15 size exclusion column to remove any unbound 
linker. A solution of LnL
a
 in methanol in thirty times excess was then added to the BSA-
NHS-MAL conjugate collected from the column and gently stirred for 24 hours at room 
temperature. The solution was again passed through a size exclusion column to remove any 
free lanthanide complex and the recovered BSA-LnL
a
 conjugate was freeze-dried. 
 
2.2.2.2 Photophysical Characterisation of LnL
a
 and LnL
a
-BSA 
It is worthwhile to compare the luminescent properties of LnL
a
 complexes with those of 
LnL
a
-BSA in order to determine whether the photophysical properties of the lanthanide 
complexes are affected when used as protein labels. 
 
    
Figure 2.6 Emission spectra of LnL
a
 (Ln = Tb, Eu or Nd). Left: TbL
a
 (―) and EuLa (---) in 
methanol, λex = 266 nm, corrected for PMT response. Right: NdL
a
 (―) in deuterated 
methanol (CH3OD), λex = 280 nm. 
 
The emission spectra in Figure 2.6 show the characteristic emission peaks expected for each 
lanthanide ion in question. The results confirm that the H3L
a
 ligand is able to successfully 
sensitise lanthanide emission because otherwise the emission intensity would be very low if 
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excited through the lanthanide directly and is not possible at the short wavelengths used for 
excitation. Although the optimum excitation wavelength for the LnL
a
 complexes is at 266 
nm, as shown by the excitation spectra presented in Figure 2.8, a slightly longer excitation 
wavelength still within the excitation range of the complex, 280 nm, was used to gain an 
emission spectrum of NdL
a
; the reason for this is because the intensity of the excitation 
source used is greater at 280 nm than 266 nm causing a slight improvement in the emission 
intensity of NdL
a
 which is weak compared to EuL
a
 and TbL
a
. Additionally, NdL
a
 was 
investigated in deuterated solvent to prevent vibrational quenching caused by solvents 
containing O-H in order to improve its emission intensity, but this was not necessary for EuL
a
 
and TbL
a
. Emission spectra of LnL
a
-BSA conjugates were then obtained in the same way. 
 
    
Figure 2.7 Emission spectra of LnL
a
-BSA (Ln = Tb, Eu or Nd). Left: TbL
a
-BSA (―) and 
EuL
a
-BSA (---) in water, λex = 266 nm, corrected for PMT response. Right: NdL
a
-BSA (―) 
in D2O, λex = 280 nm. 
 
The emission spectra in Figure 2.7 indicate that the luminescence of the lanthanide complexes 
TbL
a
, EuL
a
 and NdL
a
 is unchanged when conjugated to BSA because the spectra are 
comparable to those in Figure 2.6 of the free complexes. In each case the characteristic 
emission peaks of each lanthanide species are present and in the same intensity ratios 
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displayed for the free complexes which demonstrates that the environment surrounding the 
lanthanide has changed very little upon conjugation to BSA. The most noticeable difference 
between the spectra in Figures 2.6 and 2.7 is the appearance of a sloping background to the 
terbium emission spectrum after conjugation to BSA. This is caused by the emission spectrum 
of BSA itself which extends into the region collected for terbium emission. An emission 
spectrum of BSA can be found in the appendix. 
 
Although the appearance of the lanthanide emission spectra has not changed, it would be 
interesting to ascertain whether the protein itself can have an input into the sensitisation of the 
lanthanide. In order to do this the excitation spectra of the lanthanide species was measured 
when conjugated to BSA and when free in solution. 
 
                  
Figure 2.8 Excitation spectra of LnL
a
 in methanol and LnL
a
-BSA in water. All spectra 
corrected for lamp intensity. Left: TbL
a
 (―) and TbLa-BSA (---), λem = 546 nm. Right: EuL
a
 
(―) and EuLa-BSA (---), λem = 615 nm. 
 
The excitation spectra show that the sensitisation of terbium emission does change when 
TbL
a
 is conjugated to BSA, whereas this is not the case for EuL
a
. Excitation of the 
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lanthanide emission through its chelating ligand is centred around 260 nm, however, the 
excitation broadens in the case of TbL
a
-BSA indicating that the protein, more specifically its 
tryptophan residues, is able to sensitise terbium emission. The fluorescence of tryptophan is 
known to be excited in the range of 250-300 nm and it has previously been shown that whilst 
tryptophan is able to transfer energy more efficiently to Eu
3+
 ions than Tb
3+
 ions, the transfer 
results in very efficient sensitisation of Tb
3+
 luminescence whereas the transfer to Eu
3+
 results 
in an almost entirely non-radiative decay.
40
 This effect was reported for one previously 
published study discussed in section 2.1.3; the luminescence lifetime decrease of TbL
6b
, 
Figure 2.3, was attributed to the sensitisation of terbium by the protein resulting in a short 
component to the measured lifetime, however, in this case a europium derivative was not 
studied.
31
 Indeed, there are published reports of the exploitation of tryptophan for sensitised 
terbium luminescence from terbium complexes without intrinsic antennas or terbium ions for 
biological assay applications.
41, 42
 Another article utilises tryptophan and tryptophan 
derivatives as antennas attached to a lanthanide chelating moiety; the study found that whilst 
the luminescence of chelated Tb
3+
 was sensitised by unmodified tryptophan and all 
tryptophan derivatives, chelated Eu
3+
 displayed sensitised luminescence with only one 
tryptophan derivative and not unmodified tryptophan. In the case of the modified tryptophan 
antenna that was able to elicit sensitised Eu
3+
 luminescence its emission was red shifted in 
relation to unmodified tryptophan.
43
 
 
2.2.2.3 Treatment of Neutrophil Cells with LnL
a
-BSA (Ln = Eu, Tb or Nd) 
Previous studies by the Pikramenou group have assessed flow dynamics in channels using 
luminescent nanoparticles in flow. Where the rheology of blood vessel was of interest these 
nanoparticles were observed in flow with matter from the blood present in an artificial vessel, 
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but attempts to label blood cells themselves with lanthanide labels was unsuccessful. As 
previously discussed, there are many advantages to the use of lanthanide complexes in 
biological systems, and as such it would be extremely useful to label blood cells with 
lanthanide labels in order to study their flow in vessels more easily. A possible route to 
achieve luminescent lanthanide labelling of cells is their treatment with lanthanide labelled 
BSA. Indeed, serum albumins conjugated to luminescent or radiolabels have been previously 
shown to be taken up via endocytic pathways by murine macrophage, hepatic and renal cell 
lines and human cervical and alveolar carcinoma cell lines.
4, 44-46
 Having said this, there has 
not been a report of using lanthanide labelled BSA to stain neutrophil cells in the past. 
Luminescent europium and terbium complexes have previously been used to specifically label 
cellular compartments of neutrophils, but in this case the complexes were conjugated to 
antibodies and the cells were permeabilised using a chemical reagent to allow the conjugated 
antibodies to access the cellular interior.
47
 Labelled cells were imaged using time-gated 
microscopy techniques allowing the removal of auto-fluorescence from the images and the 
separation of signal from other probes used. More recently a gadolinium complex, based on a 
DOTA chelating group, has been attached to a peptide sequence for the specific labelling of 
receptors on the surface of neutrophils in order that the cells can be tracked by MRI studies, 
however, no internalisation of the complex was observed.
48
 Lanthanide containing 
KYF4:Yb,Er nanoparticles have also recently been shown to be taken up by neutrophil cells 
resulting in bright luminescence images of the cells, however, although BSA was used to coat 
the nanoparticles, the addition of biotin to the surface of the nanoparticles was deemed to be 
the most significant factor in terms of cellular uptake.
49
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In this case neutrophils obtained from whole blood were suspended in PBS to give a cell 
count of 10
8
 mL
-1
 and to 100 μL of cells 50 μL of LnLa-BSA was added and the cells 
incubated with the labelled BSA for 1 hour at 37 ºC. The concentration of labelled BSA was 
20 mg mL
-1
 in the case of EuL
a
-BSA and NdL
a
-BSA and was 65 mg mL
-1
 in the case of 
TbL
a
-BSA. After incubation the cells were collected by centrifugation and the supernatant 
discarded, the cells were then redispersed in PBS and this process was repeated three times to 
remove any excess BSA. Finally the cells were centrifuged to form a pellet and were then 
redispersed in 100 μL of 2% paraformaldehyde. A drop of the treated cells was then placed on 
a microscope slide with a cover slip on top and epifluorescence microscopy of the samples 
executed. 
 
 
Figure 2.9 Bright field (left) and epiluminescence (right) microscope images of neutrophils 
treated with a) TbL
a
-BSA, λex = 360 nm and b) EuL
a
-BSA λex = 394 nm. Scale bar = 50 μm. 
 
a
b
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The microscope images of the cells clearly demonstrates that the neutrophils are luminescent 
following treatment with TbL
a
-BSA and EuL
a
-BSA, however, it was not possible to gain 
luminescence images of cells treated with NdL
a
-BSA. To confirm whether the luminescence 
exhibited by the cells during microscopy was from the LnL
a
-BSA the cells were diluted and a 
suspension of cells in a cuvette examined in a steady state emission spectrometer. 
 
              
Figure 2.10 Emission spectra obtained from neutrophils treated with LnL
a
-BSA. Left: TbL
a
-
BSA where λex = 266 nm (―) or 487 nm (---). Right: EuL
a
-BSA where λex = 266 nm (―) or 
578 nm (---). All spectra corrected for PMT response. 
 
The emission spectra of the neutrophils confirm that their treatment with LnL
a
-BSA has 
resulted in the uptake of the lanthanide label by the cells. The characteristic luminescence of 
both TbL
a
 and EuL
a
 is evident both with a protein fluorescence background when the 
lanthanide is sensitised through excitation of its chelating ligand at 266 nm and without the 
protein background when the lanthanide centre is excited directly, although in the latter case 
the luminescence intensity is understandably lower due to the inefficiency of directly exciting 
the lanthanide. As with the microscopy NdL
a
 emission could not be detected, but this does 
not necessarily mean that it was not taken up by the cells, rather that the detection of NIR 
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emission is not as sensitive as that used for visible. The success of luminescently labelling 
neutrophils with both TbL
a
-BSA and EuL
a
-BSA demonstrates the potential of using BSA 
covalently linked to luminescent lanthanide labels as a vehicle for label delivery in neutrophil 
cells. 
 
2.2.2.4 Calculating the Degree of Labelling of LnL
a
-BSA 
Attempts were made to obtain mass spectra of the conjugated species, however, all attempts 
were unsuccessful with all ionisation techniques utilised. It may be the case that in modifying 
the lysine residues several of the ionisation sites of the protein were blocked preventing the 
production of a sufficiently charged molecule, but needless to say another method of 
calculating the degree of labelling was necessary. The first BSA conjugate prepared was 
TbL
a
-BSA and the degree of labelling in this case was calculated by measuring the 
absorbance of the protein before and after conjugation. This was not straight forward, 
however, as the absorbance of BSA and TbL
a
 overlap considerably, as shown by their 
absorption bands in Figure 2.11, and as such the absorbance from the individual species could 
not be resolved. 
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Figure 2.11 Molar absorption coefficient versus wavelength of native BSA in aqueous 
solution (―) and TbLa in 10% methanol in water (---). 
 
Taking into account the estimated dilution of the protein through the purification steps, the 
increase in absorbance at 278 nm was assumed to be due to the presence of TbL
a
. The 
amount of ‘extra’ absorbance measured at 278 nm was then used to calculate the 
concentration of TbL
a
 in the conjugated sample, and thus, in comparison to the concentration 
of BSA, the degree of labelling. Using this method, there were calculated to be 13 TbL
a
 
labels per molecule of BSA. However, if the measured molar absorption coefficients of the 
individual species are combined in a 13:1 ratio the result does not concur with the measured 
absorbance of the conjugate. This may be due to an inaccurate calculation of the BSA 
concentration after the conjugation, so in an attempt to confirm the degree of labelling an 
aliquot of the TbL
a
-BSA conjugate was analysed using ICP-OES for terbium and sulphur. In 
this case the concentration of terbium should relate to the concentration of label in the sample 
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and using this the amount of sulphur from the label can be deducted from the total sulphur 
measured, leaving the sulphur of the protein from which the concentration of BSA can be 
calculated, however, the measurement of sulphur was too low to be detected and as such this 
calculation could not be performed. 
 
Another method used to calculate the degree of labelling was to conjugate BSA with H3L
a
, 
using the same method used for LnL
a
, titrate in a lanthanide ion and measure the increase in 
luminescence until a plateau is reached. Since it is known that each H3L
a
 ligand binds one 
lanthanide ion, the concentration of lanthanide ion required to reach this plateau should give 
the concentration of H3L
a
 conjugated to BSA. From the titration results the absorption spectra 
can be evaluated as before using the known molar absorption coefficients of the individual 
species to give a degree of labelling. The lanthanide ion chosen for the titration was Eu
3+
 
because its emission is more removed from that of BSA which eliminates much of the 
background fluorescence that would be seen if Tb
3+
 was used and its emission in the visible 
range which allows for more sensitive detection than if Nd
3+
 was used whose emission is in 
the NIR. Before the titration was carried out, a titration of Eu
3+
 into a solution of H3L
a
 was 
conducted as a proof of concept study, the results of which can be found in the appendix. In 
addition to titrating the Eu
3+
 into conjugated BSA it was also titrated into native BSA as a 
control study. 
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Figure 2.12 Integrated emission signal of H3L
a
-BSA, A0 (top left) or BSA, A0 (top right) 
subtracted from integrated emission signal when Eu
3+
 is added, A1. Integrated emission signal 
change of native BSA subtracted from integrated emission signal change of H3L
a
-BSA 
(bottom). λex = 266 nm, λem = 550-750 nm. Corrected for PMT response. 
 
If the spectrum on the top left hand side of Figure 2.12 is considered in isolation, the 
conclusion may be drawn that there is the suggestion of a plateau at a concentration of 
approximately 150 μM Eu3+ after which the emission intensity continues to increase which 
means that the titration may need to be continued using greater concentrations of Eu
3+
, 
however, the titration of Eu
3+
 into native BSA as shown in the top right hand section of Figure 
2.12 shows that when H3L
a
 is not present there is something intrinsic to native BSA that is 
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able to sensitise Eu
3+
 emission. Indeed, it is not unlikely that Eu
3+
 should bind non-
specifically to native BSA given its role of binding ions and molecules within the body, and 
as previously discussed, the tryptophan residues of native BSA are able to transfer energy to 
Eu
3+
. Whilst it was previously shown that the energy transfer of tryptophan to EuL
a
 did not 
sensitise Eu
3+
 emission, this may have been because the sensitisation of the emission was 
dominated by the chelating ligand, whereas here, in its absence or when all ligands are 
occupied, the tryptophan sensitisation of Eu
3+
 emission, however weak, is observed. It can be 
concluded, however, that the binding of Eu
3+
 to H3L
a
-BSA is much stronger than the binding 
of Eu
3+
 to native BSA. If the change in the integrated emission of native BSA upon addition 
of Eu
3+
 is subtracted from that of H3L
a
-BSA then a much clearer plateau is seen as shown at 
the bottom of Figure 2.12. Indeed, the graph at the bottom of Figure 2.12 indicates that all 
H3L
a
 ligands are occupied by europium ions once 50 μM of Eu3+ is added. However, if this 
conclusion is followed through to the say that there must, therefore, be 50 μM of H3L
a
 in the 
H3L
a
-BSA sample, the calculated absorbance of this concentration of ligand based on its 
molar absorption coefficient is far greater than that measured for the sample prior to the 
titration. This would suggest that the absorption properties of the two species, H3L
a
 and 
native BSA, at 280 nm do not linearly combine when conjugated to form H3L
a
-BSA, and as 
such this method of calculating the degree of labelling is precluded. 
 
It is entirely possible that the H3L
a
 or LnL
a
 is able to cross link two BSA molecules since the 
ligand bears two thiol groups which could facilitate attachment to two NHS-MAL linkers 
each on different protein molecules. BSA is also known to dimerise naturally, and as such, the 
dimerisation of the protein, either naturally or through cross linking by the label, may affect 
the calculation of the degree of labelling.
1
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No further attempts were made to calculate the degree of labelling of LnL
a
-BSA as all stocks 
of the conjugated samples synthesised had been depleted and plans were made to use an 
alternative label for future experiments. 
 
2.2.3 Examining the Conjugation of EuL
b
 to BSA to give A-BSA and B-BSA 
2.2.3.1 Preparation of EuL
b
-BSA Species A-BSA and B-BSA 
Whilst the experiments with LnL
a
-BSA were successful and interesting, it was decided to 
begin protein labelling work using EuL
b
 for two reasons. Firstly, EuL
b
 possesses a quinoline 
sensitiser facilitating lanthanide sensitisation at 330 nm as opposed to 266 nm used for LnL
a
, 
which is more appropriate for use with biological materials, and secondly, because only one 
thiol is present in this molecule compared to the two in LnL
a
 which allows a better 
understanding of the conjugate produced since it may have been possible for LnL
a
 to cross 
link the protein or bind with two linker molecules on a single protein. The conjugation of 
EuL
b
 to BSA was achieved in two ways, firstly, following the same procedure as that 
described for LnL
a
 in section 2.2.2.1 to give the conjugated species A-BSA, and secondly 
using this procedure with minor modification to give the conjugated species B-BSA. 
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Scheme 2.10 Conjugation of EuL
b
 to the primary amine of a protein. 
 
As shown in Scheme 2.10, a two step conjugation was again used, however, in this case an 
attempt was made to control the degree of labelling of the protein. Two conjugates of EuL
b
-
BSA were prepared; A-BSA, conjugated as described in section 2.2.2.1, and B-BSA, whose 
conjugation differed by adding at each stage compound in ten times excess compared to a 
thirty times excess used previously and by drop-wise addition of a dilute solution of NHS-
MAL over 1 hour compared to a single addition of a concentrated solution. It was anticipated 
that A-BSA should have many lanthanide labels whereas B-BSA should have relatively few 
because of the difference in the amounts of label and linker added in each case. The 
absorption spectra of the labelled species reveal a possible difference in their degree of 
labelling. 
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Figure 2.13 Left: Molar absorption coefficient vs wavelength for native BSA in aqueous 
solution (―) and EuLb in 2% methanol in water (---). Right: Absorption spectra of A-BSA 
(―) and B-BSA (---) in aqueous solution. 
 
The absorption spectra in Figure 2.13 show that whilst the absorption of both A-BSA and B-
BSA show similarities to that obtained for EuL
b
, the characteristic absorption peak of BSA at 
around 280 nm is only a feature in the spectrum of B-BSA which could indicate that there are 
considerably more labels in the A-BSA conjugate and these labels mask the BSA absorption. 
 
2.2.3.2 Calculating the Degree of Labelling of EuL
b
-BSA 
Although overlap at 280 nm in the absorption spectra of the label and the protein still exists as 
was seen with LnL
a
-BSA, attempts were made to calculate degree of labelling through 
comparison of absorbance at 280 nm with that at 330 nm since the complex absorbs at 330 
nm but the protein does not absorb much at that wavelength, however, the absorption of the 
protein at 330 nm was sufficient to affect the calculations, as shown on the left hand side of 
Figure 2.13, so the degree of labelling could still not be calculated in this way. 
 
A Bradford assay was then employed to detect the concentration of BSA of each conjugate.
50, 
51
 The Bradford assay uses the reagent Coomassie Brilliant Blue G. 
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Figure 2.14 Structure of Coomassie Brilliant Blue G. 
  
The Bradford assay relies on the change in absorbance of Coomassie Brilliant Blue G when it 
binds to protein as opposed to when in is free in solution. The reagent binds to proteins 
through their arginine and lysine residues and its absorption maxima changes from 
approximately 450 nm when free in solution to 620 nm when bound to protein, as shown by 
the spectra on the left hand side of Figure 2.15. The shift in the absorbance of the reagent is 
due to a change in its charge upon binding. In this case the ratio of absorbance of the dye at 
595/450 nm was plotted against known protein concentration in order to achieve a linear 
calibration curve. Absorption measurements were also taken of Coomassie Brilliant Blue G 
when mixed with samples of A-BSA and B-BSA at several dilutions and the results plotted on 
the calibration curve to find the concentration of BSA in each conjugate sample, as shown on 
the right hand side of Figure 2.15. The BSA concentration could then be used to calculate the 
expected absorbance from the protein and as such the measured absorbance of the sample 
could be used to calculate the concentration of label through its contribution to the measured 
absorption above that calculated to come from the protein alone. 
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Figure 2.15 Left: Absorption spectra of Brilliant Blue G in the presence of 2.1 nM BSA (―) 
and 166.4 nM BSA (---). Right: Results of the Bradford Assay for a known amount of native 
BSA (●), A-BSA (●) and B-BSA (●). 
 
From the Bradford assay results it was calculated that A-BSA contains 122 labels per BSA 
molecule and that B-BSA contains around 4.  These results do not seem reliable especially in 
the case of A-BSA because the number of calculated labels is around double the amount of 
lysine residues present in each molecule of BSA, however, the natural ability of BSA to 
dimerise may have affected this result.
1
 Furthermore, the calculated degree of labelling may 
be incorrect either because the assumption that the absorbance of the protein and label 
together is simply a linear combination of the separate species is incorrect, which has already 
been suggested by previous results, or because Coomassie Brilliant Blue G was affected by 
the presence of the labels at the lysine residues since it binds to protein through lysine and 
arginine residues. 
 
ICP-MS was carried out on both conjugates with the aim of detecting the absolute 
concentrations of europium in the samples. The absorption spectra of the samples was 
obtained before the samples were digested in acid and diluted. The measured europium 
concentration was then used to calculate the expected absorbance from the label and as such 
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this could be subtracted from that measured and from the remaining absorbance the 
concentration of BSA calculated. The calculation method can be found in the appendix. In 
this case it was calculated that there are 0.39 labels per BSA molecule in A-BSA and 0.13 in 
B-BSA. As with the results from the Bradford assay the calculated degree of labelling seems 
unlikely. The low levels of labelling in both samples do not concur with the vast difference 
seen in the absorption spectra of the two species. 
 
Another method to detect the degree of labelling is needed, but as with LnL
a
-BSA mass 
spectra of A-BSA and B-BSA could not be obtained and there has not been an attempt to 
utilise another possible method. Both the Bradford assay and ICP-MS calculations for the 
degree of labelling are based on the assumption that the absorbance of BSA and EuL
b
 is 
simply cumulative when the two species are conjugated, and perhaps this assumption is 
incorrect which is why the results are not plausible. This assumption was originally used due 
to a number of published studies basing their degree of labelling calculations of similar 
systems around it.
28, 29, 31, 32
 However, it may be the case that it is not reliable to do so since 
the local environments around the chromophores are changed upon conjugation, thus 
affecting their absorption properties.
52
 Although both methods have proved inconclusive, both 
sets of results confirm that A-BSA contains more EuL
b
 labels per BSA molecule than B-BSA 
which was the intention of using the different approaches to the conjugation reaction. 
 
2.2.3.3 Photophysical Studies of EuL
b
 
The emission spectra of EuL
b
, A-BSA and B-BSA were measured in order to establish 
whether the conjugation had affected the luminescence properties of the label. 
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Figure 2.16 Left: Emission spectra of native BSA in aqueous solution (―) and EuLb in 
methanol (---). Right: Emission spectra of A-BSA (―) and B-BSA (---) in aqueous solution. 
All spectra λex = 330 nm, corrected for PMT response. 
 
As is evident in Figure 2.16, the emission spectra of both A-BSA and B-BSA show 
characteristic Eu
3+
 emission that is unchanged from the free complex. In addition to this there 
appears to be a slight background fluorescence detected for the conjugated species which 
could be due to the fluorescence of BSA, as demonstrated by the emission spectrum obtained 
for native BSA, or light scattering caused by particulate matter in solution such as protein 
aggregates. 
 
Since the luminescent emission peaks of EuL
b
 appear unchanged when conjugated to BSA, 
the luminescence lifetime and quantum yield were also investigated to determine whether 
conjugation affects these properties. 
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Sample Φ/% τ/μs 
EuL
b
 (methanol) 2.60 ± 0.52 798 ± 80 
EuL
b
 (aq) 0.86 ± 0.17 416 ± 42 
A-BSA (aq) 0.24 ± 0.05 441 ± 44 
B-BSA (aq) 0.55 ± 0.11 562 ± 56 
Table 2.1 Luminescence quantum yield and lifetime measurements for EuL
b
, A-BSA and B-
BSA in aqueous solution and EuL
b
 in methanol. τ measurements obtained at λem = 615 nm. 
 
The luminescence quantum yield measurements show that the free complex, EuL
b
, in 
methanol has a greater quantum yield than that of the free complex in water which is similar 
to the values obtained for the conjugated species, A-BSA and B-BSA. It must be noted, 
however, that in order to compare the samples they were made so that all samples had a 
comparable absorbance at the excitation wavelength used, 330 nm; this means that the 
comparison of quantum yield measurements between free EuL
b
 and conjugated species A-
BSA and B-BSA is unfair due to the absorbance of BSA at this wavelength, as shown in 
Figure 2.13, which acts as an inner filter of the excitation light applied. It may, therefore, be 
reasonable to suggest that the quantum yield values of A-BSA and B-BSA are similar to that 
of EuL
b
 in aqueous solution. As with quantum yield, the luminescence lifetime of the 
complex is reduced in water compared to methanol, however, the results indicate that the 
species with fewer labels per molecule of BSA, B-BSA, allows some exclusion of water from 
around the lanthanide label since its lifetime is longer than for the label in A-BSA or indeed 
the free label in water. This may be because when there are fewer labels present the BSA is 
able to partially shield the label, whereas the conjugation of more labels may alter the 
conformation of BSA preventing it from behaving in this way. The corresponding 
luminescence decay curves can be found in the appendix. 
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2.2.3.4 Study of EuL
b
-BSA (A-BSA and B-BSA) Protein Conformation 
CD spectroscopy was used to assess the protein conformation when in its native form and 
when conjugated to EuL
b
. A solution of EuL
x
 was also titrated into native BSA to examine 
whether the protein does interact with the label even when there is no potential for covalent 
conjugation. 
 
    
Figure 2.17 Left: CD spectra of native BSA (―), A-BSA (―) and B-BSA (―). Right: CD 
spectra of native BSA (―) with titration of 2 equivalents (―), 4 equivalents (―), 6 
equivalents (―) and 150 equivalents (―) of EuLx. All protein samples in aqueous solution 
and added EuL
x
 in a mix of water and methanol. 
 
It is evident that B-BSA has a very similar spectrum to that of native BSA indicating that the 
structure of BSA is not perturbed with low levels of labelling. The double negative peak 
between 200-230 nm is typical of α-helical conformation and is caused by the n → π* 
transitions of the amides involved in peptide bonds.
53, 54
 A-BSA which contains a greater 
degree of labelling does not show any α-helix characteristics in the spectrum indicating that 
the higher amount of labels has affected that protein structure. When titrating EuL
x
 into BSA, 
the spectrum of BSA changes significantly with small additions of the complex, with a 
significant reduction in α-helix content after addition of 6 equivalents of complex and does 
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not subsequently change even with addition of 150 equivalents of complex. This indicates that 
the ability to covalently bind to the protein is not necessary for an interaction to occur, 
however, there is a limited availability for the number of complexes able to interact non-
covalently. Previous reports of cationic lanthanide complexes binding to HSA indicate that 
they are able to bind non-covalently with preference of one complex for a particular binding 
site within the protein.
16, 17
 EuL
x
 used here has a neutral charge, however, there is also 
precedent for neutral lanthanide complexes to bind non-covalently to BSA through either the 
replacement of coordinated water molecules with carboxylate ions belonging to the protein or 
the interaction of the aromatic groups of the complex with the protein, as is possible in this 
case.
18
 
 
2.2.3.5 Treatment of SKOV-3 Cells with EuL
b
-BSA (B-BSA) 
SKOV-3, a human ovarian cancer cell line, was treated with either B-BSA, native BSA, EuL
b
 
or a mixture of EuL
x
 and native BSA. The cells were grown on cover slips in a 6-well plate 
and were treated in all cases with a sample containing 3.9 μM BSA and/or 25.3 μM europium 
complex, although these values could only be estimated for B-BSA. The treatment was added 
to the cells in serum free media to discount the interactions of any serum proteins usually 
found in serum containing media and the cells were incubated for 16 hours at 37 ºC with the 
applied treatment. The treatment was then removed and the cells washed three times with PBS 
before the cells were fixed and mounted onto slides for microscopy. Epifluorescence 
microscopy was then carried out on the cell samples. 
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Figure 2.18 Bright field (left) and epiluminescence (right) microscope images of SKOV-3 
cells treated with (a) B-BSA, (b) EuL
b
, (c) EuL
x
 and BSA, (d) native BSA and (e) untreated. 
In all epiluminescence images λex = 330 nm and acquisition time = 100 s. Scale bar = 50 μm. 
 
The microscope images of SKOV-3 cells show that there is rather weak luminescence seen 
from cells treated with EuL
b
 alone, Figure 2.18b, and native BSA, Figure 2.18d, in fact the 
luminescence is approximately at the same level as the autofluorescence seen from untreated 
cells. This indicates that EuL
b
 is not effectively taken up by the cells when not conjugated to 
a protein and native BSA alone does not elicit a luminescence increase from the cells. On the 
other hand, luminescence of the cells treated with the conjugated species B-BSA, Figure 
2.18a, or a mixture of EuL
x
 and BSA, Figure 2.18c, show luminescence greater than the 
autofluorescence background of untreated cells, Figure 2.18e; this may suggest that the uptake 
a b
c d
e
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of lanthanide complex by SKOV-3 cells is facilitated by the presence of BSA. It was 
previously shown by CD experiments that EuL
x
 is able to interact non-covalently with BSA 
and this interaction may have been sufficient to see it taken up into cells by a similar method 
to that shown for the covalently conjugated B-BSA. The collection of emission spectra from 
the cells to confirm europium as the origin of the luminescence was not possible due to weak 
signal. As discussed in section 2.2.2.3, it has been previously demonstrated that covalent 
attachment of a fluorescent probe to serum albumin can elicit endocytic uptake of the 
conjugate by mammalian cells.
4, 45, 46
 
 
2.2.4 EuL
b
 as a FRET Donor 
In order to demonstrate the use of EuL
b
 as a luminescent probe for FRET applications it was 
covalently attached to κ FLC using the method described for B-BSA in section 2.2.3.1. The 
conjugate κ FLC-EuLb was intended to act as a donor for FluoProbes 647H, a commercially 
available protein label, which was conjugated to BUCIS 04 an anti-κ FLC mAb.55 The mAb 
labelled with FluoProbes 647H, which will hence forth be referred to as BUCIS 04-FP, and 
the κ FLC were both supplied by, and experiments carried out in collaboration with, 
Serascience. The emission and absorbance properties of the FRET pair were measured in 
order to determine whether FRET should occur if the two proteins were to interact. 
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Figure 2.19 Emission spectrum of donor κ FLC-EuLb when λex = 330 nm (―) and absorption 
spectrum of acceptor BUCIS 04-FP (---). 
 
As demonstrated in Figure 2.19, when the donor κ FLC-EuLb is excited at 330 nm it emits in 
the range of 550-750 nm which overlaps well with the absorption of the acceptor BUCIS 04-
FP. This donor acceptor pair was, therefore, deemed to be successful and as such a FRET 
experiment was carried out where increasing amounts of BUCIS 04-FP was titrated into 1 μM 
of κ FLC-EuLb and the luminescence lifetime of κ FLC-EuLb at 615 nm was measured. It 
was anticipated that the measurement of the luminescence lifetime of the donor would be 
more sensitive than the change in emission intensity of either the donor or acceptor. 
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Figure 2.20 Change in luminescence lifetime of 1 μM κ FLC-EuLb at 615 nm with additions 
of BUCIS 04-FP. 
 
The reduction of the luminescence lifetime of κ FLC-EuLb with increasing additions of 
BUCIS 04-FP is attributed to FRET between the two luminophores as their conjugated 
proteins are interacting. 
 
If the luminescence lifetime of the donor in the absence, τD
0
, and presence, τD, of transfer is 
known then the distance between the donor and acceptor, r, can be calculated using Equation 
2.1. 
  
  
 
  
 
  
   
   
 
Equation 2.1 Calculation of the distance between the donor and acceptor during FRET. 
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R0 is the Förster critical distance for the donor and acceptor in question and can be found in 
literature. In this case R0 was estimated to be 7.6 nm based on that of a europium(III) 
complex/Cy5 system since Cy5 possesses similar photophysical properties to FluoProbes 
647H.
55, 56
 Using the data collected for the antibody κ FLC-EuLb/BUCIS 04-FP system with 
each protein at equal concentrations r was calculated to be 8.2 nm which is entirely 
reasonable given the dimensions of the mAb. The mAb is approximately 15 nm from the base 
of the stem to the top of the fragment antigen-binding region which means that the acceptor 
must be positioned at least half way along the length of the stem from its base in order to 
interact with the donor on the κ FLC.57 In addition to this, the efficiency of the transfer 
between the donor and acceptor, ΦT, can be calculated using Equation 2.2.
56
 
 
     
  
  
  
Equation 2.2 Calculation of the transfer efficiency between the donor and acceptor during 
FRET. 
 
Using the data collected for the κ FLC-EuLb/BUCIS 04-FP system, ΦT was calculated to be 
0.37. The transfer efficiency is not surprising given that the distance between the donor and 
acceptor was calculated to be 8.2 nm which is larger than the Förster critical distance of the 
pair which is 7.6 nm. By definition, the transfer efficiency at the Förster critical distance is 0.5 
and as such an efficiency below this for a pair separated by a larger distance is expected. 
Recently FRET was observed between a terbium complex and two organic dyes respectively 
when the antibodies attached to the donor and acceptor came into contact when forming an 
immunocomplex, Figure 2.1b.
36
 The efficiency of transfer in this system was found to be 0.79 
when an AlexaFluor647 acceptor was used and 0.68 when a crosslinked allophycocyanin 
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acceptor was used. Whilst the efficiencies of transfer reported are greater than that found in 
this project, it must also be noted that the distances between the donor and acceptors were 
found to be shorter than the Förster critical distance of each pair. Despite achieving a lower 
transfer efficiency in the system presented here, the results show that the system is still able to 
perform as intended and, furthermore, has an advantage over the recently published system in 
that far less of the labelling species, twenty five times less, is needed in order to conjugate the 
protein successfully. 
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2.3 Conclusions 
This chapter has described the use of two new ligands and four associated lanthanide 
complexes for protein labelling applications resulting in luminescently labelled proteins 
emitting in both the visible and NIR. The interactions of the luminescent labels with the 
proteins were examined in terms of the effect of the conjugation on the photophysical 
properties of the lanthanide complexes and on the protein structure, the latter of which being 
omitted from similar studies published previously. The effect of the labelling procedure on the 
protein is of the utmost importance because its behaviour may change as a result and, 
therefore, studies of the labelled protein may give misleading results. In this study, where a 
strategy was employed to obtain a low degree of labelling of the protein, the structure of the 
protein was unaffected by the conjugation. The lanthanide labels proved to maintain their 
luminescent properties upon conjugation, providing evidence of their potential to serve as 
luminescent protein labels. Furthermore, the conjugated species were shown to facilitate the 
uptake of luminescent lanthanide complexes by neutrophil and ovarian cancer cells which 
provides a new and alternative route to other disruptive methods for treating cells with 
membrane impermeable lanthanide complexes. EuL
b
 was also shown to not only participate 
in FRET within an appropriate system, but to respond to acceptor in a concentration 
dependent manner leading to the opportunity for the development of a bioassay. 
 
Although protein labelling using lanthanide complexes has been shown to be successful, 
improvements could be made on the work presented here by modifying the lanthanide probe 
in order to increase luminescence intensity through the utilisation of alternative antenna 
groups. This would certainly enhance the use of lanthanide complexes and conjugates for 
microscopy work as it would enable a reduction in the long exposure times currently needed 
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due to the weak luminescence exhibited LnL
a
, EuL
b
 and EuL
x
, thus reducing the potential of 
cell damage caused by the incident light. Furthermore, it would be beneficial to optimise the 
method used for conjugation of the lanthanide complexes to proteins in order to reduce the 
labelling time required which is currently 25 hours in total. 
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2.4 Experimental 
2.4.1 General Considerations 
Starting materials were obtained from Sigma Aldrich, Fluka, Fisher Scientific, Invitrogen, 
Sarstedt or Vector Laboratories and used without further purification unless otherwise stated. 
 
1
H NMR were recorded on Bruker AVIII300 and 
13
C NMR on Bruker AVIII400 
spectrometers with SiMe4 as an external reference. 
 
MALDI-TOF mass spectrometry was carried out on a Waters MALDI Micro MX mass 
spectrometer, using gentisic acid matrix. Electrospray mass spectrometry was carried out on a 
Micromass LC-TOF. 
 
HPLC was carried out on a Dionex summit system, using a Summit P580 quarternary low 
pressure gradient pump with built-in vacuum degasser. The detector was a Summit UVD 170s 
UV-Vis multi-channel detector with a preparative flow cell.  The column used was the 
Phenomenex Luna 10 μm particle size C18 preparative column. All solvents used were HPLC 
grade solvents, degassed prior to use. 
 
UV-Vis absorption spectra were carried out on Varian Cary 50 or Varian Cary 5000 
spectrometers. UV-Vis spectra were taken using 1 cm path length quartz cuvettes. 
 
CD spectra were obtained using a JASCO J180 spectropolarimeter. CD spectra were recorded 
using 1 cm path length quartz cuvettes.  
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ICP-OES and ICP-MS analysis were both undertaken at the University of Warwick, UK. ICP-
OES was conducted using a Perkin-Elmer 5300DV ICP-OES system. ICP-MS was conducted 
using an Agilent 7500cx LC-ICP-MS system. PlasmaCal calibration standards for europium, 
terbium, and sulphur were purchased from SCP science. 
 
Quantum yield measurements were made using the optically dilute relative method and 
calculated using the following equation
58
: 
      
      
      
  
      
      
  
  
 
   
  
  
  
  
Where r denotes reference, x denotes sample, Φ = quantum yield, A(λ) = absorbance at 
wavelength used for excitation, I(λ) = intensity of excitation light at wavelength used, n = 
refractive index of solvent and D = integrated area of emission spectrum. In this case the 
reference used was a solution of ruthenium(II) tris(bipyridine) dichloride in water. 
 
Elemental analyses were performed by MEDAC Ltd, Surrey, UK. Samples were prepared by 
drying in vacuo using a diffusion pump, however, part of the glass apparatus connected to the 
pump was broken after the samples were dried allowing the hygroscopic samples to be 
exposed to the air which may have led to the high water content of the samples. The data was 
fitted by adding solvent molecules used throughout the syntheses in various combinations 
until the calculated composition was as close as possible to that measured. 
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2.4.2 Chemical Syntheses 
2.4.2.1 Synthesis of 1,11-(bis(4-amidothiophenol)-1,11-dioxo-3,6,9-triaza-3-6-
9,triscarboxymethyl)undecane, H3L
a
 
 
All solvents were degassed before use. DTPA-bis(anhydride) (1.02 g, 2.8 mmol) was stirred 
in anhydrous pyridine (10 mL) to create a suspension into which 4-aminothiophenol (2.0 g 16 
mmol) was added and left to stir under nitrogen for 2 days. The yellow solution was filtered 
and the filtrate solvent removed in vacuo to give a thick yellow oil. Water (~20 mL) was 
added to dissolve the oil which dissolved upon stirring to give a dark yellow solution. To the 
stirring solution, which was at pH 5, conc. HCl was added drop-wise under a stream of 
nitrogen until pH 3 was reached at which point the solution became clear and colourless and a 
sticky yellow solid formed at the bottom of the flask. The solid was washed with water (10 
mL) and acetonitrile (2 x 25 mL). Acetonitrile (50 mL) was added to the solid and stirred 
under nitrogen overnight to yield a white powder. The solid was allowed to settle and most of 
the acetonitrile decanted off before a further 40 mL was added and stirred under nitrogen for a 
further 1.5 h. The solid was collected by suction filtration under nitrogen and washed with 
acetonitrile (2 x 10 mL) and diethyl ether (2 x 20 mL). The fine white powder was dissolved 
in anhydrous pyridine (20 mL) to give a yellow solution to which hydrazine monohydrate (3 
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mL) was added drop-wise. Solvent was removed in vacuo leaving a yellow oil. Water (10 
mL) was added to dissolve the oil to give a cloudy solution which was filtered under nitrogen. 
HCl was added drop-wise to the solution until pH 3 was reached, at which point the solution 
became clear and colourless leaving a white solid at the bottom of the flask. The water was 
removed and solid allowed to stir under nitrogen in acetonitrile for 1h. The solid was allowed 
to settle and the acetonitrile decanted before the solid was washed with acetonitrile (2 x 15 
mL) and left to stir under nitrogen in acetonitrile (50 mL) overnight. The white powder 
formed was collected by vacuum filtration under nitrogen and washed with acetonitrile (2 x 
10 mL) and diethyl ether (2 x 20 mL). The resulting white powder was dried under vacuum to 
give H3L
a
 (0.4 g, 23% yield). 
1
H NMR (300 MHz, MeOH-d4), δ ppm: 7.42 (4H, d, 
3
J = 9.0 
Hz, Hb); 7.15 (4H, d, 
3
J = 9.0 Hz, Ha); 4.19 (2H, s, Hg); 3.64 (4H, s, Hd); 3.61 (4H, s, Hc); 
3.52 (4H, t,
 3
J = 5.6 Hz, He); 3.26 (4H, t,
 3
J = 5.6 Hz, Hf). 
13
C NMR {
1
H} PENDANT (400 
MHz, D2O), δ ppm: 174.7 (1C, C12); 171.5 (2C, C8); 168.3 (2C, C5); 132.5 (2C, C4); 130.8 
(4C, C2); 123.8 (2C, C1); 122.0 (4C, C3); 58.0 (1C, C11); 56.2 (2C, C7); 55.2 (2C, C6); 54.6 
(2C, C9); 54.2 (2C, C10). MS (ES-TOF
+
): m/z 608 {M + H}
+
, 630 {M + Na}
+
, 670 {M + Cu}
+
. 
UV-Vis (MeOH) λmax nm (log ε): 264 (4.4). All data agree with that previously published and 
as such no further analysis was required.
37
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2.4.2.2 Synthesis of LnL
a
 where Ln = Eu, Tb or Nd. 
 
 
2.4.2.2.1 Synthesis of EuL
a
 
All solvents were degassed prior to use. Europium chloride hexahydrate (0.06 g, 0.16 mmol) 
was dissolved in methanol (3 mL). H3L
a
 (0.1 g, 0.16 mmol) was added to the solution and 
sonicated until all of the ligand had dissolved. Acetonitrile (30 mL) was added to the solution 
to yield a white solid which was collected by suction filtration under nitrogen and washed 
with acetonitrile and diethyl ether. The isolated solid was dried under vacuum to give EuL
a
 
(114 mg, 94% yield). MS (ES-TOF
+
): m/z 758 {M + H}
+
. HRMS (ES-TOF) calc. for 
C26H27EuN5O8S2: 754.0513. Found: 754.0510. UV-Vis (MeOH) λmax nm (log ε): 266 (4.4). 
All data agree with that previously published and as such no further analysis was required.
37
 
 
2.4.2.2.2 Synthesis of TbL
a
 
All solvents were degassed prior to use. Terbium chloride hexahydrate (0.12 g, 0.32 mmol) 
was dissolved in methanol (3 mL). H3L
a
 (0.2 g, 0.33 mmol) was added to the solution and 
sonicated until all of the ligand had dissolved. Acetonitrile (30 mL) was added to the solution 
to yield a white solid which was collected by suction filtration under nitrogen and washed 
with acetonitrile and diethyl ether. The isolated solid was dried under vacuum to give TbL
a
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(224 mg, 89% yield). MS (ES-TOF
-
): m/z 762 {M – H}-. UV-Vis (MeOH) λmax nm (log ε): 
266 (4.7). All data agree with that previously published and as such no further analysis was 
required.
37
 
 
2.4.2.2.3 Synthesis of NdL
a
 
All solvents used were degassed prior to synthesis. Neodymium chloride hexahydrate (34 mg, 
0.1 mmol) was dissolved in methanol (3 mL). H3L
a
 (58 mg, 0.01 mmol) was added to the 
solution and sonicated until all of the ligand had dissolved. The solution was added drop-wise 
to ice cold acetonitrile (30 mL) to yield a white solid which was collected by suction filtration 
under nitrogen and washed with acetonitrile and diethyl ether. The isolated solid was dried 
under vacuum to give NdL
a
 (67 mg, 97%). MS (ES-TOF
+
): m/z 749 {M + H}
+
. UV-Vis 
(MeOH) λmax nm (log ε): 266 (4.3). All data agree with that previously published and as 
such no further analysis was required.
37
 
 
2.4.2.3 Synthesis of H3L
b 
2.4.2.3.1 Preparation of Crude H3L
b
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All solvents were degassed before use. 4-aminothiolphenol was distilled at 200 °C at high 
pressure using Kugelrohr distillation to yield an off white solid (1.5 g) which was stored 
under nitrogen at -20 °C until use. 
 
DTPA-bis(anhydride) (4.3 g, 12 mmol) was stirred in anhydrous pyridine (100 mL) to create 
a suspension into which 6-aminoquinoline (1.7 g, 11.9 mmol) was added and left to stir under 
nitrogen for 45 min. 4-aminothiolphenol (1.5 g, 12.3 mmol) was added to the solution and 
stirring continued under nitrogen for a further 2 h. Water (80 mL) was added to quench the 
reaction and the solution stirred for 30 min under nitrogen. The solvent was removed in vacuo 
to give a sticky orange solid to which water (~150 mL) was added before the mixture was 
filtered under gravity to give a clear yellow solution. Conc. HCl was added drop-wise to the 
solution under a stream of nitrogen until pH 3 was reached at which point a yellow precipitate 
was formed. The clear yellow aqueous layer was decanted to leave a yellow solid that was 
washed with water (50 mL) and acetonitrile (50 mL) before being triturated in acetonitrile for 
two days under nitrogen. A bright yellow powder was formed and was collected by suction 
filtration and washed with acetonitrile (2 x 50 mL) and diethyl ether (2 x 50 mL). The 
resulting yellow powder was dried under vacuum to give a mixture, Scheme 2.4, of H3L
a
, 
H3L
c
 and the desired species H3L
b
 (2 g, 27%). MS (ES-TOF
+
): m/z 608 {H3L
a
 + H}
+
, 627 
{H3L
b
 + H}
+
, 630 {H3L
a
 + Na}
+
, 646 {H3L
c
 + H}
+
, 649 {H3L
b
 + Na}
+
, 668 {H3L
c
 + Na}
+
. 
 
2.4.2.3.2 Isolation of H3L
b
 
The asymmetric species H3L
b
 was separated from the symmetric species, H3L
a
 and H3L
c
 using 
HPLC. Prior to injection onto the column the sample was dissolved in tetrahydrofuran/water 
(1:1) and an excess of tris(2-carboxyethyl)phosphine hydrochloride was added to reduce any 
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disulphide bonds. The optimum set up for separation was found to be injection of a 1 mL 
aliquot of 100 mg/mL reduced sample onto a preparative HPLC system using a Luna C18 
reverse phase column running a water/acetone gradient (0-75% acetone over 30 mins) at 8 
mL/min. Solvents used contained 0.05% trifluoroacetic acid. Monitoring the absorbance at 
210 nm and 336 nm allowed detection of each species as eluted. After a complete run the 
column was washed with acetone and water before injection repeated. Three peaks eluted, 
peak 1 at 11 min, peak 2 at 17 min and peak 3 at 25 min and were identified using mass 
spectrometry (MALDI-TOF
+
). H3L
b
 was contained in peak 2 (m/z 626 {M + H}
+
), peak 1 
contained H3L
c
 (m/z 646 {M + H}
+
) and peak 3 contained H3L
a
 (m/z 608 {M + H}
+
). Peak 2 
was collected and solvent removed in vacuo to afford a yellow solid that was dried further in 
vacuo to yield H3L
b
 (60 mg, 3%). 
1
H NMR (300 MHz, D2O), δ ppm: 8.46 (1H, dd,
 3
J = 4.4 
Hz,
 4
J = 1.6 Hz, Hk); 8.02 (1H, m, Hi); 7.79 (1H, d, 
4
J = 2.3 Hz, Hh); 7.74 (1H, d,
 3
J = 9.1 Hz, 
Hl); 7.54 (1H, dd,
 3
J = 9.1 Hz,
 4
J = 2.3 Hz, Hm); 7.23 (1H, m, Hj); 7.00 (2H, d,
 3
J = 8.5 Hz, 
Hb); 6.66 (2H, d, 
3
J = 8.5 Hz, Ha); 3.18 (2H, s, Hc); 3.08 (2H, s, Hc); 2.95-2.91 (6H, comp, 
Hd,g); 2.52 (8H, t,
 3
J = 11.0 Hz, He,f). 
13
C NMR {
1
H} PENDANT (400 MHz, MeOH-d4), δ 
ppm: 179.5 (1C, C12); 173.6 (2C, C8); 172.3 (2C, C5); 149.4 (1C, C18); 144.1 (1C, C19); 142.5 
(1C, C13); 141.9 (1C, C4); 137.2 (1C, C16); 135.3 (1C, C21); 133.0 (1C, C15); 130.4 (2C, C2); 
128.3 (1C, C1); 124.8 (1C, C20); 121.9 (2C, C3); 121.6 (1C, C14); 117.9 (1C, C17); 59.5 (3C, 
C7,11); 59.2 (2C, C6); 58.8 (2C, C9); 58.3 (2C, C10). MS (MALDI-TOF
+
): m/z 626 {M + H}
+
. 
UV-Vis (MeOH) λmax nm (log ε) 248 (4.7), 330 (3.6). All data agree with that previously 
reported and as such no further analysis was required.
38
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2.4.2.4 Synthesis of EuL
b
 
 
All solvents were degassed prior to use. Europium chloride hexahydrate (23 mg, 0.06 mmol) 
was added to a stirring solution of H3L
b
 (23 mg, 0.06 mmol) in water (5 mL). The pH of the 
solution was raised to pH 5 by drop-wise addition of aqueous tetrabutylammonium hydroxide 
(40% w/v) solution under a stream of nitrogen. The volume of the solution was reduced in 
vacuo to <1 mL and acetonitrile was added (30 mL) to yield a precipitate. The solid was 
recovered by suction filtration under nitrogen and washed with acetonitrile (2 x 10 mL) and 
diethyl ether (2 x 10 mL). The resulting off white powder was dried in vacuo to yield EuL
b
 
(29 mg, 59%). MS (MALDI-TOF
+
) m/z 776 {M + H}
+
, 798 {M + Na}
+
. HRMS (ES-TOF) 
calc. for C29H31EuN6O8S: 776.1137. Found: 776.1149. UV-Vis (MeOH) λmax nm (log ε) 247 
(4.5), 328 (3.5). All data agree with that previously reported and as such no further analysis 
was required.
38
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2.4.2.5 Synthesis of H3L
x 
2.4.2.5.1 Preparation of Crude H3L
x
 
 
DTPA-bis(anhydride) (0.99g, 2.8 mmol) was stirred in anhydrous pyridine (100 mL) to which 
6-aminoquinoline (0.4 g, 2.8 mmol) was added and stirring continued for 45 min under 
nitrogen. Aniline (0.26 g, 2.7 mmol) was then added to the cloudy yellow solution and stirred 
for 2 h under nitrogen. Water (80 mL) was added to quench the reaction and the solution 
stirred for 30 min under nitrogen. Solvent was then removed in vacuo to give a sticky orange 
solid that was dissolved in water (~100 mL) and pH lowered to pH 3 by drop-wise addition of 
conc. HCl. The volume of the solution was reduced in vacuo before addition of acetonitrile 
(100 mL) which produced a bright yellow precipitate. Once the precipitate had settled the 
acetonitrile was decanted before addition of fresh acetonitrile and the solid was triturated for 
several hours under nitrogen. Solid was isolated by suction filtration, washed with acetonitrile 
(2 x 25 mL) and diethyl ether (2 x 25 mL). The resulting yellow powder was dried under 
vacuum to give a mixture, Scheme 2.6, of H3L
y
, H3L
z
 and the desired species H3L
x
 (0.87 g, 
54%). MS (MALDI-TOF
+
): m/z 544 {H3L
y
 + H}
+
, 566 {H3L
y
 + Na}
+
, 582 {H3L
y
 + K}
+
, 595 
{H3L
x
 + H}
+
, 617 {H3L
x
 + Na}
+
, 633 {H3L
x
 + K}
+
, 646 {H3L
z
 + H}
+
, 668 {H3L
z
 + Na}
+
, 684 
{H3L
z
 + K}+. 
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2.4.2.5.2 Isolation of H3L
x
 
The asymmetric species H3L
x
 was separated from the symmetric species, H3L
y
 and H3L
z
 using 
HPLC. The optimum set up for separation was found to be injection of a 1 mL aliquot of 100 
mg/mL sample in tetrahydrofuran/water (1:1) onto a preparative HPLC system using a Luna 
C18 reverse phase column running a water/acetone gradient (0-75% acetone over 30 mins) at 8 
mL/min. Solvents used contained 0.05% trifluoroacetic acid. Monitoring the absorbance at 
210 nm and 336 nm allowed detection of each species as eluted. After a complete run the 
column was washed with acetone and water before injection repeated. Three peaks eluted, 
peak 1 at 13 min, peak 2 at 17 min and peak 3 at 25 min and were identified using mass 
spectrometry (MALDI-TOF
+
). H3L
x
 was contained in peak 2 (m/z 595 {M + H}
+
), peak 1 
contained H3L
z
 (m/z 646 {M + H}
+
) and peak 3 contained H3L
y
 (m/z 544 {M + H}
+
). Peak 2 
was collected and solvent removed in vacuo to give a yellow oil that was dissolved in water. 
Aqueous tetrabutylammonium hydroxide solution (40% w/v) was added drop-wise until the 
solution reached pH 3. Volume reduced in vacuo and ice cold acetone (~100 mL) added to 
produce a precipitate that was collected by suction filtration, washed with acetone (2 x 25 
mL) and diethyl ether (2 x 25 mL) to afford the off white powder H3L
x
 (97 mg, 6%). 
1
H 
NMR (300 MHz, D2O), δ ppm: 8.39 (1H, dd, 
3
J = 4.4 Hz, 
4
J = 1.6 Hz, Hl); 7.91 (1H, d, 
3
J = 
8.2 Hz, Hj); 7.71 (1H, d,
 4
J = 2.3 Hz, Hi); 7.61 (1H, d, 
3
J = 9.0 Hz, Hm); 7.45 (1H, dd,
 3
J = 9.0 
Hz, 
4
J = 2.3 Hz, Hn); 7.17 (1H, m, Hk); 6.99 (2H, m, Hc); 6.84 (3H, m, Ha,b); 3.12 (2H, s, Hd); 
3.04 (2H, s, Hd); 3.02-2.79 (6H, comp, He,h); 2.51 (8H, br t, Hf,g). 
13
C NMR {
1
H} PENDANT 
(400 MHz, D2O), δ ppm: 179.3 (1C, C12); 173.3 (2C, C8); 172.7 (2C, C5); 149.1 (1C, C18); 
143.9 (1C, C19); 141.7 (1C, C13); 137.1 (1C, C4); 136.4 (1C, C16); 136.1 (1C, C21); 128.9 (1C, 
C15); 128.4 (2C, C2); 128.2 (1C, C1); 125.1 (1C, C20); 121.8 (2C, C3); 121.1 (1C, C14); 117.7 
(1C, C17); 59.5 (1C, C11); 59.1 (2C, C7) 58.9 (2C, C6); 58.8 (2C, C9); 58.3 (2C, C10). MS 
  Chapter 2
   
97 
(MALDI-TOF
+
): m/z 595 {M + H}
+
. UV-Vis (MeOH) λmax nm (log ε) 247 (4.6), 332 (3.5). 
Anal. calc. for C29H34N6O8(H2O)2.8 C: 54.0; H: 6.2; N: 13.0. Found C: 54.2; H: 5.7; N: 12.6. 
 
2.4.2.6 Synthesis of EuL
x
 
 
H3L
x
 (50 mg, 0.08 mmol) was added to a stirring solution of europium chloride hexahydrate 
(28.4 mg, 0.08 mmol) in water (3 mL). The pH of the solution was raised to pH 5 by drop-
wise addition of aqueous tetrabutylammonium hydroxide (40% w/v). The volume of the 
solution was reduced in vacuo to <1 mL to which ice cold acetone was added (30 mL) to yield 
a precipitate. The solid was recovered by suction filtration and washed with acetone (2 x 10 
mL) and diethyl ether (2 x 10 mL). The resulting off white powder was dried in vacuo to yield 
EuL
x
 (37 mg, 64%). MS (ES-TOF
+
) m/z 767 {M + Na}
+
. UV-Vis (MeOH) λmax nm (log ε) 
246 (4.5), 329 (3.3). Anal. calc. for C29H31EuN6O8(H2O)11.6 C: 36.6; H: 5.7; N: 8.8. Found C: 
36.2; H: 4.4; N: 8.2. 
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2.4.2.7 Synthesis of NHS-MAL 
 
Maleic anhydride (1.01 g, 10 mmol) and β-alanine (0.91 g, 10 mmol) were added to degassed 
DMF (10 mL) and heated until all solid had dissolved to give a yellow solution before stirring 
at room temperature for 1 h. The solution was cooled in an ice bath and N-
hydroxysuccinimide (1.45 g, 13 mmol) and DCC (4.12 g, 20 mmol) added and the solution 
stirred in the ice bath for a further 4 min. The ice bath was then removed and the solution 
stirred at room temperature for 4 h, during which time the cloudy yellow solution became 
very thick and had to be manually stirred periodically to release the stirrer bar. The solution 
was filtered under gravity and washed with DMF. The yellow/brown filtrate was mixed with 
water and an extraction with dichloromethane (2 x 50 mL) performed. The solution was dried 
with Na2CO3 and filtered under gravity. The volume of the filtrate was reduced in vacuo to 
give a brown oil. The oil was dissolved in dichloromethane and added drop-wise to petroleum 
ether 40 °C – 60 °C causing the product to precipitate as a white solid which was collected by 
filtration under gravity. The resulting off-white solid was dried under vacuum to give NHS-
MAL (0.8g, 29%). 
1
H NMR (300 MHz, CHCl3-d), δ ppm: 6.75 (2H, s, Ha); 3.95 (2H, t, 
3
J = 
6.9 Hz, Hc); 3.02 (2H, t,
 3
J = 7.0 Hz, Hb); 2.80 (4H, s, Hd). 
13
C NMR {
1
H} PENDANT (400 
MHz, DMSO-d6), δ ppm: 171.0 (2C, C2); 170.4 (2C, C6); 167.2 (1C, C5); 135.1 (2C, C1); 33.2 
(1C, C3); 29.5 (1C, C4); 25.8 (2C, C7). MS (ES-TOF
+
): m/z 289 {M + Na}
+
. UV-Vis (MeOH) 
λmax nm (log ε) 262 (3.0). All data agree with that previously published and as such no further 
analysis was required.
39
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2.4.3 Conjugation of LnL Labels to Proteins 
2.4.3.1 Conjugation of LnL
a
 to BSA 
BSA (2 mg, 32 nmol) was dissolved in NaCl/Na2HPO4 buffer (1 mL) at pH 7.4. To this a 
solution of NHS-MAL in dimethyl sulphoxide (30 μL, 102 mM) was added and the reaction 
mixture stirred gently for 1 h at 37 ºC. The solution was then passed through a Sephadex G-15 
size exclusion column and the fraction containing BSA collected and confirmed via UV-Vis. 
The BSA containing fraction was then stirred with a solution of LnL
a
 in methanol (150 μL, 
10 mM) for 24 h at room temperature. The solution was then passed through a Sephadex G-15 
size exclusion column and the fraction containing the LnL
a
-BSA was identified using UV-
Vis, collected and lyophilised. 
 
2.4.3.2 Conjugation of EuL
b
 to BSA (A-BSA) 
BSA (0.66 mg, 10 nmol) was dissolved in NaCl/Na2HPO4 buffer (0.5 mL) at pH 7.4. To this a 
solution of NHS-MAL in dimethyl sulphoxide (3 μL, 102 mM) was added and the reaction 
mixture stirred gently for 1 h at 37 ºC. The solution was then passed through a HiTrap column 
and the fraction containing BSA collected. The BSA containing fraction was then stirred with 
a solution of EuL
b
 in methanol (750 μL, 13 mM) for 24 h at room temperature. The volume 
of the solution was then reduced to <2 mL in vacuo and passed through a HiTrap column and 
the fraction containing the A-BSA was collected and lyophilised. 
 
2.4.3.3 Conjugation of EuL
b
 to BSA (B-BSA) 
BSA (2 mg, 32 nmol) was dissolved in NaCl/Na2HPO4 buffer (0.5 mL) at pH 7.4. To this a 
solution of NHS-MAL in 0.3% dimethyl sulphoxide (1 mL, 0.3 mM) was added drop-wise to 
the BSA solution as it was gently stirred over 1 h at 37 ºC. The solution was then passed 
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through a HiTrap column and the fraction containing BSA collected. The BSA containing 
fraction was then stirred with a solution of EuL
b
 in methanol (250 μL, 13 mM) for 24 h at 
room temperature. The volume of the solution was then reduced to <2 mL in vacuo and 
passed through a HiTrap column and the fraction containing the B-BSA was collected and 
lyophilised. 
 
2.4.3.4 Conjugation of EuL
b
 to κ FLC 
A solution of κ FLC in PBS (250 μL, 0.04 mM) was sterile filtered (0.2 μm) and added to a 
round bottom flask. To this a sterile filtered (0.2 μm) solution of NHS-MAL in 0.3% 
dimethyl sulphoxide (1 mL, 0.3 mM) was added drop-wise to the κ FLC solution as it was 
gently stirred over 1 h at 37 ºC. The solution was then passed through a HiTrap column and 
the fraction containing κ FLC collected. The κ FLC containing fraction was then stirred with a 
sterile filtered (0.2 μm) solution of EuLb in methanol (8 μL, 36 mM) for 24 h at room 
temperature. The solution was passed through a HiTrap column and the fraction containing 
the κ FLC-EuLb was collected. 
 
2.4.4 Cell Studies 
2.4.4.1 Neutrophil Studies 
2.4.4.1.1 Collection of Neutrophil Cells 
Neutrophils were collected by the research group of Professor Gerard Nash, University of 
Birmingham, UK, as described previously.
59
 Neutrophil cells were isolated from a sample of 
whole human blood collected in ethylenediaminetetraacetic acid coated tubes. Histopaque 
1119 (2.5 mL) was added to a 10 mL tube onto which Histopaque 1077 (2.5 mL) was added 
before gently layering blood (5 mL) on top. The tube was centrifuged at 700 x g for 50 min at 
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room temperature. The layer containing neutrophils was recovered and washed twice by 
centrifugation at 250 x g for 5 min. The cells were counted and the cell viability established 
via tryptan blue exclusion. Neutrophil cells were then redispersed in PBS to give 10
8
 cells 
mL
-1
. 
 
2.4.4.1.2 Treatment of Neutrophil Cells 
To each of three separate sample tubes neutrophil cells (100 μL) were added. To one tube a 
solution of EuL
a
-BSA in PBS (50 μL, 20 mg mL-1) was then added, to another a solution of 
NdL
a
-BSA in PBS (50 μL, 20 mg mL-1) was added and to the remaining tube a solution of 
TbL
a
-BSA in PBS (50 μL, 65 mg mL-1) was added. Following the addition of LnLa-BSA the 
cells were incubated for 1 h at 37 ºC. 
 
2.4.4.1.3 Preparation of Neutrophil Cells for Microscopy 
Following treatment the cells were isolated by centrifugation before being redispersed in PBS 
and the process repeated three times to wash the cells. A pellet of cells was then collected by 
centrifugation and redispersed in a solution of 2% paraformaldehyde to fix the cells. A drop 
of fixed cells was added to a glass slide and a cover slip placed on top. 
 
2.4.4.1.4 Microscopy of Neutrophil Cells 
Epiluminescence microscopy was carried out using an Edinburgh Instruments fluorescence 
system, FLSPM920, with a 450 W xenon arc lamp excitation source coupled to an Olympus 
IX71 inverted microscope with a LUCPLFLN 40 x 0.60 NA objective. A Hamamatsu 
EMCCD C9100-13 detected luminescence images and all images were obtained using 
Olympus Soft Imaging Solutions GmBH Cell^M 3.2 software. 
  Chapter 2
   
102 
Luminescence images of cells treated with EuL
a
-BSA were gained by excitation of the 
sample with 394 nm light and 5000 ms exposure time. Luminescence images of cells treated 
with TbL
a
-BSA were gained by excitation of the sample with 360 nm light and 10000 ms 
exposure time. 
 
2.4.4.2 SKOV-3 Studies 
2.4.4.2.1 SKOV-3 Cell Culture Maintenance 
SKOV-3 cells were grown in complete media (5 mL) in T25 flasks with vented caps in an 
incubator at 37 ˚C containing 5% CO2. Complete media consisted of Roswell Park Memorial 
Institute-1640 Medium supplemented with foetal bovine serum (10%), L-glutamine (1%) and 
streptomycin/penicillin (1%). Cell passage was carried out every 3-4 days by washing with 
PBS and detachment using trypsin followed by dilution in complete media and adding to 
either a fresh T25 flask or 6-well plates. 
 
2.4.4.2.2 Treatment of SKOV-3 Cells 
3 mL of cell solution after passage was added to each well of a 6-well plate also containing a 
glass cover slip and cells incubated at 37 ˚C in a 5% CO2 atmosphere for 24 h prior to further 
treatment. The media was then removed from the wells and the cells washed with PBS before 
addition of sample solutions (2 mL) to each well. Sample solutions were made by dissolving 
the desired sample in serum-free media containing L-glutamine (1%) and 
streptomycin/penicillin (1%). Treatments consisted of B-BSA (0.56 mg, 7.8 nmol, [Eu] ~ 50 
nmol), native BSA (0.52 mg, 7.8 nmol), EuL
b
 (0.04 mg, 50 nmol) or a mixture of native BSA 
(0.52 mg, 7.8 nmol) and EuL
x
 (0.04 mg, 50 nmol). As a control serum free media alone was 
also added to separate wells. The cells were then returned to incubate at 37 ºC for 16 h. 
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2.4.4.2.3 Fixing and Mounting SKOV-3 Cells 
Once treatments were complete media was removed from the cells and cells washed with 
PBS. Ice cold methanol (1 mL) was added to each well and cells kept at -20 ºC for 10 min. 
Methanol was then removed and cover slips were placed cells down onto a drop of 
VectaMount mounting medium on a glass slide. The slides were sealed with varnish, 
refrigerated flat and protected from light for at least 24 h prior to imaging. 
 
2.4.4.2.4 Microscopy of SKOV-3 Cells 
Epiluminescence microscopy was carried out using an Edinburgh Instruments fluorescence 
system, FLSPM920, with a 450 W xenon arc lamp excitation source coupled to an Olympus 
IX71 inverted microscope with a LUCPLFLN 40 x 0.60 NA objective. A Hamamatsu 
EMCCD C9100-13 detected luminescence images and all images were obtained using 
Olympus Soft Imaging Solutions GmBH Cell^M 3.2 software. 
 
Luminescence images of SKOV-3 cells were gained by excitation of the sample with 330 nm 
light and 100000 ms exposure time. 
 
2.4.5 Luminescence Spectroscopy 
Luminescence experiments were carried out using an Edinburgh Instruments fluorescence 
system, FLSPM920. The illumination source uses a 450 W xenon arc lamp. The detection 
system used was a Hamamatsu R928 PMT for visible and Hamamatsu R5509 PMT cooled to 
-80 ºC for NIR. The emission monochromator is fitted with two interchangeable gratings 
blazed at 500 nm and 1200 nm. Luminescence studies were carried out using quartz cuvettes 
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with four transparent polished faces and 1 x 1 cm path length. F900 spectrometer analysis 
software was used to record the data. 
 
2.4.5.1 Terbium Emission 
Luminescence spectra of TbL
a
 containing samples were gained by excitation of the complex 
at 266 nm, detection of emission in the range 455-750 nm and employing a 455 nm long pass 
filter. Where the lanthanide centre was excited directly excitation at 487 nm was used in 
conjunction with a 495 nm long pass filter end emission detected in the range 500-750 nm. 
Typically a 0.2 s dwell time and a 1 nm step size were employed with excitation and emission 
slits set to 5 nm and 3 nm respectively. 
 
2.4.5.2 Europium Emission 
Luminescence spectra of EuL
a
 containing samples were gained by excitation of the complex 
at 266 nm, detection of emission in the range 550-750 nm and employing a 550 nm long pass 
filter. Where the lanthanide centre was excited directly excitation at 578 nm was used in 
conjunction with a 590 nm long pass filter end emission detected in the range 590-750 nm. 
Luminescence spectra of EuL
b
 and EuL
x
 containing samples were gained by excitation of the 
complex at 330 nm, detection of emission in the range 550-750 nm and employing a 550 nm 
long pass filter. Typically a 0.2 s dwell time and a 1 nm step size were employed with 
excitation and emission slits set to 5 nm and 3 nm respectively. 
 
2.4.5.3 Neodymium Emission 
Luminescence spectra of NdL
a
 containing samples were gained by excitation of the complex 
at 280 nm, detection of emission in the range 800-1400 nm and employing a 715 nm long 
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pass filter. A 0.5 s dwell time and a 1 nm step size were employed and scans were repeated 
three times to record a cumulative spectrum. Excitation and emission slits set to 15 nm. 
 
2.4.5.4 BSA Emission 
In order to gain details of how the tail of the BSA emission peak may create a background in 
the emission spectra of EuL
b
 containing samples native BSA was also examined under the 
conditions described for EuL
b
. 
 
2.4.5.5 Excitation Spectra 
For EuL
a
 containing samples emission was detected at 615 nm with a 550 nm long pass filter 
and for TbL
a
 containing samples emission was detected at 546 nm with a 455 nm long pass 
filter. Excitation wavelengths in the range 200-350 nm were used. In both cases excitation and 
emission slits were set to 3 nm and 5 nm respectively with a 0.5 s dwell time and a 1 nm step 
size. 
 
2.4.5.6 Luminescence Lifetime Measurements 
Luminescence lifetimes were measured using the spectrophotometer described in section 
2.4.5 with a 100 W μF920H lamp illumination source. In the case of EuLb containing samples 
excitation was at 330 nm, emission at 615 nm and a 550 nm long pass filter used. Excitation 
and emission slits set to 5 nm and 3 nm respectively. Emission was detected over an 8 ms 
range for 120 s with a 0.1 ms lamp trigger delay.  
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3. Design of a Specific Peptide Binding Site for Luminescent Gold Nanoparticles 
 
3.1 Introduction 
3.1.1 Applications of Peptides and Nanoparticles 
Since the advent of nanomaterial research, nanoparticles at the biological interface has been a 
topic of great interest. The effect of nanomaterials on biological species is a key area of 
research, but in addition to this the benefits of combining nanomaterials with biological 
matter has been widely investigated. Peptides in particular have been added to the surface of 
nanoparticles to stabilise the nanoparticles, to act as sensors and to act as a targeting moiety to 
deliver nanoparticles with a beneficial payload to a particular cell or cellular compartment.
1
 
There have been extensive studies of so called cell penetrating peptides which usually contain 
several arginine or lysine residues which facilitate the peptide crossing the cell membrane. 
Previous research has shown that cell penetrating peptides are able to facilitate nuclear 
localisation of AuNPs in cells such as human fibroblast cells, human cervical cancer cells, 
human epithelial cancer cells and African green monkey kidney cells.
2-5
 There have also been 
studies that suggest that the cellular fate of AuNPs may depend on the AuNP size in addition 
to the cell penetrating peptide sequence used.
4-6
 It may be of interest to examine the mode of 
attachment of these peptides to AuNPs in order to better understand the use of attachment 
methods in biological applications. In all but one of the studies referenced here, the peptides 
were attached to the AuNPs by a Au-S bond, either using a thiol contained within the peptide 
sequence, or attaching the peptide to a linker possessing a thiol terminus.
2-5
 The study that did 
not exploit the high affinity of sulphur for gold did use peptides terminating in cysteine 
residues which contain a thiol group, but used this thiol to attach the peptides to BSA which 
then coated the AuNPs, presumably through electrostatic means.
6
 In all cases where the 
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peptide was attached to the AuNPs via a Au-S bond, the peptide modified AuNPs were found 
to locate in different areas of the cell to unmodified AuNPs, thus demonstrating the 
localisation effect of the peptides used and confirming their presence at the surface of the 
AuNPs.
2-5
 AuNPs modified with BSA-peptide conjugates were subject to protein 
displacement studies which revealed that up to 30% of the BSA-peptide conjugates were 
displaced from the surface of the AuNPs over four hours when in the presence of cell culture 
medium containing foetal bovine serum.
6
 Since the studies utilising Au-S chemistry did not 
quantitatively explore the displacement of the peptides from the surface of the AuNPs when 
in biological systems it is hard to compare their stability to the BSA-peptide modified AuNPs, 
however, it was noted that the final cellular localisation of the BSA-peptide modified AuNPs 
was dependent upon the peptide sequence used, demonstrating the presence of the BSA-
peptide conjugate at the surface of the AuNPs after administration to cells.
6
 
 
3.1.2 Covalent Attachment of Peptides to AuNPs 
In addition to the studies involving cell penetrating peptides, much research has been carried 
out into the modification of AuNP surfaces by peptides with a large number of papers 
describing the use of cysteine residues for the attachment of peptides to the AuNPs because of 
the affinity of its thiol side group for the gold surface.
1, 7-11
 Experiments to find alternative 
gold binding peptides have used libraries of peptides displayed on cell surfaces. These studies 
have found that although cysteine is the dominant binding residue when present, 
combinations of other residues bearing functional groups such as carboxyls can interact with 
gold and, when considered cumulatively, in comparable strength to the gold-sulphur bond.
10-12
 
The option of using combinations of amino acids to obtain a comparable binding affinity to 
gold to that achieved with a single thiol group obviously limits the number of peptides or 
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additional molecules of interest able to bind to the surface of the AuNPs. This is because the 
binding peptide will take up a larger amount of surface space to enable binding through 
several residues compared to one cysteine residue. It is for this reason that peptide sequences 
containing one or more cysteine residues will be explored for binding AuNPs in this chapter; 
the overall scope of the project, as described in Chapter 4, involves peptides binding to 
AuNPs already modified with luminescent molecules and, as such, it would be preferable for 
the peptide to bind strongly to the AuNPs through a minimal number of residues. 
 
In addition to peptides binding to formed AuNPs, it is possible to include peptides in the 
synthesis of AuNPs. In this case peptides are used to reduce gold salts and form the final 
surface layer capping the AuNPs.
13, 14
 For example, the synthesis of 10 nm AuNPs was 
achieved by using a polypeptide containing lysine residues, whose amine side groups were 
converted to nitrite by oxidation induced by the gold ions. The polypeptide capped AuNPs 
were stabilised by the repulsion of the positively charged polypeptides. The charged 
polypeptides were also able to bind to negatively charged DNA allowing gene delivery by the 
AuNPs to embryonic mouse fibroblast cells.
14
 Similarly, peptide sequences containing 
residues for reducing gold salts and a molecular recognition sequence were used to synthesise 
13 nm AuNPs. In this case tyrosine was thought to be the residue responsible for gold 
reduction and the molecular recognition sequence was shown to attach the AuNPs to surfaces 
displaying antibodies against the sequence.
13
 Whilst these interactions of peptides with 
AuNPs may be of interest in some applications, they will not be the focus of this chapter. 
Again, this is because a strong bond is needed between the peptide and AuNPs that have 
already been prepared and modified in order to fulfil the applications of the AuNPs as 
discussed in Chapter 4. 
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A peptide with the sequence CALNN is an example of a peptide that attaches to AuNPs 
through the thiol of its cysteine residue and has been shown to stabilise AuNPs in solution and 
in cells.
9, 15, 16
 The ability of CALNN to stabilise AuNPs in aqueous solution is thought to be 
because it presents a hydrophobic environment close to the AuNP surface with a hydrophilic 
portion of the peptide containing asparagine residues exposed to solution. The amino acids 
also possess side chains of increasing size from cysteine to asparagine, sterically promoting 
the formation of a monolayer on the curved surface of AuNPs, Scheme 3.1. In order to 
increase the affinity of a peptide for a gold surface, it is also possible to replace the cysteine 
residue with a group such as a thioctic acid which has the potential to be reduced at the 
surface of the AuNP and thus present two sulphur atoms through which to create bonds with 
the AuNP surface.
17
 Previous research by the Pikramenou group has shown the attachment of 
a variant of CALNN, where the cysteine residue has been replaced by a thioctic acid group, to 
AuNPs and the subsequent ability of the peptide to bind lanthanide ions.
17
 As a starting point 
for designing the peptide binding motif in this project, variants of CALNN will be used, with 
additional cysteine sites to present the potential for a greater binding affinity between the 
peptide and the AuNPs. 
 
Scheme 3.1 Schematic representation of CALNN surface coverage of AuNPs. 
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Another possible AuNP binding peptide may be found when considering the work of Roger 
Tsien’s group where tetracysteine motifs were introduced into proteins to bind biarsenical 
probes.
18, 19
 The use of cysteine residues in this case was because of their affinity for arsenic 
and because other reactive amino acids such as glutamates or lysines were considered too 
abundant in natural proteins, thus limiting the specificity of the interaction between the probe 
and the designed peptide. The initial tetracysteine containing peptide domain developed had 
the sequence WEAAAREACCRECCARA which included both an EAAAR repeat, which is 
known to form α-helices, and cysteine residues in the positions i, i+1, i+4 and i+5 allowing 
the formation of dithiol interactions at each trivalent arsenic contained within the biarsenical 
compound, Scheme 3.2. 
 
 
Scheme 3.2 Interaction of a biarsenical compound with the tetracysteine motif contained 
within a helix formation. 
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Further research suggested that including proline and glycine between the two double 
cysteines creates a hairpin conformation rather than an α-helix and produces a greater affinity 
for the biarsenical probe.
18
 The ability of the hairpin tetracysteine motif to bind the biarsenical 
probe may also be applicable to binding AuNPs and this will be explored in this chapter. 
 
3.1.3 Measuring Peptide – AuNP Interactions 
AuNPs display an SPR band in their absorption spectra which is caused by the coherent 
oscillation of free electrons across the surface of the nanoparticles when a particular 
wavelength of light is applied. This phenomenon is typically in the visible region for gold 
nanoparticles and is indicative of both size and shape of the nanoparticles. The SPR peak in 
the absorption spectrum can be used to monitor the modification of the surface of AuNPs 
because it should change as molecules adsorb to the nanoparticles. This technique has been 
previously used to measure peptide attachment to AuNPs.
1, 17, 20
 For example, a modified 
peptide sequence, thioctic acid-ALNN, induced a 2 nm bathochromic shift in the SPR 
absorption peak of 13 nm citrate-stabilised AuNPs.
17
 The position of the SPR peak in the 
absorption spectrum gradually shifted with small additions of the peptide species before 
remaining constant at a 2 nm change for several peptide additions indicating no further 
change at the surface and thus the saturation of the surface of the AuNPs with the peptide. 
Similarly, UV-Vis absorption spectroscopy was used to monitor the addition of a disulphide 
containing peptide to the surface of 13 nm citrate-stabilised AuNPs and it was found that the 
peptide induced a 5 nm bathochromic shift in the SPR peak of the AuNPs.
20
 Since the change 
in SPR position in the absorption spectrum of AuNPs changes gradually and finally reaches a 
plateau when peptides are titrated into a solution of AuNPs, it may be possible to plot a curve 
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of change in the SPR band as a function of peptide concentration and fit the curve to find 
information about the strength of binding. 
 
The binding constant of peptides to AuNPs can also be measured using ITC which measures 
changes in the temperature of a solution of AuNPs as peptides are added. ITC can give 
information about the enthalpy and entropy change, number of binding sites and the binding 
constant of a particular peptide-AuNP interaction. One study used ITC to determine the 
binding constant of anionic peptides to surface modified 2 nm cationic AuNPs to be in the 
range of 10
6
 M
-1
 by titrating a solution of AuNPs into a solution of peptide.
21
 Another study 
titrated a peptide solution into a solution of 5 nm AuNPs to find a binding constant in the 
region of 10
5
 M
-1
.
22
 In both cases ITC data was fit using a one-site binding model because, 
although AuNPs contain many possible binding sites for the peptide, each site can be 
considered equal and independent.
21, 22
 
 
3.1.4 Research Aims 
The main objective of this chapter is to identify a peptide capable of binding strongly to 
AuNPs. Three peptide sequences will be used, two based around the CALNN motif and the 
other a tetracysteine motif CCPGCC. A variety of techniques will be used to determine the 
binding affinity of each peptide to AuNPs. The work outlined here will inform the utilisation 
of the peptide binding sequence in Chapter 4 where luminescent AuNPs will be employed. 
The effect of peptide on the luminescent properties of lanthanide coated AuNPs will, 
therefore, also be explored. 
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Figure 3.1 Peptides and luminescent europium complexes used in this chapter. 
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3.2 Results and Discussion 
3.2.1 Synthesis of Citrate-AuNPs 
The preparation of citrate-stabilised gold nanoparticles was based upon a well known 
synthesis which uses the reduction of Au(III) by citrate ions resulting in a nanoparticle core of 
Au(0) capped with citrate ions.
23
 The resulting 13 nm Citrate-AuNPs were characterised by 
UV-Vis spectroscopy, DLS and ζ-potential measurements. The hydrodynamic diameters 
reported throughout this chapter are taken from the number distribution data obtained from 
DLS measurements, however, both number and intensity distribution graphs are available in 
the appendix. 
 
      
Figure 3.2 UV-Vis absorption spectrum of 
0.47 nM Citrate-AuNPs.                     
Table 3.1 DLS and ζ-potential 
measurements of Citrate-AuNPs.
 
 
The UV-Vis absorption spectrum of Citrate-AuNPs shows the characteristic SPR band at 
520 nm. The DLS measurements of Citrate-AuNPs reveals a hydrodynamic diameter of 
around 13 nm which indicates that the nanoparticles do not have any large molecules 
associated with their surface because this is the same diameter calculated in literature using 
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TEM, for AuNPs prepared using this method, which will only give information about the gold 
core of the nanoparticles.
23
 Citrate-AuNPs exhibit a ζ-potential of -33 mV which indicates 
that they are stable in solution since their surface charge is sufficient for the nanoparticles to 
repel one another, preventing aggregation of the nanoparticles. The ζ-potential is also negative 
as would be expected due to the citrate ions capping the surface of the nanoparticles. 
 
3.2.2 Preparation of Peptides 
The preparation of CCALNNCCALNN followed that of solid phase peptide synthesis using 
Fmoc protected amino acids and Fmoc-Asn(Trt)-Wang resin in a Liberty 1 CEM Microwave 
Peptide Synthesizer. The preparation was carried out on a 0.1 mmol scale with five-fold 
excess of each amino acid used. The desired peptide was isolated using HPLC and identified 
using MALDI mass spectrometry and characterised by UV-Vis spectroscopy. 
 
 
Figure 3.3 Absorption spectrum of 1 mM CCALNNCCALNN in water. 
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The absorption spectrum of CCALNNCCALNN shown in Figure 3.3 is typical of what 
would be expected for a peptide molecule with this sequence. The large absorption, with a 
molar absorption coefficient of 3500 M
-1
 cm
-1
, at around 205 nm is attributed to the peptide 
bond π → π* transition with some possible contribution from its n → π* transition.24 Peptides 
containing residues with aromatic side chains would usually exhibit absorption around 280 
nm with high molar absorption coefficients, however, in this case no such residues are 
present. A small absorption, ε = 140 M-1 cm-1, at 280 nm for this peptide is most likely to arise 
from the presence of disulphide bonds which must have formed either intra- or inter-
molecularly.
25
 
 
3.2.3 Interaction of CALNN with Citrate-AuNPs 
The peptide with the sequence CALNN is known within literature to bind to and impart great 
stability to citrate coated AuNPs.
9, 15
 It is also important to investigate the interaction of 
peptides with Citrate-AuNPs rather than lanthanide coated ones since the surface 
modifications of the AuNPs may differ depending on their application. 
 
3.2.3.1 Preparation of CALNN-AuNPs 
The absorption spectrum of Citrate-AuNPs was measured as a solution of CALNN was 
titrated into the nanoparticles. Since the SPR band in the absorption spectrum of AuNPs is 
sensitive to their surface modification, monitoring this should allow information to be 
gathered about the displacement of citrate on the surface of Citrate-AuNPs by CALNN. 
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Figure 3.4 Left: Absorption spectra of 3 nM Citrate-AuNPs with microlitre additions of a 0.5 
mM solution of CALNN. Right: Change in SPR position of 3 nM Citrate-AuNPs with 
titration of CALNN. 
 
As CALNN was titrated into Citrate-AuNPs a bathochromic shift of the SPR band was 
observed indicating a change at the surface of the AuNPs likely to be the displacement of 
citrate ions by peptide molecules binding to the gold. The 2 nm shift in SPR position concurs 
with that achieved in the literature following mixing of peptide and AuNP solutions.
9, 26
 The 
newly formed CALNN-AuNPs were centrifuged to form a pellet, the supernatant discarded 
and the pellet redispersed in deionised water before the process was repeated to remove any 
unbound peptide species. The position of the SPR peak in the UV-Vis absorption spectrum 
was unchanged by washing and centrifugation of the AuNPs. A solution of isolated CALNN-
AuNPs were then analysed by DLS measurements. 
 
Sample Hydrodynamic Diameter/nm 
Citrate-AuNPs 13 ± 2 
CALNN-AuNPs 12 ± 3 
Table 3.2 Hydrodynamic diameters of Citrate-AuNPs and CALNN-AuNPs measured by 
DLS. 
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After addition of CALNN to Citrate-AuNPs there is no real change observed in the 
hydrodynamic diameter of the AuNPs. A previously published study reports that on addition 
of CALNN to 9.3 nm citrate-stabilised AuNPs, an increase in hydrodynamic diameter of 1.2 
nm is observed.
26
 An increase of 1.2 nm is within the measured range recorded in this 
instance and as such the similarity between the hydrodynamic diameters of the two AuNP 
species is not unexpected. It has been previously hypothesised that the N-terminal cysteine 
residue binds to the surface of the AuNPs while the rest of the peptide molecule points 
outwards towards the solvent  because the two C-terminal asparagine residues are hydrophilic 
and are relatively bulky which may encourage their projection towards the surrounding 
solvent.
9
 The approximate length of the peptide is 1.5 nm and as such would be expected to 
add 3 nm to the hydrodynamic diameter of the AuNPs if it were to bind in the fashion 
described previously, however, such an increase is not observed and as such it may be 
possible that the peptide is held more closely to the surface of the AuNPs than expected. 
 
3.2.3.2 Measurement of CALNN Binding to Citrate-AuNPs 
The possibility of using CALNN as a specific binding site for AuNPs was assessed by 
measuring the binding constant of the peptide to the AuNP surface. The binding constant was 
investigated using ITC which measures the heat change as the peptide is titrated into Citrate-
AuNPs which can then be fit to find Ka. It is important with this technique that Citrate-
AuNPs and CALNN are in the same solvent as mixing of solvents can cause a heat change 
and, for this reason, Citrate-AuNPs were centrifuged to form a pellet before being 
redispersed in deionised water and the process repeated to ensure there were no excess ions 
from their synthesis in solution. CALNN was also dissolved in deionised water. This is in 
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contrast to the titration monitored via UV-Vis spectroscopy where Citrate-AuNPs were used 
as synthesised with potential excess ions present in the aqueous solution. 
 
 
Figure 3.5 ITC data for the titration of 0.03 mM CALNN into 4.5 nM Citrate-AuNPs. Top: 
change in heat measured over time as CALNN is added at specific time intervals. Bottom: 
integrated area of peaks shown in the top graph to give energy change at each addition of 
peptide against molar ratio of the two species with the fit shown as a line through the data 
points. 
 
The ITC results were analysed using Origin 7.0 software and the data fit using a 1:n binding 
model which is appropriate in this case because although there are multiple binding sites on 
the AuNP surface for the peptide to bind, the degree of cooperation between these sites is 
negligible and the peptide is present in high excess which drives a 1:1 interaction between 
peptide and AuNP binding site. The peptide is added in such excess that overall binding is 
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observed and analysed as opposed to individual events. Similarly, if the peptide binds 
sequentially through one thiol and then another group, such as an amine, this technique will 
not resolve such changes and as such only the overall binding of the peptide to AuNPs is 
considered. The fit achieved, however, does not capture the data well which may suggest that 
the experimental parameters could be optimised in the future if the experiment were to be 
repeated. For example, using different concentrations of the substrates might result in a neater 
curve and a better fit of the data. To date the concentrations used to produce the results in 
Figure 3.5 provided the best results, however, in comparison to results reported later, Figure 
3.8, it is evident that the signal detected in this case is weak which may have hampered the 
fitting of the data. Nevertheless, since additional techniques will be used to find the binding 
constant of this system these results will be corroborated. 
 
Here the change in heat of the system is measured, therefore, it is not just Ka that can be 
calculated from the results. The equation used to fit the data can be found in the appendix. 
 
Parameter Calculated Value 
Ka 9.14 x10
6
 ± 4.40 x10
6
 M
-1
 
Number of binding sites 564 ± 28.5 
ΔH -1.208 x104 ± 821.8 cal mol-1 
ΔS -8.67 cal mol-1 K-1 
Table 3.3 Calculated values for the parameters Ka, number of binding sites, ΔH and ΔS from 
ITC data measured for the titration of CALNN into Citrate-AuNPs. 
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The binding of CALNN to Citrate-AuNPs is found by ITC measurement to be an exothermic 
process which is spontaneous if not entropically favoured. The spontaneity of the reaction can 
be calculated using the above parameters in the equation below. 
 
           
Equation 3.1 Calculation of the Gibbs free energy of a reaction. 
 
Using Equation 3.1 and the results in Table 3.3 with the knowledge that the reaction was 
carried out at 298 K, ΔG was found to be -9496 cal mol-1 which indicates a spontaneous 
reaction because of its negative value. It is not surprising that the reaction is not entropically 
favoured as the peptide molecules, although displacing citrate from the AuNP surface, will 
become more ordered in binding to the gold surface and perhaps will create increased order 
within the solvation sphere surrounding each peptide coated AuNP. Importantly, Ka was 
found to be in the range of 10
6
 M
-1
 indicating strong binding. The number of binding sites 
calculated relates to 1.2 peptides per nm
2
, which is slightly lower than the 1.67-1.93 peptides 
per nm
2
 reported previously for CALNN coverage of 12.3 nm AuNPs.
9
 Treating the  13 nm 
AuNPs as spheres, their surface area can be calculated and, since the size of gold atoms is 
known, the number of gold atoms at the surface of the AuNPs can also be calculated; using 
this method, the AuNPs here are found to have 9004 gold atoms at their surface.
27
 Assuming 
that the number of binding sites calculated from the ITC data is equal to the number of surface 
gold atoms occupied the peptide interacts with just 6% of the available surface. Of course, the 
footprint of the peptide molecule and its ability to pack on the surface will also influence the 
surface coverage as well as its binding affinity, but the number of binding sites calculated 
here directly relates to the ratio of peptide to AuNPs during the titration. 
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Another, perhaps simpler, way to gain an estimation of the binding constant is to apply a fit to 
the titration curve shown in Figure 3.4 in order to find Ka. In this case a regime is used to fit a 
1:n binding event. The equation used is shown in the experimental section and the curve fit 
can be found in the appendix. 
 
System Examined Ka/M
-1
 
Citrate-AuNPs + CALNN 1.4 x10
6
 ± 2.3 x10
5
 
 
Table 3.4 Ka calculated upon fitting the curve of change in SPR absorption maximum position 
of Citrate-AuNPs with titration of CALNN. 
 
Fitting the data from the titration reveals a binding constant for CALNN onto AuNPs in the 
range of 10
6
 M
-1
 which concurs with the results from ITC analysis, demonstrating the use of 
this method as a simple way to gain an estimate of binding information. 
 
In addition to ITC measurements and UV-Vis absorption titrations, the binding of CALNN to 
gold was measured by SPR spectroscopy. A gold surface, similar to AuNPs, can exhibit an 
SPR when incident light hits the surface at the resonant angle. The resonant angle needed to 
create an SPR changes upon modification of the gold surface and as such can be used to 
measure the binding of molecules to gold. In this case solutions of CALNN in water at 
various concentrations were flowed over a gold chip and the SPR response measured. 
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Figure 3.6 Left: Sensorgrams of response units over time for 0.05 mM (―), 0.1 mM (―), 
0.25 mM (―), 0.5 mM (―), 0.75 mM (―) and 1 mM (―) CALNN flowing over a gold SPR 
chip corrected against a blank. Right: Response units taken from the peak of each sensorgram 
plotted against peptide concentration. 
 
It can be seen from the sensorgrams that as the concentration of the peptide increases the 
response units measured increase as would be expected, however, there are some anomalies in 
this general trend. The response units recorded at the top of each curve were plotted against 
the corresponding peptide concentration to give a curve from which Ka could be found using 
the same regime used to fit the UV-Vis absorption titration data.  
 
System Examined Ka/M
-1
 
Gold chip  + CALNN 1.0 x10
6
 ± 3.4 x10
7
 
 
Table 3.5 Ka calculated upon fitting the curve of change in SPR response maximum of a gold 
chip with addition of CALNN. 
 
The data point on the right-hand graph of Figure 3.6 represented by an open circle was not 
used in the data fitting as it was seen to be anomalous. The binding constant was again found 
to be in the order of 10
6
 M
-1
, however, the error relating to this value is extremely high which 
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means that the results are inconclusive. It may be noted that the binding constant calculated 
for CALNN binding to a gold surface is comparable to the peptide binding to AuNPs which 
may indicate that the binding interaction is not influenced to any great extent by the surface 
topology, such as its curvature, but due to the large error in the binding constant calculated 
further studies would be required to confirm this. SPR experiments require considerably more 
peptide than ITC and UV-Vis absorption titrations and as such were not used for binding 
studies with other peptides. 
 
3.2.4 Interaction of CCPGCC with Citrate-AuNPs 
The peptide sequence CCPGCC when part of a larger peptide chain has previously been 
shown through NMR studies to position all four thiol groups towards one face of the peptide 
sequence allowing interaction of all four cysteine side chains with an external substance.
28
 
The positioning of the thiol groups is due to the hairpin structure caused by the steric 
restrictions of the proline residue. The CCPGCC sequence when part of a larger recombinant 
protein has previously been shown to bind to AuNPs of various sizes in an oriented manner.
29
 
 
3.2.4.1 Preparation of CCPGCC-AuNPs 
As described previously, a solution of CCPGCC in water was titrated into a solution of 
Citrate-AuNPs and the titration monitored via the absorption spectra of the AuNPs in 
solution. In this case a small amount of hydrazine monohydrate was added to the peptide 
solution to reduce any possible disulphide bonds. 
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Figure 3.7 Left: Absorption spectra of 3 nM Citrate-AuNPs with microlitre additions of a 1 
mM solution of CCPGCC. Right: Change in SPR position of 3 nM Citrate-AuNPs with 
titration of CCPGCC. 
 
As CCPGCC was titrated into Citrate-AuNPs a bathochromic shift was observed for the SPR 
peak in the absorption spectrum of the AuNPs, indicating that the peptide was binding to the 
surface of the AuNPs. Absorbance above ~600 nm also increased over the course of the 
titration which may indicate flocculation of the AuNPs, however, no aggregation was 
observed. The newly formed CCPGCC-AuNPs were passed through a Sephadex G-15 size 
exclusion column to remove unbound peptide species and subsequently characterised by DLS 
measurements. The position of the SPR peak in the UV-Vis absorption spectrum was 
unchanged by isolation of the CCPGCC-AuNPs. 
 
Sample Hydrodynamic Diameter/nm 
Citrate-AuNPs 13 ± 2 
CCPGCC-AuNPs 26 ± 7 
Table 3.6 Hydrodynamic diameters of Citrate-AuNPs and CCPGCC-AuNPs measured by 
DLS. 
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CCPGCC forms a hairpin structure due to the rigid structure of its cyclic proline residue, 
Figure 3.1, and as such should be able to present all four cysteine residues to the surface of 
the AuNPs without the need for additional adjustment of its conformation. The height of the 
peptide from the AuNP surface should be around 1.5 nm if it was indeed attached through all 
four cysteine residues, however, if it were to bind through only one end of the peptide chain 
the height of the peptide from the AuNP surface would still be around 1.5 nm. In each case it 
would, therefore, be expected that the increase in hydrodynamic diameter of the AuNPs after 
CCPGCC binding should be approximately 3 nm. The larger increase in hydrodynamic 
diameter may be due to the association of solvent molecules with the peptide, or possibly, in 
this case, the peptide may be cross-linking two AuNPs which may, in part, explain the growth 
in absorption seen at above 600 nm during the titration. 
 
3.2.4.2 Measurement of CCPGCC Binding to Citrate-AuNPs 
Firstly, the binding constant was investigated using ITC measurements. As before, Citrate-
AuNPs were isolated and redispersed in deionised water and the peptide also dissolved in 
deionised water. A solution of 0.2 mM CCPGCC was titrated into 4.5 nM Citrate-AuNPs. 
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Figure 3.8 ITC data for the titration of 0.2 mM CCPGCC into 4.5 nM Citrate-AuNPs. Top: 
change in heat measured over time as CCPGCC is added at specific time intervals. Bottom: 
integrated area of peaks shown in the top graph to give energy change at each addition of 
peptide against molar ratio of the two species with the fit shown as a line through the data 
points. 
 
The ITC results were analysed using Origin 7.0 software and the data fit using a 1:n binding 
model. Fitting the data also revealed additional parameters of the system. 
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Parameter Calculated Value 
Ka 1.19 x10
7
 ± 7.09 x10
5
 M
-1
 
Number of binding sites 4.26 x10
3
 ± 9.22 
ΔH -1.126 x105 ± 421.5 cal mol-1 
ΔS -345 cal mol-1 K-1 
Table 3.7 Calculated values for the parameters Ka, number of binding sites, ΔH and ΔS from 
ITC data measured for the titration of CCPGCC into Citrate-AuNPs. 
 
As with the binding of CALNN to AuNPs, the binding of CCPGCC to AuNPs was found to 
be spontaneous, but not entropically favoured, with a Gibbs free energy of -9790 cal mol
-1
 
calculated using Equation 3.1. The binding constant in this case was found to be in the order 
of 10
7
 M
-1
. In this instance the number of binding sites occupied by the peptide is much 
higher than that measured for CALNN. Using the number of binding sites calculated from the 
ITC data, and assuming that this equals the number of gold atoms involved in binding, 
CCPGCC is found to bind to 47% of the surface of the AuNPs, 41% more than CALNN. 
 
The Ka for CCPGCC binding to AuNPs was also calculated by fitting the UV-Vis absorption 
titration data in the same way as for CALNN titrations and the fit can be found in the 
appendix. 
 
System Examined Ka/M
-1
 
Citrate-AuNPs + CCPGCC 1.2 x10
7
 ± 1.4 x10
7
 
Table 3.8 Ka calculated upon fitting the curve of change in SPR absorption maximum position 
of Citrate-AuNPs with titration of CCPGCC. 
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Fitting of the titration data revealed a Ka in the order of 10
7
 M
-1
 which does concur with the 
value for Ka calculated from the ITC data, however, the error in the value is very high which 
means that no conclusions can be drawn from this result. It may have been the case that the 
concentration of peptide added during the titration was too high, resulting in a sharp curve 
that was difficult to fit. If the titration were to be repeated using a lower concentration of 
peptide a shallower curve may result allowing a fit to be applied with less error. 
 
3.2.5 Interaction of CCALNNCCALNN with Citrate-AuNPs 
As previously discussed, it is known that the peptide sequence CALNN is able to coat AuNPs 
and stabilise them effectively.
9, 15
 It was, therefore, attempted to further investigate the affinity 
of the peptide for AuNPs by addition of an extra cysteine residue into the sequence and then 
duplicating the sequence to give CCALNNCCALNN. This sequence should allow evaluation 
of the effects of amino acid sequence and number of cysteine residues on binding to AuNPs. 
 
3.2.5.1 Computer Modelling of CCALNNCCALNN 
CCALNNCCALNN in aqueous solution was modelled using AMBER software utilised 
through the BlueBEAR facility at the University of Birmingham, UK. 
 
 
Figure 3.9 Computer model of CCALNNCCALNN in water. 
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The computer model of the peptide shows that the conformation of CCALNNCCALNN does 
not adhere to any organised secondary structure, which is perhaps not unexpected due to its 
short length. How CCALNNCCALNN interacts with AuNPs is not intuitive based on its 
structure. 
 
Scheme 3.3 Schematic representation of the interaction of CCALNNCCALNN with AuNPs. 
 
The thiol groups of the peptide are most likely to bind to the surface of the AuNP due to the 
affinity of sulphur for gold, however, the peptide may fold to allow all cysteine residues 
access to the AuNP surface, or may wrap around part of the AuNP surface for the same 
reason, or perhaps only the two terminal cysteine residues will bind to the gold surface with 
possible stabilising interactions with neighbouring peptides. 
 
3.2.5.2 Preparing CCALNNCCALNN-AuNPs 
As with the other peptides used, a solution of CCALNNCCALNN in water was titrated into a 
solution of Citrate-AuNPs and the titration monitored by UV-Vis absorption spectroscopy. A 
small amount of hydrazine monohydrate was added to the peptide solution prior to the 
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titration to reduce any disulphide bonds which could affect the interaction of the peptide with 
the AuNPs. 
 
  
Figure 3.10 Left: Absorption spectra of 3 nM Citrate-AuNPs with microlitre additions of a 1 
mM solution of CCALNNCCALNN. Right: Change in SPR position of 3 nM Citrate-
AuNPs with titration of CCALNNCCALNN. 
 
The binding of CCALNNCCALNN to the surface of AuNPs elicits a bathochromic shift in 
the SPR peak in the absorption spectra relative to Citrate-AuNPs. DLS was used to assess 
the change in hydrodynamic diameter of the AuNPs. Unlike with the other peptide coated 
AuNPs, CCALNNCCALNN-AuNPs were not isolated before further analysis because 
attempts to do so led to particle aggregation. 
 
Sample Hydrodynamic Diameter/nm 
Citrate-AuNPs 13 ± 2 
CCALNNCCALNN-AuNPs 12 ± 3 
Table 3.9 Hydrodynamic diameters of Citrate-AuNPs and CCALNNCCALNN-AuNPs 
measured by DLS. 
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The hydrodynamic diameter of the AuNPs is unchanged after addition of the peptide. The 
length of the peptide when in the conformation shown in Figure 3.9 is approximately 4 nm 
which is not reflected in the measured hydrodynamic diameter of the peptide coated AuNPs. 
This may indicate that the peptide binds to the AuNPs along its length rather than through 
terminal residues. This would potentially allow the interaction of all four cysteine residues 
with the surface of the AuNPs. 
 
3.2.5.3 Measurement of CCALNNCCALNN Binding to Citrate-AuNPs 
In this case, only fitting of the UV-Vis absorption titration was used to find the binding 
constant of the peptide to AuNPs since it has been previously demonstrated to give Ka values 
comparable to those obtained by other methods. The binding constant, Ka, may also help to 
confirm which mode of binding the peptide uses since the strength of binding should be 
suggestive of the number of thiol groups binding to the surface of the AuNPs, however, the 
interaction of other amino acids with gold, through amines for example, cannot be 
discounted.
11
 
 
System Examined Ka/M
-1
 
Citrate-AuNPs + 
CCALNNCCALNN 
2.1 x10
4
 ± 9.6 x10
3
 
Table 3.10 Ka calculated upon fitting the curve of change in SPR absorption maximum 
position of Citrate-AuNPs with titration of CCALNNCCALNN. 
 
The fit of the binding curve has revealed a binding constant of around 10
4
 M
-1
 for 
CCALNNCCALNN binding to Citrate-AuNPs. In order to draw any conclusions about the 
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strength of this binding event and the information it can reveal about the method of binding, it 
was decided pertinent to execute a comparison to CALNN and CCPGCC binding data. 
 
3.2.6 Comparison of Peptide Binding to Citrate-AuNPs 
The binding of CALNN, CCPGCC and CCALNNCCALNN to AuNPs has been analysed 
and can be compared on their measured Ka and their UV-Vis absorption titration curves. 
 
 
Figure 3.11 Change in SPR position of 3 nM Citrate-AuNPs with titration of solutions of 1 
mM CCPGCC (˟), 0.5 mM CALNN (○) and 1 mM CCALNNCCALNN (■). 
 
Of the three peptides CCPGCC demonstrates the highest affinity for AuNPs with 
CCALNCCALNN displaying the lowest affinity; this is reflected in their respective titration 
curves, Figure 3.11, with CALNN producing the sharpest change in AuNP SPR and 
CCALNNCCALNN the smallest change. It is interesting that CALNN should have a higher 
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binding constant than CCALNNCCALNN because it has fewer thiol groups for binding to 
AuNPs, however, it must be the case that the structure of CCALNNCCALNN somehow 
prevents it from binding efficiently to the surface of AuNPs as opposed to CALNN which 
binds more strongly. Certainly, the binding constants measured are not simply related to the 
number of cysteine residues contained within each peptide sequence, therefore, the structure 
and conformation and the interaction between peptides on the surface of the AuNPs must also 
have an impact on their binding.
8, 30
 
 
The difference in the number of binding sites calculated from ITC data for CALNN and 
CCPGCC is also reflected in their binding constants; CALNN occupies 6% of the surface of 
AuNPs, whereas CCPGCC occupies 47%, a difference of 41%. The binding constant of 
CCPGCC to AuNPs is around 41% greater than that found for CALNN. 
 
Since the purpose of these experiments is to find a peptide capable of specifically binding 
AuNPs only CCPGCC and CALNN were taken forward into further experiments due to their 
higher affinity for AuNPs. 
 
3.2.6.1 CALNN and CCPGCC Competition Experiments 
In order to probe the binding behaviour of the two peptides on AuNPs further, a 0.5 mM 
solution of one peptide was titrated into a 3 nM solution of Citrate-AuNPs until the 
maximum change in SPR band position in the absorption spectrum was seen and then a 1 mM 
solution of the other peptide was titrated in to see whether a further shift in the SPR band was 
observed. 
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Figure 3.12 Change in SPR peak position when the first 0.5 mM peptide solution is added in 
microlitre aliquots to 3 nM Citrate-AuNPs and then subsequent change of SPR position 
when the second 1mM peptide solution is added in microlitre aliquots. Left: CCPGCC (○) 
added first then CALNN (˟). Right: CALNN (˟) added first then CCPGCC (○). 
 
The results indicate that in each case the peptide added second is able to affect the SPR band 
of the AuNPs. Certainly in each case, the concentration of peptide bound to the surface of the 
AuNPs, as calulated from the number of binding sites revealed by ITC, is not comparable 
with the peptide added afterwards which is in great excess, possibly driving the reaction 
towards displacement at the surface. Previous experiments to find the binding constant of the 
two peptides on AuNPs have shown that CCPGCC has a higher affinity for AuNPs than 
CALNN, which means another hypothesis may be that CCPGCC is able to displace CALNN 
and in the case where CCPGCC is added first, it could bind through only two thiols leaving 
two free to futher interact with CALNN causing the subsequent SPR shift upon its addition. 
From these results it is difficult to confirm this hypothesis, therefore, a further study to 
elucidate the number of thiols used in binding to AuNPs was executed. 
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3.2.6.2 Sensing for Zn
2+
 and Ni
2+
 using Peptide-AuNPs 
Solutions of CALNN-AuNPs and CCPGCC-AuNPs were prepared as previously described 
and the AuNPs collected as a pellet by centrifugation and redispersed in deionised water 
several times to ensure no unbound peptides were present in solution. To the AuNPs solutions 
of ZnCl2 or NiCl2 were added and the resulting change in the SPR peak measured by UV-Vis 
absorption spectroscopy. 
 
   
Figure 3.13 Change in SPR peak position of 41 pM CCPGCC-AuNPs (○) and 41 pM 
CALNN-AuNPs (˟) with titration of 1 mM Zn
2+
 solution (left) or 1 mM Ni
2+
 solution (right). 
 
The change in SPR peak position of the peptide-AuNPs indicates that the addition of a metal 
cation causes a change at the surface of CCPGCC-AuNPs but not CALNN-AuNPs. Since 
Ni
2+
 is a relatively soft cation and Zn
2+
 is a borderline cation it would be reasonable to suggest 
that they are bound by the sulphurs of CCPGCC, indicating that not all of the cysteine 
residues of CCPGCC are used in binding to the surface of AuNPs. CALNN does not display 
any indication of binding the metal cations which serves to act as a control since its only 
cysteine group should be occupied in binding to the surface of the AuNPs. It may also be 
suggested that other residues present in CALNN may interact with the metal cations, and as 
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such it is unexpected not to see an interaction, however, in naturally occurring metal binding 
proteins containing asparagine residues (N), the asparagine residue is never the residue 
responsible for coordinating the metal.
31
 
 
Looking towards sensing applications, the results show that for CCPGCC-AuNPs there is a 
range where the SPR of the AuNPs does not change, after which the SPR changes linearly 
with increasing Zn
2+
 or Ni
2+
 concentration. In both cases it could be argued that CCPGCC-
AuNPs could be used to sense for Zn
2+
 or Ni
2+
 over a linear range, however, this experiment 
does not confirm whether this behaviour is also demonstrated for other metals or the range of 
the linear response and as such if the applications of these AuNPs to sensing is to be explored 
further experiments are needed. 
 
3.2.7 The Effect of CCPGCC on Luminescent AuNPs 
CCPGCC was identified as the best candidate for specific binding to AuNPs, however, it has 
been examined in terms of its intereaction with Citrate-AuNPs. The application of the 
peptide to further work will require its interaction with luminescent AuNPs and as such its 
effect on the luminescence of these AuNPs was assessed. 
 
3.2.7.1 Preparation of Luminescent AuNPs and Addition of CCPGCC 
1 mM solutions of luminescent lanthanide species EuL
a
 and EuL
b
, Figure 3.1, whose 
syntheses are described in Chapter 2, were titrated into solutions of 3 nM Citrate-AuNPs 
until a plateau was reached in the change of the SPR peak, as measured by UV-Vis absorption 
spectroscopy, to give EuL
a
-AuNPs and EuL
b
-AuNPs respectively. Following this a 1 mM 
solution of CCPGCC was added until a peptide concentration of 17 μM was reached and a 
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further shift in the SPR peak was measured indicating interaction of the peptide with the 
luminescent AuNPs. The AuNPs were then isolated as pellets by centrifugation before being 
redispersed in deionised water and the process repeated to remove any unbound species, or, 
indeed, any luminescent europium complexes that may have been displaced by the binding of 
the peptide to the AuNPs. 
 
3.2.7.2 Luminescent Properties of EuL-AuNPs with CCPGCC 
The luminescence emission properties of the luminescent AuNPs were measured before and 
after the addition of peptide. 
 
              
Figure 3.14 Emission spectra of EuL
a
-AuNPs, λex = 266 nm (left) and EuL
b
-AuNPs, λex = 
330 nm (right) with (---) and without (―) addition of CCPGCC. Spectra corrected for PMT 
response and absorbance of comparable samples equal at λex and λem (615 nm) respectively. * 
indicates scattering at double the excitation wavelength which is seen in the right hand spectra 
and not the left due to the difference in excitation wavelengths used for the complexes. 
 
The emission spectrum of EuL
a
-AuNPs after the addition of CCPGCC is reduced in intensity 
compared to that measured without peptide present. This may be indicative of displacement of 
EuL
a
 molecules from the surface of AuNPs by CCPGCC. In contrast to this, the emission 
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spectrum of EuL
b
-AuNPs is largely unchanged before and after addition of CCPGCC. The 
luminescence lifetime of the observed emission was also measured and their corresponding 
spectra can be found in the appendix. 
 
Sample τ/μs 
EuL
a
-AuNPs 524 ± 52 
EuL
a
-AuNPs + CCPGCC 341 ± 34 
EuL
b
-AuNPs 550 ± 55 
EuL
b
-AuNPs + CCPGCC 548 ± 55 
Table 3.11 Luminescence lifetime measurements of luminescent AuNPs in the presence and 
absence of CCPGCC. For all samples λem = 615 nm, EuL
a
-AuNPs λex = 266 nm, EuL
b
-
AuNPs λex = 330 nm. 
 
The luminescence lifetime of EuL
a
-AuNPs decreases after addition of CCPGCC in 
comparison to the lifetime before its addition. This may suggest that the emission of the 
lanthanide complex is quenched by the peptide rather than the peptide displacing it from the 
AuNPs as was thought as a result of the emission spectra. This could be due to the large 
solvation sphere of the peptide, as indicated by the DLS data in Table 3.4, bringing a higher 
concentration of water molecules to the proximity of the europium centre. This is clearly not 
the case with EuL
b
-AuNPs since the luminescence lifetime is not changed when CCPGCC is 
added much like the emission spectra, which could indicate that the slight difference in the 
structure of the complex prevents the peptide from binding as closely to EuL
b
 as it does for 
EuL
a
. For this reason, and for the fact that EuL
b
-AuNPs can be excited at a longer 
wavelength than EuL
a
-AuNPs which is more applicable to biological studies, EuL
b
-AuNPs 
will be taken forward for use as protein labels in cells in the next chapter. 
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3.3 Conclusions 
The aim of this chapter, which was to identify a peptide sequence capable of specifically 
binding luminescent AuNPs within cells, has been achieved by measuring the binding affinity 
of three candidate peptides to AuNPs using a variety of techniques and comparing the results 
obtained for each peptide. It was found that the number of cysteine residues contained within 
the peptide sequence was not the deciding factor on the strength of binding to AuNPs as was 
predicted to be the case. Indeed, CCPGCC was found to have the highest binding constant 
when binding to AuNPs, but it was revealed that not all of its cysteine residues are occupied 
in binding to AuNPs since the peptide was able to bind to free transition metal cations. 
Nevertheless, CCPGCC was selected as the optimum AuNP binding peptide and it was shown 
not to affect the luminescence properties of luminescent EuL
b
-AuNPs and as such will be 
taken forward with these AuNPs for further experiments in the next chapter. 
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3.4 Experimental 
3.4.1 General Considerations 
Starting materials were obtained from Sigma Aldrich, Fluka, Fisher Scientific or AGTC 
Bioproducts and used without further purification. 
 
MALDI-TOF mass spectrometry was carried out on a Waters MALDI Micro MX mass 
spectrometer, using α-cyano-4-hydroxycinnamic acid matrix. 
 
HPLC was carried out on a Dionex summit system, using a Summit P580 quarternary low 
pressure gradient pump with built-in vacuum degasser. The detector was a Summit UVD 170s 
UV-Vis multi-channel detector with a preparative flow cell.  The column used was the 
Phenomenex Luna 10 μm particle size C18 semi-preparative column. All solvents used were 
HPLC grade solvents, degassed prior to use. 
 
UV-Vis absorption spectra were carried out on Varian Cary 50 or Varian Cary 5000 
spectrometers. UV-Vis spectra were taken using 1 cm path length quartz cuvettes.  
 
All ITC measurements were carried out using a MicroCal VP-ITC system at 25 ºC. Origin 7 
MicroCal Software was used to record and analyse the data. 
 
SPR spectroscopy measurements were achieved using a Reichert Life Sciences SR7000DC 
SPR spectrometer equipped with a SR7300 semi-automatic valve. 
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3.4.2 Chemical Syntheses 
3.4.2.1 Synthesis of Citrate-Stabilised AuNPs: Citrate-AuNPs 
All glassware was cleaned in aqua regia (HCl:HNO3, 3:1), rinsed with deionised water and 
dried in a hot oven prior to use. Hydrogen tetrachloroaurate (0.08 g, 0.2 mmol) was dissolved 
in water (200 mL), stirred vigorously and heated under reflux until a rolling boil was reached. 
To the boiling solution sodium citrate (0.22 g, 0.8 mmol) in water (20 mL) was added which 
turned the solution from colourless to dark red. The solution was allowed to boil for a further 
10 min before being removed from the heat and stirred for a further 15 min. The solution was 
then left to cool to room temperature. UV-Vis (H2O) λmax nm: 520. 
 
3.4.2.2 Synthesis of CCALNNCCALNN 
The peptide was synthesised using a solid phase technique on a 0.1 mmol scale, with a five-
fold excess of each amino acid used. Liberty 1 CEM Microwave Peptide Synthesizer was 
used for the synthesis therefore the solutions needed were made up in advance and loaded into 
the synthesizer. The amino acid solutions were made as detailed in the following table: 
 
 
Deprotection solution was made by dissolving 1-hydroxybenzotriazole (3.8 g, 24.8 mmol) in 
a solution of 20% piperidine in DMF (250 mL). The activator solution was made by 
Compound Molecular Mass/g 
mol
-1
 
Mass Used/g Moles 
Used/mmol 
Dissolved 
in/mL 
Fmoc-Asn(Trt)-OH 354.4 0.95 2.68 8 DMF 
Fmoc-Leu-OH 353.4 0.42 1.19 6 DMF 
Fmoc-Ala-OH 311.3 0.37 1.19 6 DMF 
Fmoc-Cys(Trt)-OH 585.7 1.29 2.20 11 DMF 
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dissolving HBTU (8.5 g, 22.4 mmol) in DMF (50 mL). Activator base solution was made by 
adding diisopropylethylamine (17.5 mL, 100 mmol) to N-methylpyrrolidone to make a 
solution with a total volume of 50 mL. DMF was used for washing the resin in between 
synthesis steps. Fmoc-Asn(Trt)-Wang resin (0.208 g) was added to the microwave reaction 
vessel and the program allowed to run to synthesise the peptide. The synthesis program 
consisted of single coupling reactions with cysteine couplings at 50 °C and the remaining 
amino acids at 75 °C. When the peptide was complete the final amino acid was deprotected, 
but no capping was carried out. The resin was removed from the synthesizer and rinsed with 
dichloromethane (5 x 7 mL) followed by diethyl ether and left to dry. Cleavage of the peptide 
from the resin support was achieved by stirring at room temperature for 2 h in a cleavage 
cocktail comprised of trifluoroacetic acid (9 mL), thioanisole (0.5 mL), 1,2-ethanedithiol (0.3 
mL) and anisole (0.2 mL). The resin was then filtered and washed with a few millilitres of 
trifluoroacetic acid and the filtrate was reduced in volume under nitrogen gas. The peptide 
solution was added drop-wise to a 10-fold excess of cold diethyl ether upon which the peptide 
precipitated from solution and was collected via filtration to give an off-white solid. The 
crude product was then desalted by passing it through a Sephadex G-10 size exclusion column 
using 20% acetic acid. Any potential disulfide bonds were reduced by dissolving the peptide 
in a degassed aqueous solution of N-ethylmorpholine (10 mL, 0.05 M) and adding 
dithiothreitol (0.077 g, 0.5 mmol) and stirring under nitrogen at room temperature for 4 h. The 
solution was then taken to pH 3 using 10% trifluoroacetic acid solution and the solvent 
removed in vacuo to give an orange oil. The oil was dissolved in degassed water and purified 
by HPLC using a semi-preparative C-18 reversed phase column and an isocratic method of 
20% acetonitrile and 80% water for 30 min at 3 mL/minute. Solvents contained 0.05% 
trifluoroacetic acid. The peptide was found to elute from the column after 8 min and was 
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collected and lyophilised. MS (MALDI-TOF
+
): m/z 1278 {M + Na}
+
. UV-Vis (H2O) λmax nm 
(log ε): 205 (3.6), 280 (2.1). 
 
3.4.3 CALNN and CCPGCC Peptides 
CALNN and CCPGCC were both purchased in 95% purity from Alta Biosciences, University 
of Birmingham UK and were used without any further purification. 
 
3.4.4 Luminescence Spectroscopy 
Luminescence experiments were carried out using an Edinburgh Instruments fluorescence 
system, FLSPM920. The illumination source uses a 450 W xenon arc lamp. The detection 
system used was a Hamamatsu R928. The emission monochromator is fitted with two 
interchangeable gratings blazed at 500 nm and 1200 nm. Luminescence studies were carried 
out using quartz cuvettes with four transparent polished faces and 1 x 1 cm path length. F900 
spectrometer analysis software was used to record the data. 
 
3.4.4.1 Europium Emission 
Luminescence spectra of EuL
a
 containing samples were gained by excitation of the complex 
at 266 nm, detection of emission in the range 550-750 nm and employing a 550 nm long pass 
filter. Luminescence spectra of EuL
b
 containing samples were gained by excitation of the 
complex at 330 nm, detection of emission in the range 550-750 nm and employing a 550 nm 
long pass filter. A 1 s dwell time and a 1 nm step size were employed with excitation and 
emission slits set to 10 nm and 5 nm respectively. Emission scans were repeated three times 
to produce a cumulative emission spectrum. 
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3.4.4.2 Luminescence Lifetime Measurements 
Luminescence lifetimes were measured using the spectrophotometer described in section 
3.4.4 with a 100 W μF920H lamp illumination source. In the case of EuLa containing samples 
excitation was at 266 nm, whereas for samples containing EuL
b
 excitation was at 330 nm. 
Emission was detected at 615 nm and a 550 nm long pass filter used. Excitation and emission 
slits were set to 10 nm. Emission was detected over an 8 ms range for 300 s with a 0.1 ms 
lamp trigger delay. 
 
3.4.5 DLS and ζ-potential Measurements 
Measurements were obtained using a Beckman-Coulter Delsa Nano C particle analyser and 
data was recorded and analysed using Delsa Nano software. 
 
3.4.5.1 DLS Measurements 
Samples were analysed using quartz cuvettes with four transparent polished faces and 1 x 1 
cm path length. Measurements were taken over 70 accumulations through a 50 μm pinhole. 
Data were analysed using a CONTIN method. 
 
3.4.5.2 ζ-potential Measurements 
Samples were analysed using a quartz flow cell purchased form Beckman-Coulter. 
Measurements were taken over 10 repeats at a 15º scattering angle through a 50 μm pinhole. 
The Smoluchowski conversion equation was used to analyse the data. 
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3.4.6 Fitting of UV-Vis and SPR Titration Data 
 
  
    
    
             
 
  
            
 
  
 
 
          
 
This equation, where [x] is the concentration of the added species, [h] is the concentration of 
the host species and Bmax is the point where maximum change of the observed parameter is 
measured, can be used to find the binding constant of a system when the concentration of both 
species is known and there is a measured change upon binding. The equation was converted 
to a format accepted by the graphing software KaleidaGraph and this software used to fit the 
data curves. The equation was derived by a previous member of the Pikramenou group.
32
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4. Luminescent Nanoparticles for Protein Labelling in Cells 
 
4.1 Introduction 
4.1.1 Luminescent Nanoparticles and Proteins 
As the interest in the use of nanoparticles increases, so does the research into the interaction 
of nanoparticles with biological molecules such as proteins. Studies focussing on the effect of 
protein interaction with nanoparticles on the conformation of the protein are numerous, as are 
the studies into the binding interactions that facilitate protein adsorption onto nanoparticle 
surfaces.
1-13
 Unmodified nanoparticles have not been the only topic of research, with the 
effect of nanoparticle surface modification on protein adsorption also a key area of interest.
14-
19
 Nanoparticles offer a vehicle for the delivery of a large payload of luminescent material to a 
protein for imaging purposes and, where luminescent compounds are decorating the surface of 
the nanoparticles, they may also affect the interaction of the nanoparticle with the protein of 
interest. Indeed, when labelling a protein in order to study its role and function, it is important 
that the label employed, be it a nanoparticle or molecular probe, does not affect the 
conformation of the protein as this may in turn change or eliminate its inherent function. 
 
4.1.2 Understanding Nanoparticle – Protein Interactions 
It is well known that proteins adsorb onto the surface of nanoparticles to form a corona.
3, 6, 7, 
20-24
 The corona is divided into the hard corona, which contains proteins that are immediately 
surrounding the nanoparticles and dissociate over a large timescale of hours or days, if at all, 
and the soft corona which is the outer protein layer that changes comparatively quickly by 
exchange with other protein species from the surrounding environment. For example, a study 
investigating the interaction between α-synuclein, an amyloid protein, and AuNPs found that 
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the protein forms a hard corona through strong electrostatic interactions with the surface of 
the AuNPs, whereas further away from the surface the protein is involved in weaker protein-
protein interactions and is in constant exchange with free protein.
12
 In this case a combination 
of spectroscopic and light scattering techniques were used to examine the interaction between 
the protein and the AuNPs, however, a range of alternative and complimentary techniques are 
available to investigate the interaction of proteins with nanoparticles and the formation of the 
corona.  
 
4.1.2.1 Examining Protein Adsorption Mechanisms 
Several approaches are used to determine the affinity of proteins to nanoparticles and include 
ITC, SPR, DLS, affinity capillary electrophoresis, quartz crystal microbalance and 
fluorescence and UV-Vis spectroscopies.
2, 14, 20, 22
 For example, Brewer et al. measured the 
interaction of BSA with 10 nm citrate-stabilised AuNPs using a quartz crystal microbalance 
and found the binding constant to be 1 μM-1 at pH 7.2 It was proposed that the interaction is 
electrostatic in nature because, whilst both the AuNPs and BSA are negatively charged at pH 
7, the lysine groups of BSA are positively charged allowing the interaction to take place, 
Scheme 4.1. Furthermore, the analysis was used to measure the amount of BSA adsorbed and, 
when taking into account the dimensions of the protein, it was calculated that BSA must bind 
to citrate coated AuNPs by an ‘end-on’ mechanism, i.e. the portion of BSA exposed to the 
AuNP surface is that of the shortest length allowing more BSA molecules to interact with the 
AuNP surface than if the BSA bound through its largest surface. 
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Scheme 4.1 Schematic representation of BSA and a AuNP at pH 7. 
 
An alternative approach examined the formation of a protein corona around citrate-stabilised 
AuNPs that were exposed to cell culture medium containing 10% foetal bovine serum.
3
 In this 
study UV-Vis spectroscopy and light scattering techniques were used to measure the 
formation of the protein corona over time. It was found that the protein corona was loosely 
attached to the AuNPs at first, but over time became irreversibly attached, suggesting an 
electrostatic mechanism as opposed to a covalent mechanism of interaction which would form 
a strong interaction more quickly. 
 
A more recent study used alternative techniques to examine the interactions between BSA and 
citrate capped AuNPs and also suggests that it is of an electrostatic nature.
5
 In this research 
light scattering was used to measure the diffusion time of the AuNPs in the absence and 
presence of protein and this was used to calculate the thickness of the protein corona because 
the increased dimensions of the AuNPs caused by adsorbed protein should affect their 
diffusion. AuNPs were exposed to BSA at concentrations equal to that of serum found in 
human blood. AuNPs of 51, 70 and 93 nm were used in the experiments and it was found that 
the size of the AuNPs did not impact on the adsorption of the protein which was found to 
form a monolayer across the surface of all of the AuNPs; this conclusion was based on the 
known dimensions of the protein and the measured 5 nm increase in the radii of the AuNPs of 
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all sizes. The magnitude of the negative ζ-potential of the citrate-stabilised AuNPs was 
reduced upon BSA adsorption which is suggested to be indicative of electrostatic interactions 
between the anionic citrate and cationic lysine side chains as opposed to displacement of the 
citrate by the one thiol group found on the surface of BSA. Interestingly, poly(ethylene 
glycol) coated AuNPs of 56 nm diameter did not display any protein adsorption which may 
confirm the electrostatic interaction between BSA and citrate ions since the poly(ethylene 
glycol) layer was attached using sulphur-gold chemistry which would have displaced the 
citrate ions and reduced the surface charge of the AuNPs, as confirmed by ζ-potential 
measurements, eliminating the opportunity for BSA to adsorb electrostatically. Having said 
this, the poly(ethylene glycol) layer may be up to 5 nm if fully extended and as such could 
sterically prevent BSA from binding to the surface of the AuNPs through its thiol group if this 
is indeed the mechanism through which it adsorbs. 
 
Tsai and co-workers, however, conclude that BSA covalently binds to AuNPs through its one 
surface available thiol.
11
 This conclusion is based upon the measured affinity of the protein 
for AuNPs of 10, 30 and 60 nm diameters which is suggested to be high and, therefore, 
indicative of covalent binding. DLS, infra-red spectroscopy and asymmetric-flow field flow 
fractionation were combined to assess the formation of a protein corona in the presence of 
BSA over a range of protein concentrations. The surface change of the AuNPs was plotted as 
a function of protein concentration and the data fit to find the equilibrium binding constant 
which, for the systems explored, was found to be in the range of 0.51 - 1.65 μM-1. 
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4.1.2.2 The Effect of Nanoparticle Surface Chemistries on Protein Adsorption 
Proteins may react in different ways to nanoparticles comprised of different materials which is 
not unexpected.
16
 Proteins may also interact differently with nanoparticles of the same 
material, but with differing surface chemistries. For example, Boulos and co-workers 
examined the interaction of BSA with AuNPs of various sizes and surface charges.
14
 
Fluorescence quenching of the BSA when in the presence of the AuNPs was measured in 
addition to the employment of affinity capillary electrophoresis and it was found that, 
although BSA demonstrated a similar affinity for all AuNPs tested, there was a faster 
adsorption of BSA onto positively charged AuNPs in comparison to those with a negative 
surface charge. Zeng and colleagues also used capillary electrophoresis to measure the 
interaction of β-casein with AuNPs possessing two different surface chemistries.19 The 
AuNPs were of identical shape and dimensions, however, one sample had 100% coating with 
carboxyl terminated polyhistidine, whereas the other was only 95% coated with this and the 
remaining 5% surface coverage was provided by polyhistidines with an amide blocking their 
terminal carboxyl. Both sets of AuNPs displayed very similar properties such as ζ-potential 
and mobility, however, the small change in surface chemistry meant that β-casein displayed 
an affinity that was five times greater in the case of the AuNPs with 95% carboxyl terminated 
polyhistidine coating than AuNPs with 100% coating by the same ligands. It was suggested 
that this small change in surface chemistry of the AuNPs reduced the repulsion between the 
carboxyl groups and the acidic protein leading to a stronger interaction. 
 
Alternatively, DLS and TEM have been used to investigate the effect of the surface chemistry 
of AuNPs on the adsorption of serum proteins.
15
  AuNPs of 39 nm diameter were either 
citrate-stabilised or coated with thioglycolic acid, cysteine or poly(ethylene glycol). The 
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serum proteins used in the experiments were BSA, transferrin and fibrinogen. The results 
show that the capping of AuNPs with poly(ethylene glycol) prevents protein adsorption, with 
longer chain lengths prohibiting BSA adsorption completely. Fibrinogen caused aggregation 
of AuNPs with all surface coatings except poly(ethylene glycol), whereas BSA and transferrin 
formed mono or bilayer coronas of 6 - 8 nm around citrate and thioglycolic acid capped 
AuNPs. The dissociation constants of BSA and transferrin with citrate and thioglycolic acid 
coated AuNPs were found to be in the range of 10
-8
 - 10
-6
 M. 
 
4.1.2.3 Examining the Effect of Adsorption on Protein Conformation 
Alternative methods are often used for the exploration of how interaction with nanoparticles 
affects the structure of the protein. These techniques include spectroscopic methods such as 
CD, fluorescence, Fourier transform infrared and NMR.
4, 7, 8, 10, 22, 25
 For example, a recent 
study found that when polymer nanoparticles were exposed to serum containing cell growth 
media BSA was the most abundant protein in the resulting corona. Further investigations 
involving the titration of nanoparticles into a BSA solution showed, through CD 
measurements, that the structure of BSA was altered upon interaction with the nanoparticles.
25
 
A previous study into AuNPs of various sizes with a range of common blood proteins used 
CD analysis to find that, generally, the structure change in proteins is small and localised 
when interacting with AuNPs and that the effect on structure is greater with larger particles, 
however, it was concluded that it was not possible to find overall trends since the nature of the 
protein change was different for each protein examined.
7
 Recently, the interaction of α-
synuclein with 20 nm cationic poly(allylamine hydrochloride) coated AuNPs was examined 
through CD measurements.
13
 The CD spectra of the protein revealed that, although the protein 
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is naturally unstructured, interaction with AuNPs was able to increase the β-sheet content and 
reduce the α-helix content of the protein. 
 
Whilst there are a range of techniques available to assess nanoparticle-protein interactions, it 
is fair to conclude that the best analysis will encompass more than one technique. Indeed, 
much of the research found in literature does not rely on a single method, possibly because of 
the effect of nanoparticles within the analysis. Certainly, the presence of noble metal 
nanoparticles can affect spectroscopy data due to inner filter effects. 
 
4.1.3 Nanoparticle Protein Corona and Cells 
The formation of a protein corona around nanoparticles upon mixing with biological fluids 
alters the surface of the nanoparticle and how it appears to tissues, cells and receptors.  A 
recent study investigated the loading of substances such as doxorubicin into agglomerates of 
lysozyme and citrate AuNPs and subsequent coating with serum albumin, Scheme 4.2.
26
 
 
 
Scheme 4.2 Schematic representation of loading of doxorubicin into AuNP-lysozyme 
agglomerates and subsequent coating with serum albumin. 
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In this case the motivation for employing serum albumin was to stabilise the agglomerates 
and because it was suspected its presence may facilitate cell uptake. Indeed, BSA was shown 
to prevent alteration in the absorption spectra of the agglomerates after centrifugation and 
redispersion and the albumin coated agglomerates were taken up by human cervical cancer 
cells allowing the release and toxic effects of doxorubicin to ensue.
26
 
 
Several other recent publications have also reported the effect of protein corona on the 
cellular uptake of nanoparticles. In comparison to the delivery of bare nanoparticles, where 
the presence of a protein corona was avoided by use of serum free cell growth media, it was 
found that the protein corona reduced uptake of unmodified silica and carboxylated 
polystyrene nanoparticles by human lung cancer cells by limiting their adhesion to the cell 
membrane.
27
 In this case the nanoparticles were fluorescently labelled and as such the number 
of nanoparticles internalised per cell could be measured directly using flow cytometry. The 
adhesion of the nanoparticles to the cell membrane was examined by initial incubation of the 
cells with nanoparticles at 4 ºC, preventing active uptake of the nanoparticles, and subsequent 
washing of the cells and incubation with nanoparticle free media at 37 ºC, allowing 
internalisation of any nanoparticles adhered to the cell surface, before flow cytometry 
analysis. Similarly, the protein corona of the same types of nanoparticles was found to affect 
cellular uptake in addition to thrombocyte activation, haemolysis and endothelial cell death.
24
 
Investigating the protein corona of polymer nanoparticles, another study found that BSA was 
the most abundant protein in the corona when the nanoparticles were introduced to serum 
containing cell growth media. The identities of the proteins in the corona were revealed by 
their isolation and subsequent separation by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis. CD analysis showed that BSA was denatured upon interaction with 
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nanoparticles and this led to decreased adhesion to the cell membrane and a reduction in the 
efficiency of uptake by human monocytic cells. In contrast, the protein corona coated 
nanoparticles were found to trigger receptor-mediated phagocytosis in differentiated 
macrophage-like cells, but in this case without affecting uptake efficiency. The cell adhesion 
and uptake of the nanoparticles was again investigated using flow cytometry as described for 
the previous study discussed.
25
 
 
A recent study examined the biodistribution of AuNPs in mice after intra-venous 
administration.
28
 Citrate-stabilised AuNPs and AuNPs coated with HSA or apolipoprotein E, 
which are both proteins found in the blood, were compared in terms of their accumulation in 
certain organs. In this case the AuNPs were radio-labelled with 
198
Au and the proteins labelled 
with fluorescent dyes. Gamma spectroscopic radio analysis of tissue sections and fluorescence 
analysis of histology sections were used to quantify AuNP uptake. It was found that after 19 
and 48 hours the accumulation of 15 nm citrate capped AuNPs was greater than 95% in the 
liver whereas only 52% of 15 nm AuNPs coated with HSA and 72% of 15 nm AuNPs coated 
with apolipoprotein E accumulated in the liver. In comparison to 15 nm citrate capped 
AuNPs, 15 nm protein conjugated AuNPs displayed increased accumulation in the spleen, 
with 18% of HSA coated AuNPs also accumulating in the lungs. Evidence of HSA coated 15 
nm AuNPs was also found in brain tissue. The protein modification of 80 nm AuNPs, 
however, did not affect biodistribution in comparison to citrate-stabilised AuNPs of the same 
size. This demonstrates the use of protein modification of 15 nm AuNPs for organ targeting 
and increased exposure to the systemic system in mice which may be of use for therapeutic 
applications. 
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4.1.4 Nanoparticles for Cell and Protein Labelling 
The possible negative effect of nanoparticles on protein structure may be seen as a 
disadvantage of their use; however, as discussed previously, nanoparticles can be used 
effectively to deliver therapies into cells, therefore presenting the opportunity for delivery of 
other species such as imaging agents. Research by the Pikramenou group has demonstrated 
the use of luminescent europium coated 13 nm AuNPs attached to a cell penetrating peptide 
for labelling of human platelets, which do not respond to alternative labelling methods such as 
microinjection or transfection. The platelets were imaged using luminescence microscopy 
which detected emission from the europium delivered using the AuNPs.
29
 Further to this, 
human lung cancer cells were labelled with luminescent ruthenium coated AuNPs of 13 and 
100 nm without any observed toxicity, and, in the latter case, the ruthenium luminescence 
showed the AuNPs were co-localised with chromatin, a complex of protein and DNA.
30
 
 
In addition to general cellular labelling, nanoparticles have also been shown to be useful in 
the fluorescent labelling and detection of proteins. One example uses AuNPs coated with GFP 
for detection of an array of serum proteins in vitro.
31
 In this case GFP fluorescence is 
quenched by its electrostatic interaction with AuNPs, but is observed after displacement of the 
GFP from the AuNPs by other proteins. A signature response to individual serum proteins is 
reported. Another study uses the absorption profile of 18 and 33 nm AuNPs to detect HSA.
32
 
AuNPs were coated with HSA and when a polyclonal antibody was introduced it became 
bound to the HSA coated AuNPs changing their absorption profile. The use of this system in 
human urine samples allows the free HSA contained within the sample to compete with the 
HSA coated AuNPs for binding to the antibody; thus, the absorption response can be used to 
calculate the concentration of HSA contained within the sample. 
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Whilst the discussed research is extremely useful for protein labelling and detection in vitro, 
nanoparticles have the potential to label proteins in cells which would allow the investigation 
of protein interactions and function within cells. Research combining cellular targeting of 
luminescent nanoparticles and protein labelling using fluorescent nanoparticles is needed. 
 
4.1.5 Research Aims 
The main objective of the research in this chapter is to explore the possibility of specific and 
selective labelling of a protein within cells using luminescent nanoparticles, Scheme 4.3. The 
luminescent nanoparticles consist of a gold core decorated with luminescent lanthanide 
complexes; the luminescence properties of the lanthanide complexes when in contact with 
proteins were established in Chapter 2. The labelling of a particular protein involves genetic 
engineering to induce the expression of the protein of interest with the addition of a 
nanoparticle binding motif, as designed in Chapter 3. Initial studies will demonstrate the 
interaction of nanoparticles with protein in vitro before proceeding to investigate the ability of 
the nanoparticles to label proteins in cells. 
 
Scheme 4.3 Schematic representation of specific labelling of a recombinant protein with 
luminescent AuNPs. 
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Figure 4.1 Luminescent lanthanide complexes used in this chapter. 
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4.2 Results and Discussion 
4.2.1 Citrate-Stabilised AuNPs and Protein 
In order to investigate the interaction of proteins with citrate-stabilised AuNPs (Citrate-
AuNPs) in vitro, BSA was chosen as a model protein. BSA is widely available and there is a 
wealth of comparable publications describing the interactions of BSA with nanoparticles of 
various materials, shapes and with a range of surface modifications. Unmodified citrate-
AuNPs were first investigated for their interactions with BSA before continuing experiments 
with luminescent AuNPs in order to assess whether surface modification affects the 
interaction. The synthesis of Citrate-AuNPs can be found in Chapter 3. 
 
4.2.1.1 Surface Coverage of Citrate-AuNPs by BSA 
As previously discussed, the unique surface properties of AuNPs gives rise to a UV-Vis 
absorption band which changes as a result of surface modification or aggregation of the 
AuNPs. UV-Vis spectroscopy was, therefore, used to examine the interaction of BSA with the 
surface of AuNPs. 
 
   
Figure 4.2 Left: Absorption spectra of 1 nM Citrate-AuNPs with microlitre additions of 0.1 
mM BSA in water. Right: Change in SPR position of 1 nM Citrate-AuNPs with titration of 
BSA. 
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It is clear from the change in the SPR absorption peak of the Citrate-AuNPs that BSA is able 
to interact with the surface of the AuNPs. Although both the Citrate-AuNPs and BSA are 
negatively charged, the interaction is not unexpected because the surface of BSA has many 
lysine residues which, at pH 7, are positively charged and can, therefore, initiate an 
electrostatic interaction with the Citrate-AuNPs.
2, 3, 5
 In order to elucidate more information 
about this interaction, BSA solutions of different concentrations were titrated into Citrate-
AuNPs. The UV-Vis spectra were collected and analysed as seen in Figure 4.2 and the results 
are shown in Figure 4.3. 
 
   
Figure 4.3 Left: Change in SPR position of 1 nM Citrate-AuNPs with titration of BSA in 
water at a concentration of 0.1 mM (●) and 0.8 mM (□). Right: Absorption spectra of 1 nM 
Citrate-AuNPs (―) with a single 1 mL addition of 0.8 mM BSA (- -) and 10 mins after 
protein addition (-∙-). 
 
The results in Figure 4.3 show that the change at the surface of the AuNPs is the same, within 
experimental error, when BSA of different concentrations is titrated into a solution of 
Citrate-AuNPs. A previous study has observed higher binding constants for initial BSA 
addition to citrate coated gold surfaces than for subsequent BSA binding; this is because the 
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positive lysine residues of incoming BSA.
2
 The same conclusion, however, cannot be drawn 
from the results here because of the lack of difference in surface modification of the AuNPs 
between the different concentrations of BSA added. It may be the case that at both 
concentrations used, the initial protein additions are able to coat the surface of the AuNPs and 
prevent the adsorption of subsequently added protein. The addition of 0.8 mM BSA in a 
single 1 mL addition, rather than through titrations of microlitre quantities, resulted in the 
same shift in the SPR of the AuNPs as seen for the titrations. This indicates that within the 
concentration range used here the adsorption of BSA onto the surface of AuNPs does not 
differ depending on the ratio of BSA to AuNPs since at the beginning of the titrations there 
was much less BSA present and yet this did not affect the attainment of the ~7 nm shift in 
SPR position. The absorption spectra on the right of Figure 4.3 also demonstrates the stability 
of BSA coated AuNPs because their absorption profile does not change with time. 
 
The interaction of BSA with AuNPs can also be investigated by examining the fluorescence 
of the protein. 
           
Figure 4.4 Left: Emission spectra of 2 μM BSA in water in the absence (―) and presence of 1 
nM Citrate-AuNPs (---), λex = 290 nm. Right: Emission spectra of 0.3 μM TbL
a
-BSA in 
water in the absence (―) and presence of 0.2 nM Citrate-AuNPs (---), λex = 279 nm. All 
spectra corrected for PMT response. 
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BSA contains two tryptophan residues that give a fluorescence peak at ~340 nm when excited 
in the range 250-300 nm. It has previously been demonstrated that adsorption of BSA onto the 
surface of noble metal nanoparticles results in quenching of the fluorescence by the metal 
surface. Quenching of the fluorescence form BSA can, therefore, indicate adsorption of the 
protein onto the nanoparticles.
7, 9, 14
 In the case of native BSA, the emission spectra shown in 
Figure 4.4 show a clear quenching of protein based fluorescence indicating adsorption onto 
the surface of Citrate-AuNPs and confirming the interaction seen in the UV-Vis results. It is 
interesting to compare this to the change in fluorescence seen for lanthanide labelled BSA, 
TbL
a
-BSA which is synthesised and characterised in Chapter 2, because the quenching effect 
of the Citrate-AuNPs on the protein fluorescence is much less pronounced. In both samples 
the ratio of protein to AuNPs is roughly equal which means the difference in quenching 
between the two proteins must be due to the modification of the protein with the lanthanide 
complex. It could be said that the process of labelling BSA with the lanthanide complex has 
affected its conformation and, therefore, its ability to adsorb onto the AuNPs, but it may also 
be the case that the lanthanide label, which also absorbs in the same range as BSA, may be 
absorbing some of the excitation light which means that the fluorescence of BSA is not as 
intense as would be expected even before the addition of AuNPs. Certainly, in both cases 
Citrate-AuNPs are able to act as an inner filter by increasing the absorption of the sample 
and scattering light. In addition to indicating the interaction between BSA and AuNPs, the 
fluorescence quenching may arise from a change in the environment of the tryptophan 
residues which would occur if the protein had changed conformation when adsorbing onto 
Citrate-AuNPs. In order to confirm whether a change in protein conformation has occurred a 
further technique is required. 
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4.2.1.2 Effect of Citrate-AuNPs on Protein Conformation 
CD analysis was used to investigate the change in the conformation of BSA in solution when 
Citrate-AuNPs are titrated into it. 
 
 
Figure 4.5 CD spectra of 0.1 μM BSA (―), 0.1 μM BSA + 31 pM Citrate-AuNPs (---) and 
0.1 μM BSA + 124 pM Citrate-AuNPs (-●-). All samples in water. 
 
The concentration of BSA required to obtain a good CD profile is much lower than the 
concentration of BSA used in the UV-Vis absorption titrations, therefore, the concentration of 
Citrate-AuNPs used was also lower. In this experiment the ratio of BSA to AuNPs is much 
lower than used for the UV-Vis titrations, which would allow the BSA to spread across the 
surface of the AuNPs if, indeed, that is the mechanism of the interaction. The negative 
ellipticity of BSA at 209 and 220 nm is indicative of its α-helical content and shows a small 
decrease as higher amounts of Citrate-AuNPs are added. The small decrease in ellipticity 
-40
-30
-20
-10
0
10
20
30
40
180 200 220 240 260 280 300 320
C
D
/m
d
e
g
/nm
  Chapter 4
   
170 
 
observed does not indicate any spreading or denaturing of BSA on the surface of the AuNPs, 
but a small local change in the structure of the protein. This is in agreement with previous 
studies of serum albumins on AuNPs of various sizes and in a range of concentration ratios.
4, 
7, 8
 This confirms that the interaction of BSA with Citrate-AuNPs does not alter its 
conformation significantly. Since this indicates that BSA does not spread across the surface of 
AuNPs it also confirms the suggestion that the small differences in the SPR shift of the 
AuNPs observed in the UV-Vis titration experiments when varying concentrations of BSA are 
present, Figure 4.3, are not caused by BSA adsorbing by spreading across the surface of the 
AuNPs in one case and tightly packing on the surface without spreading in another, but 
instead can be attributed to experimental error since the SPR changes in each case are within 
the experimental error of ± 0.5 nm. 
 
4.2.2 Luminescent AuNPs and Protein 
AuNPs coated with luminescent lanthanide complexes were chosen as imaging agents for 
protein labelling. The interaction of protein with lanthanide coated AuNPs was, therefore, 
investigated in order to assess the effect of the interaction on both the luminescence properties 
of the nanoparticles and the structure of the protein. It will be interesting to compare the effect 
on the protein to those observed with Citrate-AuNPs because any differences will be caused 
by the modification of the surface of the AuNPs. BSA was again used as a model protein. 
During the course of this work Gunnlaugsson and colleagues have published an investigation 
into the binding of BSA to AuNPs coated with a europium complex.
33
 In this case the 
europium was chelated by a DOTA type ligand and attached to the surface of AuNPs via an 
alkyl thiol group. The complex was not luminescent, but was able to interact with a β-
diketonate antenna upon which europium luminescence was observed. Interaction of the 
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luminescent AuNPs with BSA caused quenching of the europium luminescence, thus 
presenting the potential of the system as a sensor for BSA. Subsequent introduction of 
ibuprofen, which binds to site II of BSA, resulted in a recovery of europium emission leading 
to a further possibility of the system acting as a sensor for molecules that bind to site II of 
BSA when BSA is present.
33
 
 
4.2.2.1 Surface Coverage of TbL
a
-AuNPs by BSA 
 
       
Figure 4.6 Absorption spectra of Citrate-
AuNPs (―), TbLa-AuNPs (---) and TbLa-
AuNPs + BSA (-●-).                             
Table 4.1 λmax of SPR band of 13 nm 
AuNPs with different surface 
modifications. 
a
 ± 0.5 nm
 
After the addition of TbL
a
 to the AuNPs the sample was passed through a Sephadex G-15 
size exclusion column to remove any unbound lanthanide complex before BSA was added. It 
is apparent that the surface environment of the Citrate-AuNPs is modified upon addition of 
TbL
a
 but that no further change in at the surface is detected after addition of BSA which leads 
to the assumption that BSA does not interact with TbL
a
-AuNPs. 
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The interaction of BSA with partially coated TbL
a
-AuNPs was also assessed by UV-Vis 
spectroscopy. 
 
       
Figure 4.7 Absorption spectra of Citrate-
AuNPs (―), pTbLa-AuNPs (---) and 
pTbL
a
-AuNPs + BSA (-●-).                              
Table 4.2 λmax of SPR band of 13 nm 
AuNPs with different surface 
modifications. 
 a
 ± 0.5 nm
 
The shift in the SPR band of Citrate-AuNPs after addition of TbL
a
 is approximately half of 
the maximum shift that can be achieved when adding this complex to 13 nm Citrate-AuNPs, 
as seen previously, indicating that the surface of the AuNPs is not fully coated by the 
lanthanide complex.
34
 The partially coated AuNPs are denoted as pTbL
a
-AuNPs. The AuNPs 
were then passed through a Sephadex G-15 size exclusion column to remove any unbound 
TbL
a
, after which the SPR position was unchanged. Subsequent addition of BSA, however, 
does not have a further effect of the position of the SPR band of the AuNPs, which may mean 
that the protein is not able to interact with the surface of the AuNPs when their surface is even 
partially coated by TbL
a
. The AuNPs with each surface coating were analysed by measuring 
their ζ-potentials. 
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Sample ζ-potential/mV 
Citrate-AuNPs -33 ± 0.5 
BSA-AuNPs -44 ± 0.2 
pTbL
a
-AuNPs -25 ± 2.0 
pTbL
a
-AuNPs + BSA -16 ± 0.7 
Table 4.3 ζ-potential measurements of 13 nm AuNPs with various surface modifications. 
 
The ζ-potential measurements reveal that Citrate-AuNPs have a negative surface charge 
which would be expected due to the presence of the anionic citrate at their surface. The 
magnitude of the negative charge is sufficient to stabilise the AuNPs because of their 
repulsion of one another preventing aggregation. After addition of BSA to Citrate-AuNPs, 
the magnitude of the negative charge is increased which, may be expected due to the overall 
negative charge of the protein, however, this does not concur with previous reports that found 
that the negative value obtained for citrate-stabilised AuNPs was slightly reduced after 
addition of BSA.
2, 5
 When TbL
a
 is added to Citrate-AuNPs the magnitude of the negative 
surface charge is reduced which is due to the displacement of anionic citrate from the surface 
of the AuNPs by neutral TbL
a. The most interesting result, however, is the ζ-potential 
measurement of pTbL
a
-AuNPs after addition of BSA. In this case the negative surface 
charge of the AuNPs is further reduced to the point where the AuNPs may become unstable 
and susceptible to aggregation. This result is somewhat counterintuitive because, firstly, the 
absorption results show no change to the surface environment of the AuNPs which leads to 
the assumption of no BSA interaction, which would mean no change in the ζ-potential, and 
secondly, if there is an interaction BSA is negatively charged and so should increase the 
surface charge of the AuNPs as seen with fully coated BSA-AuNPs. This may be because the 
interaction of BSA with pTbL
a
-AuNPs is weak and that the displacement of the citrate 
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anions by TbL
a
 has reduced the interaction of the AuNPs with the cationic surface groups of 
BSA, allowing these to present towards the solution, reducing the negativity of the ζ-potential 
of the pTbL
a
-AuNPs. 
 
The effect of the interaction between BSA and pTbL
a
-AuNPs was also probed by measuring 
the fluorescence of BSA. 
 
 
Figure 4.8 Emission spectra of 2 μM BSA in water in the absence of any AuNPs (―), in the 
presence of 1 nM pTbL
a
-AuNPs (---), and in the presence of 1 nM Citrate-AuNPs (-●-). λex 
= 290 nm. All spectra corrected for PMT response. 
 
The fluorescence of BSA is quenched upon interaction with pTbL
a
-AuNPs, indicating that 
some adsorption onto the AuNPs has taken place. The quenching effect of Citrate-AuNPs, 
however, is far greater than that of pTbL
a
-AuNPs which may suggest that the interaction 
between BSA and pTbL
a
-AuNPs is not as strong as that between BSA and Citrate-AuNPs. 
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This may explain why the UV-Vis absorption experiments were able to characterise the 
interaction between BSA and Citrate-AuNPs well, but not that of BSA and pTbL
a
-AuNPs. 
 
4.2.2.2 Effect of Luminescent AuNPs on Protein Conformation 
CD measurements were used to assess the effect of BSA conformation as a result of 
interaction with luminescent AuNPs.  In this case 0.1 μM BSA was in solution with 42 pM of 
either Citrate-AuNPs or pTbL
a
-AuNPs. 
 
 
Figure 4.9 CD spectra of 0.1 μM BSA in the presence of 42 pM Citrate-AuNPs (―) or 42 
pM pTbL
a
-AuNPs (---). 
 
The CD spectra of BSA in Figure 4.9 indicate that the conformation of the protein is less 
perturbed by the presence of pTbL
a
-AuNPs than Citrate-AuNPs due to the higher 
magnitude of the negative α-helical peaks in the former case. This may mean that BSA is able 
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to interact to a greater extent with Citrate-AuNPs than pTbL
a
-AuNPs; it is fair to conclude 
that due to the electrostatic nature of the interaction of BSA with Citrate-AuNPs, the 
displacement of the citrate by charge neutral TbL
a
 would reduce this interaction. 
 
4.2.2.3 Emission Properties of Luminescent Nanoparticles with Protein  
The emission properties of the lanthanide nanoparticles were assessed by taking TbL
a
-
AuNPs with and without the presence of protein and recording steady state emission spectra 
of the lanthanide luminescence. In all cases the concentration of TbL
a
-AuNPs was 
approximately 1 nM. A solution of BSA in water was added to TbL
a
-AuNPs to reach a final 
BSA concentration of 3.3 μM. Emission of BSA alone in solution is also presented for 
comparison and has been normalised to match the emission counts of TbL
a
-AuNPs with 
BSA. 
 
Figure 4.10 Emission spectra of 1 nM TbL
a
-AuNPs (―), 1 nM TbLa-AuNPs + 3.3 μM BSA 
(---) and 11 μM BSA (-●-) normalised to TbLa-AuNPs + BSA. λex = 266 nm, corrected for 
PMT response. 
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The emission spectra demonstrate that the characteristic Tb
3+
 emission is seen when TbL
a
-
AuNPs are in solution with and without BSA. There is a background observed when BSA is 
present and this is caused by the fluorescence of BSA itself, as demonstrated by the emission 
spectrum of BSA. The emission results indicate that the luminescent nanoparticles are 
appropriate for protein labelling due to the preservation of their luminescent properties when 
in the presence of protein. 
 
4.2.2.4 Emission Properties of Luminescent Nanoparticles with Cell Growth Media 
As discussed within the literature, it is well known that proteins found within cell growth 
media readily form a corona around nanoparticles.
3, 25
 It was thought prudent, therefore, to 
examine the properties of the luminescent AuNPs when suspended in the cell growth media 
that will be used for cell studies. In this case EuL
b
-AuNPs were examined in serum 
containing Dulbecco’s Modified Eagle’s Medium. The synthesis and characterisation of EuLb 
can be found in Chapter 2. EuL
b
-AuNPs were made by titrating a solution of EuL
b
 into 
Citrate-AuNPs until the SPR peak of the AuNPs stopped shifting; excess EuL
b
 was then 
removed by centrifugation. 100 μL EuLb-AuNPs were suspended in either complete media or 
distilled water to give a total volume of 1 mL. The absorption spectra of the samples were 
recorded before and after isolating the AuNPs by centrifugation, discarding the supernatant 
and re-suspending in distilled water and repeating to wash the AuNPs. It was reasoned that if 
the protein corona was able to displace any lanthanide complex from the surface of the 
AuNPs then the wash steps would remove the unbound lanthanide complex. The wash steps 
were also carried out on the EuL
b
-AuNPs in water for consistency in case the washing 
process itself affected the EuL
b
-AuNPs. The emission spectra of the samples were then 
recorded. 
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Figure 4.11 Top left: Absorption spectra of EuL
b
-AuNPs diluted in media before (―) and 
after (---) washing. Top right: Absorption spectra of EuL
b
-AuNPs diluted in water before 
(―) and after (---) washing. Bottom left: Absorption spectra of EuLb-AuNPs diluted in 
media (―) or water (---) both after washing. Bottom right: Emission spectra of EuLb-AuNPs 
diluted in media (―) or water (---) both after washing. λex = 330 nm, corrected for PMT 
response. 
 
The absorption spectra of the AuNPs in Figure 4.11 show that those originally dispersed in 
media suffered some changes during the washing steps, with a possible indication of some 
flocculation, although no aggregation was apparent. The AuNPs dispersed in water 
throughout show a broader SPR band than those in media from the beginning, but this does 
not change after washing. The differences in the SPR bands may be due to the difference in 
dielectric constant of the surrounding media given that all samples, once in water, give a 
similar SPR peak, whereas only those dispersed in cell culture media display a different 
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curve.
35, 36
 Indeed the SPR curve of the AuNPs originally dispersed in cell culture media 
matches those of AuNPs in water once isolated and redispersed in water. Both samples of 
EuL
b
-AuNPs after wash steps have very similar absorbance arising from the AuNPs at ~520 
nm and from the EuL
b
 complex at ~330 nm which means that they are comparable for 
emission studies. The emission spectra of both samples are remarkably similar and clearly 
show the characteristic emission peaks of Eu
3+
. The emission spectra confirm that any protein 
corona formed when EuL
b
-AuNPs are suspended in media does not affect their luminescence 
properties, further reinforcing their suitability for protein labelling in cells. 
 
4.2.3 EuL
b
-AuNPs as Protein Labels in Cells 
4.2.3.1 Target Protein and Its Expression in HeLa Cells 
As discussed in Chapter 3, of the peptides studied CCPGCC showed the greatest affinity for 
AuNPs and as such will be used as the binding motif for the luminescent AuNPs. In order to 
label a protein of interest the binding motif will need to be expressed in cells as part of a 
recombinant protein. In this case enhanced GFP was chosen as the target protein to be 
labelled in cells because it is fluorescent and as such should allow co-localisation with the 
EuL
b
-AuNPs to be established through fluorescence microscopy. More specifically, the 
recombinant protein has the binding motif contained within the peptide sequence 
FLNCCPGCCMEP which is fused to the C-terminal of enhanced GFP. The recombinant 
protein will henceforth be referred to as GFP-4C. Previously published work has established 
the ability of a similar recombinant protein of enhanced GFP and CCPGCC to bind to AuNPs 
in vitro in an oriented fashion through the tetracysteine motif.
37
 Furthermore, the recombinant 
protein was found to have strong affinity for AuNPs of a range of sizes and a recombinant 
protein with the dicysteine motif, as opposed to the tetracysteine, did not have any higher 
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affinity for AuNPs than native enhanced GFP.
37
 This research confirms the possibility of 
using the tetracysteine motif CCPGCC as a binding sequence for AuNPs when fused to a 
protein of interest. 
 
A plasmid expressing GFP-4C was transformed into Escherichia coli and amplified. The 
amplified plasmid was harvested and purified before being used to transfect HeLa cells, a 
human cervical cancer cell line. 
 
 
Figure 4.12 Confocal microscopy images of (a) HeLa cells and (b) HeLa cells transfected for 
24 h to express GFP-4C. Left: bright field and Right: Fluorescence where λex = 488 nm and 
λem = 500-550 nm. Scale bar = 10 μm. 
 
The images in Figure 4.12 reveal the success of the transfection of HeLa cells to express GFP-
4C. The untreated HeLa cells display some autofluorescence, however, the signal is much 
lower than that exhibited by the transfected cells, indicating that the fluorescence does indeed 
originate from GFP-4C. It is not uncommon to see autofluorescence from HeLa cells 
examined under these conditions originating from molecules such as flavin adenine 
a
b
  Chapter 4
   
181 
 
dinucleotide.
38
 The fluorescence of the transfected cells is diffuse across the cells which 
means that GFP-4C is located throughout the cell cytoplasm. 
 
4.2.3.2 Treatment of HeLa Cells with Citrate-AuNPs 
After establishing the success of transfecting HeLa cells to express GFP-4C, the uptake of 
AuNPs by HeLa cells was then examined. Firstly, HeLa cells both expressing and not 
expressing GFP-4C were treated with Citrate-AuNPs for 24 hours. Transfected HeLa cells 
either had the transfection media removed after 24 hours and prior to the addition of Citrate-
AuNPs, which were incubated with the cells for a further 24 hours, or were treated with 
transfection media for 48 hours with the Citrate-AuNPs being added to the transfection 
media for the final 24 hours. 
 
 
Figure 4.13 Confocal microscopy images of (a) HeLa cells transfected for 24 h to express 
GFP-4C with subsequent treatment with 0.9 nM Citrate-AuNPs for 24 h after the removal of 
Lipofectamine 2000 and (b) HeLa cells transfected for 48 h to express GFP-4C with treatment 
with 0.9 nM of Citrate-AuNPs for the final 24 h in the presence of Lipofectamine 2000. 1) 
bright field, 2) fluorescence where λex = 488 nm and λem = 500-550 nm, 3) reflectance where 
λex = 637 nm and λem = 400-700 nm and 4) overlay of fluorescence and reflectance images. 
Scale bar = 10 μm. 
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Transfection factors have previously been used for cellular delivery of AuNPs and other 
luminescent nanoparticles.
39-41
 In this case it would seem that the presence of the transfection 
factor Lipofectamine 2000 is affecting the uptake of the Citrate-AuNPs because large 
aggregates are seen in both the bright field and reflectance images where the transfection 
factor is not present, Figure 4.13a, but not when the transfection factor is present, Figure 
4.13b. Typically AuNPs are observed as dark objects in bright field images and bright spots in 
reflectance images if their dimensions make them large enough to be detected.
42
 Reflectance 
imaging can typically detect AuNPs with diameters above 30 nm, and particles with diameters 
of 30 - 40 nm offer good signal to noise ratio in bright field imaging.
42, 43
 It is, therefore, 
assumed that the dark objects in the bright field images and the corresponding bright spots in 
the reflectance images are clusters of Citrate-AuNPs since individual particles are likely to 
be too small to be detected. The apparent presence of AuNP clusters indicates aggregated 
AuNPs; in contrast, the lack of these features when the transfection factor is present does not 
necessarily mean that AuNPs are not present, but perhaps that the transfection factor has aided 
their delivery without aggregation which would mean that they are small enough to go 
undetected by these microscopy techniques. It is clear that where AuNPs are visible, Figure 
4.13a, that they could possibly be in the vicinity of a discrete amount of GFP-4C, however, 
since the fluorescence of the protein is diffuse it is difficult to conclude whether the this is, in 
fact, due to interaction. In order to gain more information about the localisation of the 
Citrate-AuNPs within the cells, TEM was used to gain images of the cells after transfection 
and treatment with Citrate-AuNPs over two timeframes with transfection factor present. 
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Figure 4.14 TEM micrographs of HeLa cells treated with Citrate-AuNPs for a) 30 min and b) 
24 h. Both treatments in the presence of Lipofectamine 2000. 
 
The TEM micrographs clearly show that when the Citrate-AuNPs treatment has been applied 
for only 30 minutes, Figure 4.14a, the Citrate-AuNPs are transported into the cells in a small 
tightly packed cluster, with a diameter of 75 nm, across its longest dimension, contained 
within an endosome. On the other hand, Citrate-AuNPs incubated with HeLa cells for 24 
hours, Figure 4.14b, contain larger, more diffuse collections of AuNPs, with dimensions up to 
400 nm, within the cell with evidence that they have escaped the endosome. If the Citrate-
AuNPs are free within the cytoplasm then it may be possible for them to interact with GFP-
4C, which would not be possible if they were trapped within endosomes. In order to see if the 
cellular uptake of luminescent AuNPs followed similar mechanisms, these experiments were 
repeated using EuL
b
-AuNPs. 
 
 
2 μm 0.2 μm 50 nm
1 μm 0.2 μm 50 nm
a
b
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4.2.3.3 Treatment of HeLa Cells with EuL
b
-AuNPs 
Administration of Citrate-AuNPs to HeLa cells transfected to express GFP-4C revealed that 
the presence of transfection factor seemed to be advantageous for the uptake of AuNPs by the 
cells without significant aggregation and allowed some endocytic uptake in as little as 30 
minutes. With these results in mind EuL
b
-AuNPs were administered to HeLa cells either for 
the final 30 minutes or 24 hours of a 48 hour transfection to express GFP-4C. The cells were 
then imaged using confocal microscopy. 
 
 
Figure 4.15 Confocal microscopy images of HeLa cells transfected for 48 h to express GFP-
4C with treatment with 0.9 nM EuL
b
-AuNPs for the final a) 30 minutes or b) 24 h of 
transfection. 1) bright field, 2) fluorescence where λex = 488 nm and λem = 500-550 nm, 3) 
reflectance where λex = 637 nm and λem = 400-700 nm and 4) overlay of fluorescence and 
reflectance images. Scale bar = 10 μm. 
 
Unlike the results for Citrate-AuNPs, EuL
b
-AuNPs appear to show large aggregates of 
AuNPs within cells after a 24 hour treatment with transfection factor present, apparent in both 
the bright field and reflectance images, whereas no aggregates are seen after only a 30 minute 
treatment. The aggregates appear to be located within the cells as does GFP-4C, but again the 
a
b
1
1
2
2
3
3 4
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diffuse nature of the GFP-4C fluorescence prevents the investigation into whether there is an 
interaction between the two species. The emission from EuL
b
 may have given more 
information about the location of the AuNPs, particularly where the lack of aggregation 
prevented them from being detected in bright field or reflectance modes, but unfortunately 
this could not be imaged. This may be due to the fact that the laser lines available for use with 
the microscope were not at the optimum wavelength for excitation of the complex because 
organic probes with longer excitation wavelengths are routinely studied using the equipment 
and, since the complex has a long luminescence lifetime, it emits a low number of photons at 
any one time making their detection difficult even with optimal excitation. 
 
The difference in cellular uptake of Citrate-AuNPs and EuL
b
-AuNPs may be because the 
surface modification of the AuNPs has affected the mechanism by which the AuNPs are taken 
up into the cells. In order to examine whether the presence of the transfection factor affects 
the uptake of EuL
b
-AuNPs in the same way as Citrate-AuNPs, HeLa cells were incubated 
with EuL
b
-AuNPs with and without Lipofectamine 2000 present and the cells digested and 
analysed for gold content using ICP-MS. 
 
Sample Average number of EuL
b
-AuNPs per 
cell/10
3
 
HeLa cells + EuL
b
-AuNPs 750 ± 195 
HeLa cells + EuL
b
-AuNPs + Lipofectamine 2000 680 ± 156 
Table 4.4 Average numbers of AuNPs per HeLa cell as calculated from counting cells present 
and absolute concentration of Au present in each sample measured by ICP-MS. 
 
ICP-MS data reveals that the average number of EuL
b
-AuNPs per HeLa cell is the same 
within error whether transfection factor is present or not. If the presence of transfection factor 
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does affect the uptake mechanism of AuNPs by HeLa cells it does not affect the overall 
numbers of AuNPs taken up. The calculations to determine the average numbers of AuNPs 
per cell can be found in the experimental section. 
TEM was again used to image the AuNPs more closely, and as such assess their uptake in 
HeLa cells more thoroughly. 
 
 
Figure 4.16 TEM micrographs of HeLa cells treated with EuL
b
-AuNPs for a) 30 min and b) 
24 h. Both treatments in the presence of Lipofectamine 2000. 
 
TEM reveals that when HeLa cells are treated with EuL
b
-AuNPs for 30 minutes with 
transfection factor present, Figure 4.16a, there is no evidence of the uptake of AuNPs into the 
cell. This is in contrast to Citrate-AuNPs which were taken up by endocytosis under the 
same conditions, indicating that the surface modification of the AuNPs does indeed affect 
cellular uptake. After a 24 hour treatment of HeLa cells with EuL
b
-AuNPs in the presence of 
transfection factor, Figure 4.16b, there are large collections of AuNPs clearly visible within 
2 μm 0.1 μm
2 μm 0.2 μm0.2 μm
a
b
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the cell. These collections of AuNPs have diameters of up to 500 nm across their largest 
dimension. Some of the collections of AuNPs are contained within vesicles, however, for 
others it is possible that AuNPs are free within the cytoplasm of the cell. If AuNPs are free 
within the cell cytoplasm it is possible that an interaction between them and GFP-4C could 
occur, but other methods to determine this are needed. 
 
Confocal microscopy and TEM have revealed the presence of both AuNPs and GFP-4C 
within HeLa cells, however, these methods have not presented the opportunity to draw 
conclusions about whether AuNPs do attach specifically to GFP-4C within cells. In order to 
gain more information about this HeLa cells were treated as for imaging purposes, but instead 
of being mounted were lysed in order to isolate AuNPs that had been taken up by the cells and 
examine whether GFP-4C is associated with the AuNPs. 
 
 
Figure 4.17 Aggregates of AuNPs, indicated by red circles, seen after centrifugation of HeLa 
cells after lysis. HeLa cells were all transfected for 48 h to express GFP-4C with 1) no 
additional treatment, treatment with Citrate-AuNPs for the final 2) 30 minutes or 3) 24 h of 
transfection or treatment with EuL
b
-AuNPs for the final 4) 30 minutes or 5) 24 h of 
transfection. 
3 4 51 2
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When cell lysis is performed, the cell solution is centrifuged and the cell debris contained 
within the resulting pellet is discarded because the cell contents remain within the 
supernatant, however, in this case dark aggregates resembling clumps of AuNPs were evident 
in the pellet indicating that AuNPs may be present in the pellet. Both the pellet and 
supernatant were examined for the presence of GFP-4C by measuring its fluorescence using a 
steady state fluorometer. 
 
    
Figure 4.18 Emission spectra of GFP-4C from the supernatant (left) and pellets (right) of 
HeLa cells transfected to express GFP-4C for 48 h and with no additional treatment (―), 
treatment with Citrate-AuNPs for the final 30 minutes (―) or 24 h of transfection (―) or 
treatment with EuL
b
-AuNPs for the final 30 minutes (―) or 24 h of transfection (―). In all 
cases λex = 488 nm and spectra corrected for PMT response. * indicates Raman scattering of 
water. 
 
The emission spectra in Figure 4.18 clearly show the characteristic emission expected for 
GFP with its emission peak around 510 nm, however, the emission is much more intense in 
the supernatant than the pellet. Indeed, the fluorescence intensity of GFP-4C from the pellet 
samples is so low that the Raman scattering of water can be seen at around 586 nm, as 
indicated by * in Figure 4.18 and seen under similar spectroscopy conditions previously.
44
 
This leads to the conclusion that there is more GFP-4C located within the cell cytoplasm, now 
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found in the supernatant, than associated with AuNPs, now found within the pellet. This is 
consistent with the fact that AuNPs were observed in discrete locations within the cells, 
however, GFP-4C was diffuse throughout the cell which would indicate that even if some of 
the protein was associated with AuNPs, the majority of it would not be. Certainly, the 
measurement of GFP-4C fluorescence within the pellet samples indicates that some of the 
protein is strongly associated with AuNPs. This conclusion is further strengthened by the fact 
that the most GFP-4C fluorescence from pellet samples is seen from samples that were 
revealed by TEM to have the most AuNP uptake, namely HeLa cells transfected for 48 hours 
with AuNPs applied in the final 24 hours of transfection. Interestingly, there is some GFP-4C 
fluorescence and AuNP presence in the pellet seen for HeLa cells treated with EuL
b
-AuNPs 
for the final 30 minutes of a 48 hour transfection, however, of the cells imaged using TEM no 
evidence of AuNPs was observed; this may indicate that of the population of cells some take 
up AuNPs, whereas a significant number do not take up any AuNPs at all. TEM also showed 
uptake of Citrate-AuNPs administered in the same way, however, there is negligible GFP-4C 
fluorescence measured from the pellet of cells treated in this way which confirms that the 
containment of AuNPs within endosomes prevents their interaction with GFP-4C. Finally, 
cells without any AuNP treatment show no GFP-4C fluorescence from the pellet which 
confirms that the fluorescence measured from the other samples is not an artefact of the 
procedures employed. 
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4.3 Conclusions 
The work in this chapter provides evidence of the potential for the use of luminescent AuNPs 
to act as protein labels. It has been demonstrated that the interaction of proteins with AuNPs 
differs depending on the surface coating of the AuNPs, with an anionic citrate coating 
allowing a strong interaction between BSA and Citrate-AuNPs without evidence of 
significant effect upon the conformation of the protein. Luminescent AuNPs coated with a 
charge neutral lanthanide complex, TbL
a
, showed a much weaker interaction with BSA and 
as such affected its structure to a much smaller degree than Citrate-AuNPs. In addition to 
this the luminescence properties of TbL
a
-AuNPs and EuL
b
-AuNPs were unaffected by 
protein or cell growth media confirming their potential as luminescent protein labels in cell 
studies. Preliminary results indicate that Citrate-AuNPs and EuL
b
-AuNPs are able to label a 
fusion protein containing the AuNP binding peptide, CCPGCC, however, the use of EuL
b
-
AuNPs as luminescent protein labels within cells was not demonstrated due to the inability to 
image europium luminescence from the treated cells. Further experiments are required to 
confirm the interaction of AuNPs with GFP-4C within cells which could include the 
expression of the protein as part of a known cellular structure and coating of AuNPs with a 
species able to participate in FRET with GFP-4C such as a terbium complex with improved 
antennas for increased luminescence intensity than that exhibited by TbL
a
 or EuL
b
. 
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4.4 Experimental 
4.4.1 General Considerations 
Cell culture materials were obtained from either Invitrogen, Electron Microscopy Sciences or 
Life Technologies. Complete cell growth media was further sterile filtered after formulation.  
 
UV-Vis absorption spectra were carried out on Varian Cary 50 or Varian Cary 5000 
spectrometers. UV-Vis spectra were taken using 1 cm path length quartz cuvettes.  
 
CD spectra were obtained using a JASCO J180 spectropolarimeter. CD spectra were recorded 
using 1 cm path length quartz cuvettes. 
 
ICP-MS analysis was undertaken at the University of Warwick, UK, and conducted using an 
Agilent 7500cx LC-ICP-MS system. PlasmaCal calibration standard for gold was purchased 
from SCP science. 
 
4.4.2 Plasmid Construct 
Mammalian expression plasmid for C-terminal fusion of tetracysteine peptide 
(FLNCCPGCCMEP) fused to enhanced GFP was obtained from Roger Tsien, University of 
California, San Diego, USA. The vector used was pCDNA3.1 with ampicillin and neomycin 
resistance. 
 
4.4.3 Amplification of Plasmid 
A pellet of frozen DH5 α Eschericha coli (50 μL) was thawed on ice. The plasmid was added 
to water (30 μL) and briefly centrifuged and vortexed. Plasmid solution (5 μL) was added to 
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the bacteria and kept on ice for a further 30 min. A 45 s heat shock at 42 ºC was then applied 
to the bacteria mixture before being put on ice for a further 2 min. Lysogeny broth (500 μL) 
was added to the bacteria and the mixture shaken at 37 ºC for 1 h. 150 μL of the bacteria 
mixture was added and streaked across a lysogeny broth agar plate with ampicillin. The plate 
was left to incubate at 37 ºC for ~ 18 h. Single colonies were picked from the plate and added 
to separate culture tubes each containing lysogeny broth (3 mL) and ampicillin (3 μL). The 
culture tubes were shaken at 37 ºC for ~ 18 h. The bacteria were then collected by 
centrifugation and the plasmid harvested using a QIAprep Spin Miniprep Kit, QIAGEN. The 
purified plasmid was eluted into buffer (50 μL) and its concentration found by measuring 
absorbance of the solution at 260 nm. 
 
4.4.4 HeLa Studies 
4.4.4.1 Cell Culture Maintenance 
HeLa cells were grown in complete media (10 mL) in T75 flasks with vented caps in an 
incubator at 37 ˚C containing 5% CO2. Complete media consisted of Dulbecco’s Modified 
Eagle’s Medium supplemented with foetal bovine serum (10%) and streptomycin/penicillin 
(1%). Cell passage was carried out every 3-4 days by washing with PBS and detachment 
using trypsin followed by dilution in complete media and adding to either a fresh T75 flask or 
6-well plates. 
 
4.4.4.2 Treating Cells 
1 mL of cell solution after passage was added to each well of a 6-well plate and cells 
incubated at 37 ˚C in a 5% CO2 atmosphere for 24 h prior to further treatment. A glass cover 
slip would first be added to the well if the cells were to be used for microscopy. For 
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transfection a transfection mixture was made using media (50 μL per well) and Lipofectamine 
2000 (1 μL per well) and allowing to stand at room temperature for 5 min before mixing with 
media (50 μL per well) and plasmid (2 μg per well) and allowing to stand at room temperature 
for 20 min. Once the cells had been incubated in the 6-well plate for 24 h the media was 
removed and replaced with fresh media (1 mL) before addition of transfection media to each 
well. The plates were then returned to incubate for 24-28 h. After 24 h of transfection the cells 
were either washed with PBS and fresh media added before AuNP treatment, or AuNP 
treatment was added directly to the cells in transfection media. AuNP treatment was 
administered by adding 9.4 nM AuNPs (100 μL) to each well and returning to incubate for a 
further 24 h. To achieve a 30 min treatment with AuNPs, AuNPs were administered in the 
same way 30 min before the end of a 48 h transfection. 
 
4.4.4.3 Fixing and Mounting Cells 
4.4.4.3.1 Preparation for Confocal Microscopy 
Once treatments were complete media was removed from the cells and cells washed with 
PBS. 4% paraformaldehyde (2 mL) was added to each well and cells left at room temperature 
for 5 min. Paraformaldehyde was then removed and cells washed again with PBS before 
cover slips were placed cells down onto a drop of Prolong Gold mounting medium on a glass 
slide. The slides were sealed with varnish, refrigerated flat and protected from light for at least 
24 h prior to imaging. 
 
4.4.4.3.2 Preparation for TEM 
Once treatments were complete media was removed from the cells and cells washed with 
PBS. Wells were filled with 2.5% gluteraldehyde in PBS and the plates sealed and 
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refrigerated for 72 h before cells being sectioned and mounted onto TEM grids by the Centre 
for Electron Microscopy, University of Birmingham, UK. 
 
4.4.4.4 Microscopy of Cells 
4.4.4.4.1 Confocal Microscopy 
Confocal microscopy was carried out using a Nikon A1R inverted confocal microscope 
employing a 60x oil immersion objective and using Nikon NIS-Elements Advanced Research 
software version 3.2. GFP fluorescence images were gained using a 488 nm laser excitation 
source and detection in the range of 500-550 nm. Reflectance images were gained using 637 
nm excitation source and detection in the range of 400-700 nm. 
 
4.4.4.4.1.1 Overlaying Fluorescence and Reflectance Confocal Microscope Images 
MATLAB software was used to overlay confocal fluorescence and confocal reflectance 
microscope images all of 512 x 512 pixels using the following code: 
base=imread('Fluorescence Image.gif'); 
I=imread('Reflectance Image.gif'); 
base_points = zeros(4, 2); 
base_points(1,1) =1; 
base_points(1,2)=1; 
base_points(2,1) =1; 
base_points(2,2)=512; 
base_points(3,1) =512; 
base_points(3,2)=1; 
base_points(4,1) =512; 
base_points(4,2)=512; 
input_points = zeros(4, 2); 
input_points(1,1) =1; 
input_points(1,2)=1; 
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input_points(2,1) =1; 
input_points(2,2)=512; 
input_points(3,1) =512; 
input_points(3,2)=1; 
input_points(4,1) =512; 
input_points(4,2)=512; 
TFORM=cp2tform(input_points,base_points,'affine'); 
registered=imtransform(I,TFORM,'FillValues', 0, 'XData', [1 size(base,2)], 'YData', [1 
size(base,1)]); 
figure, imshow(registered) 
hold on 
h=imshow(base, gray(256)); 
set(h, 'AlphaData', 0.2); 
 
4.4.4.4.2 TEM 
TEM micrographs were obtained using a JEOL 1200EX transmission electron microscope 
fitted with a LaB6 filament and employing an 80 keV beam. 
 
4.4.4.5 Cell Lysis 
Lysis buffer was made by adding Triton X100 (100 μL) and 1 protease inhibitor tablet to PBS 
(9.9 mL). After treatments cells were washed with PBS and lysis buffer (500 μL) added to 
each well. Cells were then scraped from the bottom of the wells and transferred to a centrifuge 
tube and vortexed every few minutes for a total of 1 h. The solutions were then centrifuged to 
obtain cell contents in the supernatant and cell debris in the pellet. The supernatant was 
decanted into a clean tube and the pellets resuspended in water before being centrifuged again 
and the process repeated in order to wash the pellets. 
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4.4.4.6 ICP-MS Analysis of Cells 
1 mL of cell solution after passage was added to each well of a 6-well plate and cells 
incubated at 37 ˚C in a 5% CO2 atmosphere for 24 h. Following this the media was removed 
and replaced with 1 mL fresh media and the cells incubated for a further 24 h prior to further 
treatment. EuL
b
-AuNPs treatment was added directly to the cells requiring treatment; AuNP 
treatment was administered by adding 9.4 nM AuNPs (100 μL) to each well and returning to 
incubate for a further 24 h. Lipofectamine 2000 (1 μL per well) was also added to the 
corresponding cells. After treatment the treatment media was removed, cells washed with 
PBS and trypsin (0.5 mL) added to each well before incubating the cells at 37 ºC for a further 
5 min. Media (3 mL) was then added to each well and mixed with the contents of the well 
before being transferred to a 15 mL centrifuge tube. The cells were centrifuged to form a 
pellet, the supernatant discarded and the cells resuspended in media (1 mL per tube). Cells 
were counted using a haemocytometer before being centrifuged again to form a pellet. The 
supernatant was discarded and cells re-suspended in ICP-MS grade HCl (300 μL per tube) 
and HNO3 (100 μL per tube) and placed in an ultrasonic bath at 40 ºC for 3 h. Cell solutions 
were then diluted with deionised water (3.6 mL per well) for analysis. The results were as 
follows: 
 
Sample Average Number of Cells Average Au Content/ppb 
Untreated HeLa cells 115000 22.09 
HeLa cells + Lipofectamine 2000 75000 29.80 
HeLa cells + EuL
b
-AuNPs 85000 504.30 
HeLa cells + EuLb-AuNPs + 
Lipofectamine 2000 
80000 522.70 
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As an example, the working used to calculate the average number of AuNPs per cell for HeLa 
cells treated with EuL
b
-AuNPs but no Lipofectamine 2000 is as follows: 
 
[Au] = 504.03 parts per billion = 5.043 x10
-4
 g L
-1
 
5.043 x10
-4
 g L
-1
/197 g mol
-1
 = 2.56 x10
-6
 mol L
-1
 of Au 
It has previously been shown that for AuNPs of this size there are 106801 atoms of gold per 
AuNP.
34
 
2.56 x 10
-6
 mol L
-1
/106801 = 2.40 x 10
-11
 mol L
-1
 AuNPs 
In the 4 mL sample: 2.40 x 10
-11
 mol L
-1
 x 4 x 10
-3 
L = 9.60 x 10
-14
 mols of AuNPs 
9.60 x 10
-14
 mol x 6.02x10
23
 mol
-1
 = 5.80 x 10
10
 AuNPs in sample 
5.80 x 10
10
 AuNPs/ 85000 cells = 679906 AuNPs per cell. 
 
4.4.5 Luminescence Spectroscopy 
Luminescence experiments were carried out using an Edinburgh Instruments fluorescence 
system, FLSPM920. The illumination source uses a 450 W xenon arc lamp. The detection 
system used was a Hamamatsu R928 PMT. The emission monochromator is fitted with two 
interchangeable gratings blazed at 500 nm and 1200 nm. Luminescence studies were carried 
out using quartz cuvettes with four transparent polished faces and 1 x 1 cm path length. F900 
spectrometer analysis software was used to record the data. 
 
4.4.5.1 Terbium Emission 
Luminescence spectra of TbL
a
 containing samples were gained by excitation of the complex 
at 266 nm, detection of emission in the range 455-750 nm and employing a 455 nm long pass 
filter. Typically a 0.2 s dwell time and a 1 nm step size were employed with excitation and 
emission slits set to 5 nm and 3 nm respectively. 
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4.4.5.2 Europium Emission 
Luminescence spectra of EuL
b
 containing samples were gained by excitation of the complex 
at 330 nm, detection of emission in the range 550-750 nm and employing a 550 nm long pass 
filter. Typically a 0.2 s dwell time and a 1 nm step size were employed with excitation and 
emission slits set to 5 nm and 3 nm respectively. 
 
4.4.5.3 BSA Emission 
Fluorescence spectra of BSA containing samples were gained by excitation of the protein at 
280 nm, detection of emission in the range 310-450 nm and employing a 305 nm long pass 
filter. A 0.5 s dwell time and a 1 nm step size were employed. Excitation and emission slits 
were set to 5 nm and 3 nm respectively. 
 
In order to gain details of how the tail of the BSA emission peak may create a background in 
the emission spectra of TbL
a
 containing samples native BSA was also examined under the 
conditions described for TbL
a
. 
 
4.4.5.4 GFP Emission 
Fluorescence spectra of GFP containing samples were gained by excitation of the protein at 
488 nm, detection of emission in the range 500-650 nm and employing a 495 nm long pass 
filter. A 0.5 s dwell time and a 1 nm step size were employed. Excitation and emission slits 
were set to 5 nm and 3 nm respectively. Emission data was collected over three repeats to 
produce a spectrum. 
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4.4.6 ζ-potential Measurements 
ζ-potential measurements were obtained using a Beckman-Coulter Delsa Nano C particle 
analyser and data was recorded and analysed using Delsa Nano software. Samples were 
analysed using a quartz flow cell purchased form Beckman-Coulter. Measurements were 
taken over 10 repeats at a 15º scattering angle through a 50 μm pinhole. The Smoluchowski 
conversion equation was used to analyse the data.  
  Chapter 4
   
200 
 
4.5 References 
1. Y. D. Álvarez, J. A. Fauerbach, J. V. Pellegrotti, T. M. Jovin, E. A. Jares-Erijman and 
F. D. Stefani, Nano Lett., 2013, 13, 6156-6163. 
2. S. H. Brewer, W. R. Glomm, M. C. Johnson, M. K. Knag and S. Franzen, Langmuir, 
2005, 21, 9303-9307. 
3. E. Casals, T. Pfaller, A. Duschl, G. J. Oostingh and V. Puntes, ACS Nano, 2010, 4, 
3623-3632. 
4. S. Chakraborty, P. Joshi, V. Shanker, Z. A. Ansari, S. P. Singh and P. Chakrabarti, 
Langmuir, 2011, 27, 7722-7731. 
5. S. Dominguez-Medina, S. McDonough, P. Swanglap, C. F. Landes and S. Link, 
Langmuir, 2012, 28, 9131-9139. 
6. L. A. Dykman and N. G. Khlebtsov, Chem. Rev., 2014, 114, 1258-1288. 
7. S. H. D. Lacerda, J. J. Park, C. Meuse, D. Pristinski, M. L. Becker, A. Karim and J. F. 
Douglas, ACS Nano, 2010, 4, 365-379. 
8. S. Laera, G. Ceccone, F. Rossi, D. Gilliland, R. Hussain, G. Siligardi and L. Calzolai, 
Nano Lett., 2011, 11, 4480-4484. 
9. J. Mariam, P. M. Dongre and D. C. Kothari, J. Fluoresc., 2011, 21, 2193-2199. 
10. Q. Shao, P. Wu, P. Gu, X. Xu, H. Zhang and C. Cai, J. Phys. Chem. B, 2011, 115, 
8627-8637. 
11. D.-H. Tsai, F. W. DelRio, A. M. Keene, K. M. Tyner, R. I. MacCuspie, T. J. Cho, M. 
R. Zachariah and V. A. Hackley, Langmuir, 2011, 27, 2464-2477. 
12. J. A. Yang, B. J. Johnson, S. Wu, W. S. Woods, J. M. George and C. J. Murphy, 
Langmuir, 2013, 29, 4603-4615. 
13. J. A. Yang, W. Lin, W. S. Woods, J. M. George and C. J. Murphy, J. Phys. Chem. B, 
2014, 118, 3559-3571. 
14. S. P. Boulos, T. A. Davis, J. A. Yang, S. E. Lohse, A. M. Alkilany, L. A. Holland and 
C. J. Murphy, Langmuir, 2013, 29, 14984-14996. 
15. M. Cui, R. Liu, Z. Deng, G. Ge, Y. Liu and L. Xie, Nano Res., 2014, 7, 345-352. 
16. S. R. Saptarshi, A. Duschl and A. L. Lopata, J. Nanobiotechnol., 2013, 11, 26. 
17. D. Wang, J. Ye, S. D. Hudson, K. C. K. Scott and S. Lin-Gibson, J. Colloid Interface 
Sci., 2014, 417, 244-249. 
  Chapter 4
   
201 
 
18. M. Yu, C. Zhou, J. Liu, J. D. Hankins and J. Zheng, J. Am. Chem. Soc., 2011, 133, 
11014-11017. 
19. S. Zeng, Y.-m. M. Huang, C.-e. A. Chang and W. Zhong, Analyst, 2014, 139, 1364-
1371. 
20. T. Cedervall, I. Lynch, S. Lindman, T. Berggard, E. Thulin, H. Nilsson, K. A. Dawson 
and S. Linse, Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 2050-2055. 
21. M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall and K. A. Dawson, Proc. 
Natl. Acad. Sci. U. S. A., 2008, 105, 14265-14270. 
22. M. Mahmoudi, I. Lynch, M. R. Ejtehadi, M. P. Monopoli, F. B. Bombelli and S. 
Laurent, Chem. Rev., 2011, 111, 5610-5637. 
23. C. Rocker, M. Potzl, F. Zhang, W. J. Parak and G. U. Nienhaus, Nat. Nanotechnol., 
2009, 4, 577-580. 
24. S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk, D. 
Fischer, K. Kiouptsi, C. Reinhardt, K. Landfester, H. Schild, M. Maskos, S. K. Knauer 
and R. H. Stauber, Nat. Nanotechnol., 2013, 8, 772-U1000. 
25. Y. Yan, K. T. Gause, M. M. J. Kamphuis, C.-S. Ang, N. M. O'Brien-Simpson, J. C. 
Lenzo, E. C. Reynolds, E. C. Nice and F. Caruso, ACS Nano, 2013, 7, 10960-10970. 
26. R. Khandelia, A. Jaiswal, S. S. Ghosh and A. Chattopadhyay, Small, 2013, 9, 3494-
3505. 
27. A. Lesniak, A. Salvati, M. J. Santos-Martinez, M. W. Radomski, K. A. Dawson and C. 
Åberg, J. Am. Chem. Soc., 2013, 135, 1438-1444. 
28. M. Schäffler, F. Sousa, A. Wenk, L. Sitia, S. Hirn, C. Schleh, N. Haberl, M. Violatto, 
M. Canovi, P. Andreozzi, M. Salmona, P. Bigini, W. G. Kreyling and S. Krol, 
Biomaterials, 2014, 35, 3455-3466. 
29. A. Davies, D. J. Lewis, S. P. Watson, S. G. Thomas and Z. Pikramenou, Proc. Natl. 
Acad. Sci. U. S. A., 2012, 109, 1862-1867. 
30. N. J. Rogers, S. Claire, R. M. Harris, S. Farabi, G. Zikeli, I. B. Styles, N. J. Hodges 
and Z. Pikramenou, Chem. Commun., 2014, 50, 617-619. 
31. M. De, S. Rana, H. Akpinar, O. R. Miranda, R. R. Arvizo, U. H. F. Bunz and V. M. 
Rotello, Nat. Chem., 2009, 1, 461-465. 
32. L. Anfossi, C. Baggiani, C. Giovannoli and G. Giraudi, Anal. Bioanal. Chem., 2009, 
394, 507-512. 
33. S. Comby and T. Gunnlaugsson, ACS Nano, 2011, 5, 7184-7197. 
  Chapter 4
   
202 
 
34. D. J. Lewis, T. M. Day, J. V. MacPherson and Z. Pikramenou, Chem. Commun., 2006, 
42, 1433-1435. 
35. M. A. Mahmoud, M. Chamanzar, A. Adibi and M. A. El-Sayed, J. Am. Chem. Soc., 
2012, 134, 6434-6442. 
36. A. C. Sabuncu, J. Grubbs, S. Qian, T. M. Abdel-Fattah, M. W. Stacey and A. Beskok, 
Colloids Surf. B, 2012, 95, 96-102. 
37. A. M. W. Reed and S. J. Metallo, Langmuir, 2010, 26, 18945-18950. 
38. M. S. Islam, M. Honma, T. Nakabayashi, M. Kinjo and N. Ohta, Int. J. Mol. Sci., 
2013, 14, 1952-1963. 
39. R. Lévy, U. Shaheen, Y. Cesbron and V. Sée, Nano Rev., 2010, 1, 4889. 
40. V. S e, P. Free, Y. Cesbron, P. Nativo, U. Shaheen, D. J. Rigden, D. G. Spiller, D. G. 
Fernig, M. R. H. White, I. A. Prior, M. Brust, B. Lounis and R. Lévy, ACS Nano, 
2009, 3, 2461-2468. 
41. B. Sikora, K. Fronc, I. Kaminska, K. Koper, S. Szewczyk, B. Paterczyk, T. 
Wojciechowski, K. Sobczak, R. Minikayev, W. Paszkowicz, P. Stepien and D. 
Elbaum, Nanotechnology, 2013, 24, 235702. 
42. G. F. Wang, A. S. Stender, W. Sun and N. Fang, Analyst, 2010, 135, 215-221. 
43. G. Rong, H. Wang, L. R. Skewis and B. r. M. Reinhard, Nano Lett., 2008, 8, 3386-
3393. 
44. C. Xu, J. B. Shear and W. W. Webb, Anal. Chem., 1997, 69, 1285-1287. 
 
 
  
  Chapter 5
   
203 
 
5. Overall Summary, Conclusions and Future Work 
 
5.1 Overall Summary and Conclusions 
The use of luminescent lanthanide complexes based on a DTPA backbone have been shown 
to successfully label proteins in vitro and to maintain their luminescence properties upon 
doing so. The lanthanide complexes used, LnL
a
, where Ln = Tb, Eu and Nd, and EuL
b
, 
contain thiol groups for their attachment to AuNPs in addition to their interaction with NHS-
MAL for covalent attachment to proteins. Control over the degree of labelling of the proteins 
was established through varying the ratio of NHS-MAL and EuL
b
 to protein during 
conjugation. It was found that when fewer labels are present per molecule of BSA, the protein 
structure is unaffected by the presence of the label as shown by CD studies. The system 
developed for protein labelling in vitro, therefore, upholds the key principles discussed in 
Chapter 1, specifically both the protein and the label are unaffected by the conjugation 
procedure. 
 
The conjugation of the complexes to BSA was not only useful for the luminescent labelling of 
the protein, but it also provided a route through which these complexes could be taken up by 
two human cell lines which were not able to take up the lanthanide complexes in isolation. 
Neutrophil cells were of interest due to their use in blood flow studies, however, previous 
attempts by the Pikramenou group to label them with luminescent lanthanide complexes had 
been unsuccessful. EuL
a
-BSA and TbL
a
-BSA were both shown to be taken up into the cell 
because neutrophils treated with these proteins exhibited the corresponding lanthanide 
luminescence. The luminescent cells were clearly visible through epiluminescence 
microscopy and as such may be used in rheology studies in the future. Human ovarian cancer 
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cells treated with EuL
b
-BSA emitted a stronger signal than untreated cells or cells treated 
with only EuL
b
 when imaged using epiluminescence microscopy, however, cells treated with 
a mixture of EuL
x
 and BSA also showed similarly high luminescence. EuL
x
 is able to interact 
with BSA as shown by the change in CD spectra of BSA when the complex is present, 
however, the interaction must be through non-covalent means due to the lack of thiol groups 
preventing covalent attachment in the same way as EuL
b
. This means that both covalent and 
non-covalent association of these complexes with BSA can facilitate their cellular uptake. 
This may be of importance when it is desirable to use membrane impermeable luminescent 
lanthanide complexes for cellular staining because it would circumvent the need for the use of 
methods such as electroporation or microinjection which may perturb the cells under 
investigation. 
 
EuL
b
 was used to label κ FLC in addition to BSA and when conjugated to κ FLC it was able 
to participate in FRET. In this case EuL
b
 was used as the donor species and a commercially 
available dye, FluoProbes 647H, was the acceptor and was conjugated to an anti-κ FLC mAb. 
FRET occurred when the two proteins interacted. Furthermore, the shortening of the lifetime 
of EuL
b
 in the presence of the acceptor was shown to be dependent on the concentration of 
the acceptor, thus demonstrating the potential application of the system for immunoassays. 
 
The precise number of labels conjugated to BSA could not be established. The use of 
absorption of the conjugated species could not be used to elucidate the number of labels due 
to the overlap of peak absorption of the protein with the labels. Analysis by Bradford assay 
and MS also proved inconclusive, most likely due to the label blocking the primary amines of 
the protein, preventing ionisation and interaction with the reagent in the assay. ICP-MS 
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investigations revealed the absolute concentration of europium in samples of EuL
b
-BSA and 
this result was used to calculate the absorption expected from the label which was then 
subtracted from the measured absorption of the samples to reveal the absorption arising from 
BSA, however, the degree of labelling calculated using this method seemed unlikely and did 
not concur with the absorption profile of the conjugated species. This indicates that the 
conjugation of EuL
b
 to BSA does not result in a species whose absorption properties are a 
linear combination of the individual species and it is for this reason that alternative methods 
of analysis are needed. All attempts to elucidate labelling information did confirm that the 
attempt to limit the number of labels per molecule of BSA was successful although the exact 
number of labels was not established. 
 
The first step towards using luminescent lanthanide coated AuNPs to label proteins within 
cells was to develop a peptide sequence capable of preferentially binding to AuNPs which 
could then be expressed by a cell as part of a protein of interest. Through investigating the 
interactions of three peptides, CALNN, CCPGCC and CCALNNCCALNN with Citrate-
AuNPs it was possible to determine the affinity of each peptide for the AuNPs. ITC, UV-Vis 
absorption titrations and SPR spectroscopy were shown to provide concurrent results when 
used to find the binding constant of peptide to AuNPs and as such not all methods were 
utilised for each peptide. The analyses revealed that CCPGCC had the strongest affinity for 
AuNPs and CCALNNCCALNN the weakest. This may not be intuitive from the peptide 
sequences as it is expected that the strongest interaction is between the thiol of cysteine and 
the AuNPs, however, the number of cysteine residues, and thus thiol groups, does not 
correlate to the strength of binding. It is fair to conclude, therefore, that in addition to the 
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available cysteine residues, the overall conformation of the peptide must be considered in 
terms of its ability to present its thiol groups to the surface to the AuNPs. 
 
Titration of Zn
2+
 and Ni
2+
 into CCPGCC-AuNPs and CALNN-AuNPs resulted in a change 
in the SPR absorption of CCPGCC-AuNPs but not in the case of CALNN-AuNPs. This 
indicates that the metal cations are able to interact with CCPGCC-AuNPs but not CALNN-
AuNPs; the most likely site of interaction between a metal cation and a peptide is through the 
thiol groups of the peptide which leads to the conclusion that CCPGCC does not bind to the 
surface of AuNPs using all of its cysteine residues which leaves one or more free for 
interaction with the metal cations, CALNN on the other hand uses its only cysteine residue to 
bind to the AuNPs and so cannot also bind the metal cations. 
 
The effect of CCPGCC upon the luminescence of modified AuNPs was found to differ 
depending on the lanthanide complex used to coat the AuNPs. EuL
a
-AuNPs suffered changes 
in their luminescence properties when the peptide was present, however, EuL
b
-AuNPs did 
not and it was for this reason, and for the slightly lower energy excitation wavelength over 
EuL
a
-AuNPs, that EuL
b
-AuNPs were taken forward for use as protein labels within cells. In 
addition to their interactions with peptides, luminescent lanthanide coated AuNPs were 
examined in terms of their interaction with protein as they were to be used as protein labels. 
The fluorescence and CD spectra of BSA was affected to a lesser extent when interacting with 
pTbL
a
-AuNPs than Citrate-AuNPs indicating that even partial surface coverage of the 
AuNPs by TbL
a
 limits interaction with the protein which is desired since direct interaction 
with the peptide binding site rather than the protein is needed for specific protein labelling. 
Furthermore, the luminescence properties of TbL
a
-AuNPs is unaffected by the presence of 
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BSA and that of EuL
b
-AuNPs was shown to be unaffected by dispersion in cell growth media 
which contains a variety of protein and salts amongst other species. These experiments 
confirm that luminescent lanthanide coated AuNPs are suitable for protein labelling within 
biological systems. 
 
The expression of GFP-4C by HeLa cells resulted in diffuse fluorescence throughout the cells 
which meant that the co-localisation of the AuNPs with the protein was not established. TEM 
studies and reflectance confocal microscopy revealed the uptake of AuNPs by HeLa cells and 
the presence of transfection factor Lipofectamine 2000 appeared to facilitate uptake of the 
AuNPs without aggregation which presents a method for treatment of HeLa cells with 
AuNPs. Lysis of the cells resulted in the formation of a pellet which is likely to be aggregated 
AuNPs and after washing this pellet exhibited characteristic GFP emission which may suggest 
that some GFP-4C was indeed associated with the AuNPs. The remaining cell lysate also 
exhibited GFP emission which is not unexpected since GFP-4C appeared to be expressed 
throughout whole cell whilst AuNPs may not have had access to all cellular locations and 
may have been taken up in too low a concentration to bind to all of the available GFP-4C. 
 
Overall, it has been shown that luminescent lanthanide complexes EuL
a
, TbL
a
, NdL
a
 and 
EuL
b
 are suitable as protein labels in vitro. TbL
a
-AuNPs and EuL
b
-AuNPs are able to 
interact with BSA without their luminescence or the structure of BSA being affected and as 
such also have potential as protein labels. Whilst a peptide binding study revealed that peptide 
CCPGCC is an ideal candidate for a specific site to bind AuNPs within cells, the results 
obtained for the labelling of GFP bearing this motif in cells with EuL
b
-AuNPs require further 
confirmation. 
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5.2 Future Work 
Whilst the use of LnL
a
 and EuL
b
 for covalent protein labelling was found to be successful it 
may be of interest to define the degree of labelling of the protein. So far, a technique for 
elucidating this information has not been found, however, the use of alternative methods such 
as analytical ultracentrifugation may prove more fruitful. In the case of analytical 
ultracentrifugation, the exact number of labels per molecule may not be determined, but a 
close estimate may be achieved. 
 
In order to further investigate the interactions between GFP-4C and lanthanide coated AuNPs 
it may be useful to harvest GFP-4C from cells and investigate its interaction with lanthanide 
coated AuNPs in vitro to confirm whether it binds in a similar fashion as the CCPGCC motif 
alone. Further to this, the analysis of cell lysis materials could be extended to include the 
characterisation of peptides associated with AuNPs in the pellets by MS to indicate whether 
AuNPs bind to GFP-4C specifically or are able to bind to other proteins within the cell. 
 
Furthermore, to establish the presence of an interaction between AuNPs and GFP-4C within 
cells, it may be useful to refine the transfection of the cells so that GFP-4C is located within 
discrete cellular compartments. This would allow the location of GFP-4C to be established 
more accurately and, therefore, help to conclude whether any AuNPs are in the vicinity of 
GFP-4C. Additionally, the AuNPs could be coated in a probe able to participate in FRET with 
GFP-4C which would give further information about the proximity of the two species. In 
terms of the lanthanide coated AuNPs themselves, the lanthanide complex used could be 
improved in order to aid their detection inside cells. To achieve this the antenna group of the 
lanthanide complex could be changed to a species such as a xanthone derivative. 
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The use of luminescent lanthanide coated AuNPs for protein labelling within cells will also 
require further investigations going forward in terms of their interaction with the cell. The 
uptake of AuNPs by cells could be assessed accurately by using flow cytometry detecting 
reflectance from the AuNPs. Toxicology assays will need to be performed in order to 
establish the impact of treatment with AuNPs on cell viability. In addition to this the areas of 
the cell accessible to the AuNPs will need to be confirmed. This may be achieved by using 
fluorescent stains specific for cellular structures in combination with confocal fluorescence 
and reflectance microscopy. Additionally, further TEM studies of treated cells should be 
conducted to confirm the locations of AuNPs within the cells. These investigations should be 
carried out at various time points during and after treatment of cells with AuNPs in order to 
establish the transport of the AuNPs through the cell and, therefore, which proteins the 
AuNPs are potentially able to label. Furthermore, these experiments should be extended to a 
variety of alternative cell lines to demonstrate the suitability of the luminescent AuNPs for 
protein labelling in a range of cells. 
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Appendix 
A.1 Material Corresponding to Chapter 2 
A.1.1 Figures Corresponding to Chapter 2 
               
Figure A.1 Emission spectra of native BSA in aqueous solution using for emission detection a 
310 nm long pass filter (left) or a 455 nm long pass filter (right). λex = 266 nm, corrected for 
PMT response. 
 
 
 
     
Figure A.2 Left: Emission spectra of Eu
3+
 as it is titrated into a solution of H3L
a
. Right: 
Integrated emission signal of H3L
a
, A0, subtracted from integrated emission signal when Eu
3+
 
is added, A1. λex = 266 nm, λem = 550-750 nm, corrected for PMT response. 
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Figure A.3 Luminescence decay curves for EuL
b
 containing samples. In all cases λex = 266 
nm, λem = 615 nm. Top left: EuL
b
 in methanol; top right: EuL
b
 in aqueous solution; bottom 
left: A-BSA in aqueous solution; bottom right: B-BSA in aqueous solution. 
 
A.1.2 Calculation of Degree of Labelling of EuL
b
-BSA from ICP-MS Data 
In all cases the molar extinction coefficients of BSA and EuL
b
 in aqueous solution were 
determined experimentally using solutions of each species in isolation. 
 
A.1.2.1 Calculation of Degree of Labelling of A-BSA from ICP-MS Data 
[Eu] measured by ICP-MS = 39.155 parts per billion = 39.155 µg L
-1
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39.155 x10
-6
 g L
-1
/153 g mol
-1
 = 2.56 x10
-7
 mol L
-1
 in submitted sample 
Since 1 mL of neat sample diluted in 5 mL for analysis, neat concentration in sample is: 
(2.56 x10
-7
 mol L
-1
 x 5 x10
-3
 L)/1x10
-3
 L = 1.28 x10
-6
 mol L
-1
 in original sample 
Since there is one atom of europium per label is follows that the concentration of EuL
b
 label 
in the original sample is also 1.28 x10
-6
 M. 
Calculated absorbance at 280 nm of EuL
b
: 1.28 x10
-6
 M x 1 cm x 9760 M
-1
 cm
-1
 = 0.01 
Measured absorbance of sample at 280 nm = 0.15 
Absorbance at 280 nm arising from BSA = 0.15 – 0.01 = 0.14 
Concentration of BSA = 0.14/(42430 M
-1
 cm
-1
 x 1 cm) = 3.30 x10
-6
 M 
1.28 x10
-6 
M/3.30 x10
-6
 M = 0.39 EuL
b
 labels per BSA molecule 
 
A.1.2.2 Calculation of Degree of Labelling of B-BSA from ICP-MS Data 
[Eu] measured by ICP-MS = 19.195 parts per billion = 19.195 µg L
-1
 
19.195 x10
-6
 g L
-1
/153 g mol
-1
 = 1.25 x10
-7
 mol L
-1
 in submitted sample 
Since 1 mL of neat sample diluted in 5 mL for analysis, neat concentration in sample is: 
(1.25 x10
-7
 mol L
-1
 x 5 x10
-3
 L)/1x10
-3
 L = 6.25 x10
-7
 mol L
-1
 in original sample 
Since there is one atom of europium per label is follows that the concentration of EuL
b
 label 
in the original sample is also 6.25 x10
-7
 M. 
Calculated absorbance at 280 nm of EuL
b
: 6.25 x10
-7
 M x 1 cm x 9760 M
-1
 cm
-1
 = 0.01 
Measured absorbance of sample at 280 nm = 0.22 
Absorbance at 280 nm arising from BSA = 0.22 – 0.01 = 0.21 
Concentration of BSA = 0.21/(42430 M
-1
 cm
-1
 x 1 cm) = 4.95 x10
-6
 M 
6.27 x10
-7 
M/4.95 x10
-6
 M = 0.13 EuL
b
 labels per BSA molecule 
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A.2 Material Corresponding to Chapter 3 
A.2.1 Figures Corresponding to Chapter 3 
             
Figure A.4 DLS number (left) and intensity (right) distributions for Citrate-AuNPs. 
 
 
 
 
 
 
               
Figure A.5 DLS number (left) and intensity (right) distributions for CALNN-AuNPs. 
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Figure A.6 Titration of CALNN into Citrate-AuNPs followed by absorption spectroscopy 
and its fit to find Ka. 
 
  
Figure A.7 Response units taken from the peak of each sensorgram as CALNN was passed 
across a gold chip plotted against peptide concentration and fit to find Ka. 
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Figure A.8 DLS number (left) and intensity (right) distributions for CCPGCC-AuNPs. 
 
 
 
 
 
 
Figure A.9 Titration of CCPGCC into Citrate-AuNPs followed by absorption spectroscopy 
and its fit to find Ka. 
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Figure A.10 DLS number (left) and intensity (right) distributions for CCALNNCCALNN-
AuNPs. 
 
 
 
 
  
Figure A.11 Titration of CCALNNCCALNN into Citrate-AuNPs followed by absorption 
spectroscopy and its fit to find Ka. 
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Figure A.12 Luminescence decay curves of EuL
a
-AuNPs (top) and EuL
b
-AuNPs (bottom) in 
the absence (left) and presence (right) of CCPGCC peptide. 
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A.2.2 Equations Corresponding to Chapter 3 
 
  
     
 
     
 
 
 
 
 
 
 
  
  
    
     
 
 
      
  
    
     
 
 
 
      
     
   
 
      
     
 
      
 
 
 
 
  
 
 
 
 
 
 
 
Equation A.1 Equation used to in Origin 7.0 software to fit ITC data using a 1:n binding 
model where ΔH is the enthalpy change, K the binding constant, n the number of binding 
sites, [Xt] the total peptide concentration, [Mt] the total concentration of AuNPs, V0 the 
effective volume of the calorimeter cell and dQ is the heat change at each addition during the 
titration. 
    
 
